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Regulation of cholesterol levels within cells and organisms is crucial for their
survival. Maintenance of cellular cholesterol homeostasis occurs mainly at the
transcriptional level, via the Sterol Regulatory Element Binding Proteins (SREBP),
the Liver X Receptors (LXR), and the Unfolded Protein Response (UPR)/ER Stress
Response. This thesis attempts to characterize the in vivo physiological role of
novel downstream target genes of these transcription factors: StARD5 and
ADAM11.
This thesis outlines the development and characterization of a floxed mouse
allele of the UPR-upregulated, reticuloendothelial gene StARD5, as well as two
different transgenic mouse lines, one which expresses the human StARD5 gene in
the liver and one which expresses the human StARD5 in the reticuloendothelial
system. We show that StARD5 plays an indispensable role in early embryogenesis
since homozygous knockouts are not viable. Haploinsufficiency in the adult mouse
does not alter plasma cholesterol or triglyceride levels, liver cholesterol levels,
gallbladder bile composition, glucose tolerance, cholesterol efflux from
macrophages, or atherosclerosis susceptibility.
Two isoforms of the ADAM11 gene were identified, differing only in their
cytoplasmic tails, with one highly expressed in the liver and the other highly
expressed in the brain. The liver isoform of ADAM11 was induced by dietary
cholesterol and the LXR transcription factor. In order to study the function of this
gene, this thesis describes the development of a floxed mouse allele of ADAM11.
Utilizing low and high cholesterol and cholic acid containing diets and the ADAM11
knockout, we did not find a phenotype for ADAM11 with respect to plasma
cholesterol or triglyceride levels, liver lipid levels, gallbladder bile composition,
glucose tolerance, or atherosclerosis susceptibility. We show that loss of ADAM11
in mice fed a high cholesterol diet lowers free plasma campesterol levels, without
having an effect on total campesterol levels or other phytosterols. Using a yeast
two-hybrid screen, we identified 3HAO as a putative ADAM11 cytoplasmic tail
binding partner, which interacted non-specifically with the two cytoplasmic tail

forms. ADAM11 knockout mice were previously shown to have a neurological
phenotype to which we now add absence-like epilepsy.
Finally, this thesis also outlines the development of a floxed mouse allele of
the dietary cholesterol-downregulated, SREBP-upregulated liver gene StARD4;
initial studies indicate that a full StARD4 knockout is viable.
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Chapter 1: Introduction
The Physiological and Pathophysiological Significance of Cholesterol
Cholesterol is a 27-carbon, four-ringed planar hydrophobic molecule that
plays a vital physiological role in all mammalian cells. It is the most abundant sterol
in the human body and is a fundamental component of cell membranes, enabling
membrane permeability and providing rigidity to the phospholipid bilayer (Simons
and Ikonen, 2000). Cholesterol is one of the major components of lipid rafts,
membrane microdomains that serve as a platform for various cellular events,
including signaling, cell-cell communication, and membrane trafficking (Tabas,
2002a).

Cholesterol covalently modifies and activates proteins, e.g. sonic

hedgehog, a protein essential for proper embryonic development. It serves as the
building blocks for the calcium and phosphorus-regulating hormone vitamin D3
(cholecalciferol), and for the steroid hormones, including sex and stress hormones,
specifically progesterone, estrogen, testosterone, cortisol, and aldosterone (Rose,
1998). Cholesterol is essential for the biosynthesis of bile acids, which aid in the
digestion and absorption of lipids, fats, and fat-soluble vitamins and are a major
mode for cholesterol excretion (Rose, 1998).
Cholesterol is thus critical for organismal homeostasis, and its levels must
be carefully regulated, as cholesterol imbalance can lead to serious pathological
consequences. Cholesterol synthesis, influx, and efflux must be tightly controlled
not only to assure adequate supply and proper distribution of this essential lipid,
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but also to avoid excess. Excess cellular free cholesterol is cytotoxic, and excess
plasma cholesterol in the form of LDL is a major risk factor for atherosclerosis, a
disease that kills nearly a million Americans each year (Anderson, 2001; Tabas,
2002b). In atherosclerosis, excess plasma cholesterol is deposited into the arterial
subendothelial space, setting off a cascade of inflammatory responses including
infiltration of monocytes, as well as proliferation and migration of smooth muscle
cells, elaboration of extracellular matrix (ECM) in the arterial wall, and cellular
apoptosis. Excess cholesterol in the biliary system can also result in disease, as
elevated cholesterol is the major risk factor in the development of cholesterol
gallstones, which account for nearly 80 percent of all gallstones. Every year,
gallstones afflict over 20 million Americans and force almost half a million Americans
to undergo cholecystectomy (surgical removal of their gallbladder) (Rose, 1998).
Sources of Cholesterol: de novo Synthesis and Dietary Uptake
Total body cholesterol originates from dietary intake as well as de novo
synthesis. In the U.S., the typical daily internal production of cholesterol is about
1g and the typical daily dietary intake is 300–500 mg, while the total body content
is approximately 35 g (Ikonen, 2006; Levy et al., 2007). The intestines are
responsible for absorbing dietary cholesterol as well as reabsorbing biliary
cholesterol (Rose, 1998). De novo synthesis of cholesterol occurs mainly in the
liver, intestines, adrenal glands and reproductive organs, where it is synthesized
through the HMG-CoA reductase pathway from acetyl CoA, a metabolic product of
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glycolysis and fatty acid oxidation. The liver is the major site of synthesis, producing
approximately 25% of de novo cholesterol
The liver exerts an extremely important role in maintaining organismal
homeostasis; it synthesizes the majority of serum proteins, detoxifies hazardous
materials, and controls metabolism. The liver carefully regulates the bodyʼs
cholesterol balance by maintaining an equilibrium between cholesterol
biosynthesis, degradation, utilization, uptake, transport, efflux, and storage (Rose,
1998). It receives cholesterol from the diet via chylomicron remnants and from
extrahepatic synthesis via plasma lipoproteins. Cholesterol is utilized by liver cells
(hepatocytes) either for incorporation into membranes, elimination into bile as free
cholesterol or bile acids, or secreted as a component of plasma lipoproteins (Rose,
1998).
Mouse as a Model Organism for Studying Cholesterol and Atherosclerosis
Currently, the most popular in vivo model for the study of cholesterol
transport and atherosclerosis is the mouse (mus musculus). Compared to humans,
mice have high levels of HDL (high density lipoprotein) and low levels of VLDL (very
low density lipoprotein) and LDL (low density lipoprotein). This anti-atherogenic
profile makes mice relatively resistant to the development of atherosclerosis
(Ikonen, 2006). Genetic and dietary manipulations have been developed to
promote atherosclerosis in mice, usually involving increases in the levels of the
apoB containing lipoproteins (LDL and VLDL). Among mouse strains, C57Bl6 mice
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are one of the most sensitive to atherosclerosis.
Induced mutant mice deficient in apolipoprotein E (ApoE) or the LDL receptor
(LDLR) are sensitized to developing atherosclerosis, and consequently are the two
most popular murine models for studying this disease (Ikonen, 2006). Both apoE
and the LDLR are involved in lipoprotein clearance. ApoE is the ligand for receptors
that clear chylomicron and VLDL remnants. The LDLR is responsible for the
clearance of LDL, which occurs mostly in the liver.
Using gene microarrays to identify novel dietary cholesterol-regulated genes
in the mouse liver, Soccio and then Maxwell identified the novel cholesterolregulated genes, ADAM11 and StARD4, respectively. Soccio found that StARD4
represented a subfamily of START domain containing genes, which also include
StarD5 and StarD6. This thesis will employ dietary and genetic manipulations in
mice to better understand the physiological functions of ADAM11 and StARD5.
Cholesterol Regulation of Gene Expression
Many of the genes important for regulating cholesterol homeostasis are
regulated by cholesterol itself at the transcription level, more specifically by one of
three major transcriptional pathways: the sterol regulatory element binding proteins
(SREBPs), the liver X receptors (LXRs), and the Unfolded Protein Response
(UPR)/Endoplasmic Reticulum (ER) Stress Response. These pathways will be
described in detail in the following three sections.

4

The Sterol Regulatory Element-Binding Proteins (SREBP) Pathway
The sterol regulatory element-binding proteins (SREBPs) compose a family
of transcription factors that regulate expression of genes involved in the synthesis
and uptake of sterols, fatty acids, triglycerides, and phospholipids (Brown and
Goldstein, 1999; Eberlé et al., 2004; Espenshade and Hughes, 2007; Horton et al.,
2002). SREBP family members are initially synthesized on the ER membrane as
inactive 1150 amino acid precursor proteins that contain the following domains: an
N-terminal basic helix-loop-helix (bHLH) leucine zipper transcription factor domain
that projects into the cytosol; two hydrophobic membrane spanning regions
separated by a short hydrophilic loop that projects into the ER lumen; and a Cterminal regulatory domain that projects into the cystosol (Brown and Goldstein,
1999; Eberlé et al., 2004).
In mammalian cells, there are two SREBP genes (SREBP-1 and -2)
encoding three distinct SREBP isoforms: 1a, 1c, and 2. Alternative promoters of
SREBP-1 generate SREBP-1a and -1c, which differ only in the length of their Nterminal transcription factor domain (Eberlé et al., 2004; Espenshade and Hughes,
2007). Transgenic mice over-expressing the active domain (N-terminal) of either
SREBP-1a, 1c, or 2 have been used to identify target genes (Horton et al., 1998;
Shimano et al., 1996; Shimano et al., 1997a). These studies revealed SREBP-1c
preferentially enhances transcription of genes involved in fatty acid synthesis
(lipogenic genes), but not cholesterol synthesis (cholesterogenic genes), whereas
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SREBP-2 preferentially enhances the expression of cholesterogenic genes, but
not lipogenic genes. SREBP-1a is a potent activator of all SREBP-responsive
genes, including those involved in both lipogenesis and cholesterologenesis. It is
thought that SREBP-1a plays a limited role physiologically, because it is present
in the liver at much lower concentrations than either SREBP-1c or SREBP-2.
Knockout mice for each of the SREBPs have been made, but have been less
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Figure 1.1. Regulation of SREBP proteolytic activation by cellular sterol levels. When sterols
are abundant, SREBPs remain in the ER as inactive precursors associated with SCAP and Insig.
When sterols are scarce, SCAP and Insig undergo conformational changes, which allow SCAP to
interact with the COPII complex rather than Insig. This leads to the transport of the SCAP-SREBP
complex from the ER to the Golgi apparatus, where the site 1 and site 2 protease (S1P and S2P)
cleave SREBP, releasing the N-terminal bHLH transcriptional activation domain. The bHLH of
SREBP is translocated to the nucleus and binds to target gene promoters via an SRE binding site.
This leads to the activation of target genes involved in the synthesis and uptake of cholesterol and
fatty acids.
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revealing. Homozygosity for the SREBP-1a or SREBP-2 knockout traits results in
embryonic lethality (Liang et al., 2002; Shimano et al., 1997b). However,
homozygotes for the SREBP-1c knockout trait are viable and exhibit decreased
lipogenesis, confirming the role for SREBP-1c suggested by the transgenic mouse
studies (Shimano et al., 1997b).
The activity of SREBPs is regulated by several processes, including
proteolysis within the secretory pathway, transcriptional control, post-translational
modification, and interactions with coactivators (Bengoechea-Alonso and Ericsson,
2007). SREBPs are synthesized as inactive precursors tethered to the ER, with
their carboxy(C)-terminal ends forming complexes with the membrane-bound,
sterol-responsive

chaperone

SREBP-cleavage-activating-protein

(SCAP)

(Espenshade and Hughes, 2007). When cellular sterols are abundant, cholesterolbound SCAP binds SREBP and forms a complex with the oxysterol-bound ER
resident proteins insulin-induced-gene Insig1 and Insig2, promoting SREBP
retention in the ER and thus blocking the transcription of SREBP-responsive genes
(Yang et al., 2002). The importance of SCAP in regulating SREBP activity was
demonstrated in transgenic mice carrying a SCAP mutant protein (D443N), which
is unable to bind to Insig; this mutation resulted in constitutive nuclear localization
of SREBP and up-regulation of SREBP target genes (Espenshade and Hughes,
2007; Korn et al., 1998). When cellular sterols are low, SCAP, which has a sterol
sensing domain, undergoes a conformational change, releasing Insig (Brown et al.,
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2002; Turtoi et al., 2008). This conformational change promotes the binding of the
SCAP-SREBP complex to COPII vesicles via interactions with Sar1 and the
Sec23/24 complex; this allows the SCAP-SREBP complex to translocate from the
ER to the Golgi (Espenshade and Hughes, 2007). In the Golgi, the membranebound serine-protease site-1-protease (S1P) cleaves the luminal loop of SREBP,
allowing the membrane-bound zinc-metalloprotease site-2-protease (S2P) to
cleave SREBP, and thereby releasing the N-terminal domain of SREBP into the
cytoplasm. This N-terminal domain, the active bHLH-Zip transcription factor,
interacts with importin via its nuclear localization signal and is translocated into the
nucleus, where it activates transcription by binding to sterol regulatory elements
(SREs) and by interacting with other transcription factors (Espenshade and
Hughes, 2007).
SREBPs are also regulated transcriptionally. Transcriptional coactivators,
such as CBP/p300, Mediator, and PGC-1beta, play an important role in regulating
SREBP activity (Bengoechea-Alonso and Ericsson, 2007).

Transcription of

SREBP-1c can also be regulated by insulin via a PI(3)-kinase dependent pathway,
and by activation by the Liver X Receptor (LXR) alpha (Bengoechea-Alonso and
Ericsson, 2007). SREBP-2 autoregulates its own expression through binding to
the SRE located in its promoter. SREBP activity can also be regulated via posttranslational modification in the nucleus, including phosphorylation, acetylation,
sumoylation, and ubiquitination (Bengoechea-Alonso and Ericsson, 2007).
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The LXR Pathway and the Process of Reverse Cholesterol Transport
The liver X receptor (LXR) transcription factors represent another family of
transcription factors that regulates the expression of genes involved in reverse
cholesterol transport, dietary cholesterol absorption, bile acid metabolism, glucose
metabolism, and lipid biosynthesis (Repa and Mangelsdorf, 2002; Schoonjans et
al., 2000). Liver X receptors (LXRalpha (NR1H3) and LXRbeta (NR1H2), are
members of the nuclear hormone receptor superfamily of ligand-activated
transcription factors that work in concert with co-activators and co-repressors to
regulate gene expression. The LXRs are composed of the following domains: an
N-terminal ligand-independent transcriptional activation domain (AF-1); a zinc finger
DNA-binding domain (DBD), which binds to specific DNA sequences called
hormone response elements (HREs); a flexible hinge region; a large ligand-binding
domain (LBD), often with a lipophilic core and a dimerization interface; and a liganddependent transcriptional activation domain (AF-2) (Repa and Mangelsdorf, 2002).
LXRalpha is expressed in the liver, spleen, adipose tissue, lung, and pituitary, while
LXRbeta is expressed ubiquitously.

Multiple studies have shown that LXR

activation inhibits atherosclerosis, while LXR deficiency in macrophages increases
lesion formation. Consequently, LXRs and their downstream genes have emerged
as potential therapeutic targets for atherosclerosis (Repa and Mangelsdorf, 2002;
Tontonoz and Mangelsdorf, 2003).
The LXRs function as obligate heterodimers with 9-cis retinoid X receptors
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(RXR (NR2B1)) to activate gene transcription (Hu et al., 2003). These heterodimers
bind to LXR-responsive elements (LXREs) that consist of direct repeats (DRs) of
the core sequence AGGTCA separated by 4 nucleotides (DR-4) (Repa and
Mangelsdorf, 2002; Tontonoz and Mangelsdorf, 2003; Yan and Olkkonen, 2008).
LXRs are activated when sterols are abundant in the cell, and increase the
expression of genes controlling sterol and fatty acid homeostasis. In the absence
of ligand, the LXR/RXR heterodimer binds to co-repressors turning off expression
of these target genes. In the presence of ligand, a conformational change in the
heterodimer allows the release of co-repressors and the binding of co-activators,
thereby activating transcription. Oxysterols, hydroxylated derivatives of cholesterol,
as well as glucose and D-glucose-6-phosphate, act as specific agonists for LXRs
(Repa and Mangelsdorf, 2002). Among the naturally occurring oxysterols, 22(R)hydroxycholesterol, which is expressed in the gonads and the adrenals,
24(S)-hydroxycholesterol, which is expressed in the brain, and 24(S),25epoxycholesterol, which is a byproduct of liver cholesterol biosynthesis and builds
up in liver after cholesterol feeding, have been identified as high affinity ligands for
LXR (Fu et al., 2001; Lala et al., 1997; Schoonjans et al., 2000). The most
abundant oxysterol in plasma, 27-hydroxycholesterol, is only a weak LXR agonist.
27-hydroxycholesterol, because of its abundance in plasma and presence in
macrophages, might be the most physiologically relevant LXR ligand. Moreover,
several synthetic, nonsteroidal LXR-selective agonists (T0314407, T0901317,
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Figure 1.2. Gene activation by LXRs in the presence of oxysterol ligands. LXRs heterodimerize
with RXR and bind to LXRE sites in the promoters of target genes. In the absence of ligand, the
LXR-RXR heterodimer binds co-repressors and target genes are turned off. In the presence of
ligand, such as oxysterols, the LXR-RXR heterodimer releases co-repressors, binds co-activators,
and activates transcription. LXR target genes are generally involved in cholesterol efflux and
reverse cholesterol transport.

GW3965) have also been identified (Collins et al., 2002; Schultz et al., 2000).
The use of natural and synthetic LXR ligands and LXR knockout mice have
been useful in elucidating the functions and the target genes of the LXRs. Upon
cholesterol feeding LXRalpha knockout mice fail to up-regulate transcription of the
gene encoding cholesterol 7alpha-hydroxylase (Cyp7a), the rate-limiting enzyme
in bile acid synthesis. This resulted in a rapid accumulation of large amounts of
cholesterol in the liver and provides evidence that LXR-alpha can act as a sensor
of dietary cholesterol (Peet et al., 1998). In contrast, cholesterol feeding of LXRbeta knockout mice did up-regulate Cyp7a in the liver and did not result in
accumulation of cholesterol in the liver, indicating distinct metabolic roles for LXRalpha and LXR-beta (Alberti et al., 2001).
When sterols are abundant in cells, LXRs bind their oxysterol ligands and
activate transcription of downstream genes. Most known LXR target genes remove
excess cholesterol through efflux, catabolism or decreased absorption. In other
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words, they function in the process of reverse cholesterol transport (RCT), a
process by which cholesterol is transported via HDL from peripheral cells to the
liver, where it can be excreted into bile as free cholesterol or bile acids (Repa and
Mangelsdorf, 2002). The importance of the LXR pathway in RCT has been
demonstrated using LXR knockouts, transgenics, and agonists. In macrophages,
LXRs activate members of the integral membrane ATP-binding cassette (ABC)
transporter protein family, including ABCA1, which is critical for the efflux of excess
cellular cholesterol to pre-betaHDL and to the apolipoprotein acceptor AI (ApoAI),
and ABCG1 which plays a similar role in cholesterol efflux to HDL (Costet et al.,
2000; Venkateswaran et al., 2000). LXRs stimulate macrophage and adipocyte
transcription of the ApoE gene, which encodes a secreted protein that resides on
the surface of chylomicron and VLDL remnants and serves as a ligand for hepatic
receptor removal of these particles from plasma (Joseph et al., 2004). LXRs also
up-regulate expression of genes that encode three lipoprotein remodeling enzymes:
lipoprotein lipase (LPL), which catalyzes the hydrolysis of lipoprotein triglycerides
and may promote the conversion of triglyceride-rich lipoproteins to cholesterol-rich
remnants (Zhang et al., 2001); cholesterol ester transfer protein (CETP), which in
humans mediates the transfer of HDL cholesterol esters to apoB containing
particles (LDL) for return to the liver (Luo et al., 2001; Luo and Tall, 2000; Matsuura
et al., 2006; Steffensen and Gustafsson, 2004); and phospholipid transfer protein
(PTLP), which modulates HDL metabolism (Cao et al., 2002). In the liver, LXRs
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up-regulate the expression of scavenger receptor B-1 (SRB-1), which mediates
the liver uptake of cholesterol from HDL (Malerød et al., 2002; Silver and Tall,
2001). In the liver, LXRs also activate Cyp7a1, which converts cholesterol into bile
acids, as well as the transporter proteins ABCG5 and ABCG8, which form a

Figure 1.3. Overview of lipoprotein metabolism along with the process of Reverse
Cholesterol Transport. Dietary cholesterol in the intestines are packaged into large ApoB-48
containing chylomicrons and secreted. In the plasma, chylomicrons acquire ApoE and ApoC; they
are converted into chylomicron remnants via lipoprotein lipase (LPL) and are taken up by the liver.
The liver produces apoB100 containing, triglyceride-rich VLDL. Through the action of LPL and
hepatic lipase (HL), VLDL is converted into IDL, and LDL. LDL can be taken up into the liver and
in in the periphery via the binding of apoB100 to the LDLR. Peripheral cells can efflux cholesterol
to nascent ApoAI via ABCA1, creating pre-HDL particles, which are converted to HDL by LCAT.
Peripheral cells can efflux cholesterol(C) to HDL via ABCG1. Cholesterol ester transfer protein
(CETP) transfers cholesterol ester(CE) and phospholipid transfer protein (PLTP) transfers
phospholipids between HDL and ApoB containing lipoproteins. HDL can be taken up by the liver
via SR-B1. Cholesterol in the liver may be converted to bile acids via Cyp7a1 or effluxed directly
into the bile via ABCG5/8 or other ABC transporters.
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heterodimer in the apical (canalicular) membrane of the hepatocyte and pump
cholesterol out of the liver into bile (Yu et al., 2003). In the intestine, LXRs activate
ABCA1, ABCG5, and ABCG8 to decrease absorption of dietary cholesterol (Repa
et al., 2002). All of these processes seem to have the net effect of removing excess
cholesterol from the periphery to the liver and then out into bile.
In addition to their ability to modulate cholesterol metabolism, LXRs are also
key regulators of hepatic lipogenesis and glucose metabolism.

LXRs can

transcriptionally activate SREBP-1c expression enhancing lipogenesis and leading
to hypertriglyceridemia (Repa et al., 2000; Schultz et al., 2000). Treatment of mice
with synthetic LXR ligands can cause hepatic steatosis (Schultz et al., 2000). LXRs
can increase hepatic glucose utilization and decrease hepatic glucose output by
induction of glucokinase and decreasing hepatic gluconeogenic genes such as
phosphoenolpyruvate carboxykinase and glucose-6-phosphatase; thereby
improving glucose tolerance (Wójcicka et al., 2007). Recent studies have shown
that LXRs also possess anti-inflammatory activity, repressing several inflammatory
genes (iNOS, COX2, IL-6 IL-1β
, MCP-1, MCP-3, and MMP9) after bacterial, LPS,
TNF-α, or IL-1
βstimulation (Yan and Olkkonen, 2008).
In summary, LXR has the ability to promote reverse cholesterol transport,
improve glucose tolerance, and limit inflammation. All of which make LXRs
attractive targets for pharmacological intervention for the treatment of
cardiovascular, metabolic, and/or inflammatory diseases.
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The Endoplasmic Reticulum Stress Response /
The Unfolded Protein Response
The ER accounts for nearly 50% of the cellular membranes and is a major
site of cellular calcium storage, sterol and lipid synthesis, and protein synthesis,
folding, and modification (Maxfield and Menon, 2006). The ER also plays a major
role in sensing cellular homeostasis. Only properly folded and modified proteins in
the ER are exported to the Golgi, while mis-folded or mis-modified proteins are
degraded. Disruption of this process via generation of reactive oxygen species
(ROS), excessive secretory protein synthesis, or cholesterol overload results in “ER
stress” and causes activation of three trans-membrane proteins (PERK, IRE-1, and
ATF6), which bring about the Unfolded Protein Response (UPR), also called the
ER Stress Response (Kaufman et al., 2002; Schroder and Kaufman, 2005; Shen
et al., 2004).
The ER proteins ATF6, IRE-1, and PERK are normally bound and
sequestered by BiP (GRP78), an ER chaperone. BiP preferentially binds to misfolded proteins, and in their presence, ATF6, IRE-1, and PERK become untethered
and initiate the UPR (Kaufman et al., 2002). ATF6, the ER-membrane bound
activating-transcription-factor-6, translocates to the Golgi, where it is cleaved by
S1P and S2P, releasing its N-terminal domain, an active basic leucine zipper (bZIP)
transcription factor, which translocates to the nucleus (Haze et al., 1999). IRE1, the
ER type I trans-membrane kinase/endoribonuclease, homodimerizes and
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undergoes trans-autophosphorylation, which then allows it to mediate splicing of
XBP1 mRNA resulting in the synthesis of the active bZIP transcription factor XBP1
(Back et al., 2005). PERK, another type I transmembrane kinase, phosphorylates
eIF2alpha, which attenuates translation of most mRNAs, while also selectively
enhancing the translation of another bZIP transcription factor ATF4 (Brewer and
Diehl, 2000).
The three transcription factors, ATF6, XBP1, and ATF4, up-regulate
expression of target genes by interacting with the ERSE (ER Stress Response
Element) in their promoters. The induced target genes increase the folding capacity
of the ER by increasing the capacity of the ER to synthesize phospholipids, to reesterify sterols, and to process proteins by promoting proper folding, i.e.,
chaperones and folding enzymes (Back et al., 2005; Kaufman et al., 2002; Schroder
and Kaufman, 2005; Sriburi et al., 2004). They also down-regulate the ER load by
decreasing transcription and translation of most other genes. By up-regulating ER
associated degradation (ERAD), they also increase the clearance of
unfolded/misfolded proteins from the ER. If, however, these processes fail to
remedy the stress, the UPR can ultimately signal apoptosis and eliminate the
unhealthy cell via activation of the C/EBP homologous protein transcription factor
(CHOP), as well as c-Jun NH2-terminal kinase (JNK) and caspases. It is now
known that this apoptotic pathway plays a fundamental role in the pathogenesis of
multiple

human

diseases

including
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Figure 1.4. Signaling the Unfolded Protein Response (UPR) / ER Stress Response Pathway.
Three proximal sensors IRE1, PERK and ATF6 regulate the UPR through their respective signaling
cascades. Under non-stressed conditions, BiP binds to the lumenal domains of IRE1, ATF6, and
PERK. Upon accumulation of unfolded proteins in the ER lumen, BiP is sequestered, releasing
IRE1, PERK, and ATF6. IRE1 mediates non-traditional splicing of Xbp1 mRNA. ATF6 is activated
by proteolysis in the Golgi similar to SREBP processing. The PERK pathway phosphorylates eIF2α,
which leads to transient attenuation of global translation, but activation of ATF4 translation. The
ER stress signals are then transduced via these three parallel transcription factors: ATF4, XBP1,
and ATF6.

neurodegenerative diseases (Malhotra and Kaufman, 2007; Zhang and Kaufman,
2006).
Accumulation of free cholesterol (FC) in the ER has been shown to trigger
the UPR (Tabas, 2002b). Normally, the ER cholesterol concentration is quite low
and maintained that way by the combined efforts of cholesterol efflux/transporters
and ER cholesterol esterification via ACAT. The latter converts ER free cholesterol
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to cholesterol esters, which are relatively inert and can be stored in cytoplasmic
droplets (Feng et al., 2003a). However, when these mechanisms fail or are
overwhelmed, cholesterol accumulates in the ER, which perturbs the normally
cholesterol-low ER membrane. Utilizing an in vitro cell culture model, the Tabas
laboratory has clearly shown that loading macrophages with free cholesterol by
incubation with acetylated LDL in the presence of an ACAT inhibitor causes
depletion of ER calcium stores, activation of the UPR and ultimately apoptosis
(Feng et al., 2003a; Tabas, 2002b).
UPR activation occurs at all stages of atherosclerotic lesion development
(Zhou et al., 2005).

During atherosclerogenesis, macrophages take up

cholesterol/lipoproteins via scavenger receptors, the expression of which on cells
is independent of cellular cholesterol status. This leads to excess cellular FC
provoking the UPR, which early on enhances cell survival, but prolonged ER stress,
at least in part due to FC accumulation, leads to apoptosis. This is evidenced by
the correlation of FC accumulation with the expression of CHOP and apoptosis in
advanced atherosclerotic lesions in ApoE knockout mice (Zhou et al., 2005).
Intracellular Cholesterol Transport
In mammalian cells, there are marked asymmetries in free cholesterol
concentration and distribution between cellular organelles. Approximately, 65% to
80% of free cholesterol, resides in the plasma membrane (PM); in contrast, only
0.1% to 2% of free cholesterol resides in the ER, despite the fact that the surface

18

areas of these two membranes in a cell are approximately equal (Liscum and Munn,
1999; Maxfield and Menon, 2006; Maxfield and Wustner, 2002; Prinz, 2002; Prinz,
2007). In the PM, free cholesterol comprises approximately 30% to 45% of total
lipid, whereas in the ER and mitochondria cholesterol comprises less than 10% of
total lipid. The free cholesterol concentration in the Golgi is intermediate between
the PM and the ER (Repa and Mangelsdorf, 2002; Liscum and Munn, 1999;
Maxfield and Wustner, 2002; Prinz, 2002). Moderate changes in total cellular
cholesterol have drastic effects on cholesterol levels within the ER, stimulating the
signaling mechanisms involved in maintaining homeostasis.

The exact

mechanisms for forming and maintaining this large gradient across organelles need
to be elucidated; a sorting mechanism must exist to include or exclude cholesterol
at various membranes. Understanding the process of cellular cholesterol transport,
either via vesicular or non-vesicular pathways, could clarify the mechanism(s)
behind this gradient (Ikonen, 2006, 2008; Prinz, 2007).
In eukaryotic cells most organelles, with the exception of mitochondria,
transport cargo in small, membrane-enclosed vesicles that move along the
cytoskeleton by an ATP dependent process. Evidence for this mechanism derives
from the observations that treating cells with Brefeldin A, which disrupts the
cytoskeleton, inhibits delivery of newly synthesized cholesterol from the ER to the
PM, and ATP depletion by metabolic poisons also disrupts intracellular sterol
transport (Prinz, 2007). In addition, it is known that Rab GTPases are key
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regulators of vesicular trafficking and disrupting them with Rab-GDI (GDP
dissociation inhibitors) impairs cholesterol movement, while over-expression of Rab
GTPases alter cellular cholesterol distribution between membranes. The latter
suggests that cholesterol transport by vesicles is necessary for the proper
distribution of cholesterol between membranes (Ikonen, 2008). There is some
evidence that cholesterol is sorted into vesicles headed toward the PM and
excluded from vesicles headed to the ER.

For example, cholesterol and

sphingomyelin are both excluded from CopI-vesicles, which move from the Golgi
back to the ER (Brügger et al., 2000; Prinz, 2007). Sorting cholesterol between
vesicles and membranes could also be driven by membrane curvature and
microdomain formation within membranes (Prinz, 2007; Roux et al., 2005). Thus
vesicles can move sterols within cells, but much remains to be learned about the
mechanisms involved and their importance in cellular cholesterol homeostasis.
It is clear that non-vesicular cholesterol transport plays a large role in cellular
cholesterol homeostasis. For example, blocking the vesicular pathway does not
significantly alter the cholesterol gradient across organelles, suggesting that the
bulk of intracellular sterol trafficking occurs via a non-vesicular pathway (Prinz,
2007; Soccio and Breslow, 2004). Moreover, treating cells with enough Brefeldin A
to block over 90% of protein secretion only decreases newly synthesized
cholesterol transport to the PM by 20% (Prinz, 2007; Soccio and Breslow, 2004).
Non-vesicular trafficking is mediated by various diffusible carrier proteins that
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contain a hydrophobic region allowing hydrophobic cholesterol molecules to be
transported across the aqueous cytosol. The next sections will review some of the
putative intracellular cholesterol transport proteins, including the Nieman Pick C
proteins, the oxysterol binding protein-related proteins, the sterol carrier protein-2,
the caveolins, and the steroidogenic acute regulatory–related lipid transfer domain
proteins.
The Role of Niemann Pick C Proteins
Niemann Pick Type C (NPC) disease is a rare autosomal recessive, lipid
storage disorder that manifests as a progressive neurodegenerative disease
(Ikonen, 2006; Liscum and Sturley, 2004; Prinz, 2007). It is caused by mutations
in either the NPC1 or NPC2 genes and is characterized by the intracellular
accumulation of cholesterol and other lipids, particularly sphingolipids, in the late
endosomal/lysosomal compartment. NPC1 is a late endosomal membrane protein
that contains a sterol sensing domain (SSD) capable of binding cholesterol, and is
essential for the transfer of cholesterol out of endosomes and lysosomes. NPC2,
also known as HE-1, is a small, soluble cholesterol-binding glycoprotein that resides
in the lumen of late endosomes and lysosomes (Cheruku et al., 2006; Friedland et
al., 2003; Ko et al., 2003; Patel et al., 1999; Sleat et al., 2004; Watari et al., 1999).
The crystal structure of NPC2 reveals a hydrophobic tunnel too small to contain a
cholesterol molecule; so the protein is thought to undergo a conformational change
to accommodate cholesterol (Friedland et al., 2003).
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The loss of NPC1 or NPC2 in mouse models leads to intracellular sterol
accumulations, similar to the phenotype seen in NPC disease. ApoE knockout mice
whose macrophages are heterozygous for NPC1 deficiency have diminished
lesional necrosis and macrophages that resist apoptosis (Feng et al., 2003b). ApoE
knockout mice whose macrophages are homozygous for NPC1 deficiency have
larger lesions with evidence of atherothrombosis, and arterial medial degradation
(Feng and Tabas, 2002; Welch et al., 2007). LDLR knockout mice whose
macrophages are homozygous for NPC1 deficiency have larger lesions and
macrophages with impaired cholesterol efflux and increased ROS (Zhang et al.,
2008).
The Role of Oxysterol Binding Protein (OSBP) - Related Proteins (ORPs)
A family of oxysterol binding protein (OSBP)-related proteins (ORP) has
been described containing 12 members in humans and mice, and seven members
in budding yeast (OSPB-homologoues (Osh) (Fairn and McMaster, 2008; Yan and
Olkkonen, 2008). ORPs are thought to play roles in lipid distribution and
metabolism, cell signaling, and vesicular transport (Beh and Rine, 2004; Fairn and
McMaster, 2008; Prinz, 2007; Yan and Olkkonen, 2008). The C-terminus of all
ORPs contain the lipid binding OSBP-related protein domain (ORD) with the
signature OSBP motif (EQVSHHPP). ORPs appear to bind 25-hydroxycholesterol
(25OH) and other oxysterols via this domain; sterol binding assays have shown
that 25OH can bind to OSBP, ORP1, ORP2, ORP3, ORP4, ORP5, ORP6, ORP7,
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ORP8, ORP10 and ORP11. ORP 5 and 8 also contain a putative trans-membrane
domain at their C-termini. The N-termini of ORPs are variable and can contain
FFAT motifs, pleckstrin homology domains (PH), and ankyrin repeats. The Nterminal domains may mediate interactions with other proteins or subcellular
localization, but their exact roles are still unknown. Alternative splicing is common
in ORPs and results in long (denoted by –L) and short (denoted by –S) forms of
these proteins; the short forms lacks the N-terminal region present in the long forms.
The subcellular localization of ORPs can vary. For example, OSBP changes its
intracellular location in the presence of oxysterols.
Much of our understanding of the functions of ORPs has come from work in
the yeast S. cerevisiae (Beh and Rine, 2004; Fairn and McMaster, 2008; Prinz,
2007; Yan and Olkkonen, 2008). In this model organism ORPs are referred to as
Oshs. In vitro it was shown that Osh 4 (Kes1) can extract cholesterol from
liposomes and transfer it to acceptor membranes, suggesting that ORPs may
function as soluble sterol transporters. Deleting any one of the seven Osh proteins
has little effect on sterol transfer, suggesting redundant functionality. However,
conditional deletion of all seven Osh proteins (osh-del, osh4-1) alters intracellular
sterol distribution, causes vacuolar fragmentation, causes accumulation of lipid
droplets in the cytoplasm and within vacuolar fragments, and eventually leads to
cell death (Beh and Rine, 2004; Fairn and McMaster, 2008; Prinz, 2007; Yan and
Olkkonen, 2008).
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The exact role of mammalian ORPs is unknown, and there is no direct
evidence that mammalian ORPs function as sterol transfer proteins. In mammalian
cells, ORPs can be subdivided into six subfamilies based on sequence homology
(OSBP and ORP4; ORP1 and 2; ORP5 and 8; ORP3, 6, and 7; ORP9; and ORP10
and 11).
OSBP is normally localized in the cytoplasm, but relocates to the Golgi when
cells are treated with 25-hydroxycholesterol (Fairn and McMaster, 2008). Overexpression of OSBP in CHO cells increases cholesterol and sphingomyelin
synthesis, possibly due to sequestration of endogenous sterols. Knocking down
OSBP via RNAi causes no significant change in cholesterol or fatty acid synthesis
(Fairn and McMaster, 2008).

OSBP appears to be involved in regulating

sphingomyelin production by recruiting the CERT-dependent ceramide transporter
StARD11 (more on this gene in the START section) from the ER to the Golgi (Perry
and Ridgway, 2005, 2006). Adenoviral over-expression of OSBP in mouse liver
leads to an increase in plasma VLDL and triglycerides (TG), due in part to upregulation of hepatic SREBP-1c, causing increased hepatic triglyceride synthesis
(Yan et al., 2007b). The close OSBP homologue, ORP4 has two splice variants:
ORP4L and ORP4S, both of which co-localize with the intermediate filament
vimentin. Over-expression of ORP4S causes a collapse of the vimentin network,
suggesting a role for ORP4S in the regulation of microtuble formation (Wang et al.,
2002). Cells over-expressing ORP4S also display reduced esterification of low-
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density-lipoprotein(LDL)-derived cholesterol, suggesting ORP4 modulates the
transfer of LDL derived free cholesterol from the lysosome to the ER where it
undergoes esterification by ACAT, perhaps by a vesicular pathway along a
microtubular network involving vimentin (Wang et al., 2002).
The ORP1 and ORP2 subfamily may also play a role in intracellular lipid
metabolism.

ORP1 has two splice variants and the expression of ORP1S

predominates in heart and skeletal muscle, whereas ORP1L expression
predominates in brain, lung, and macrophages (Johansson et al., 2003). ORP1L
localizes to the late endosomal compartment and via its ankyrin repeat region
interacts with and stabilizes the late endosomal GTPase Rab7. In cell culture overexpression of ORP1L enhances LXRalpha-mediated transactivation of a reporter
gene, suggesting a role for ORP1L in transport of LXRalpha-ligands such as
oxysterols (Johansson et al., 2003). In vivo macrophage over-expression of ORP1L
driven by the scavenger receptor A promoter increases atherosclerotic lesions in
LDLR knockout mice, also suggesting it may play a role in macrophage sterol
metabolism (Yan et al., 2007a).
ORP2 has only one known form (Laitinen et al., 2002), and over-expression
in CHO or HeLa cells causes up-regulation of cellular cholesterol efflux, reducing
cellular free cholesterol. Cells over-expressing ORP2 also decreased cholesterol
esterification, reduced triglycerides, and caused a shift of polyunsaturated fatty
acids from neutral lipids to phospholipids (Hynynen et al., 2005; Käkelä et al., 2005).
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ORP8, which localizes to the ER via its C-terminal trans-membrane domain,
may also play a role in cellular lipid metabolism. Immunohistochemical analysis
has revealed that ORP8 is highly expressed in macrophages in human
atherosclerotic lesions (Yan et al., 2008). RNAi knock down of ORP8 expression in
THP-1 macrophages results in increased in ABCA1 expression and concomitantly
an increase in cholesterol efflux to ApoA1 (Johansson et al., 2003).
ORP9 can negatively regulate Akt phosphorylation and in this manner
influence Akt signaling pathways that control cell cycle, survival, and glucose
metabolism (Lessmann et al., 2007; Wyles and Ridgway, 2004). There is some
evidence that ORP3 might interact with the actin cytoskeleton, and in this manner
influence cell polarity and cell adhesion (Collier et al., 2003; Lehto et al., 2005;
Lehto et al., 2008). The roles of ORP5, 6, 7, 10, and 11 have not been explored.
The Role of Sterol Carrier Protein-2 (SCP-2)
Sterol carrier protein-2 was discovered as a soluble protein that binds and
transfers cholesterol as well as phospholipids (Gallegos et al., 2001). The SCP-2
gene has two initiation sites that produce distinct proteins, the 58-kDA sterol carrier
protein-x (SCP-x) and the 15-kDA pro-SCP-2 protein, which share the same Cterminus (Gallegos et al., 2001). Both can be post-translationally cleaved to
produce the same active 13-kDa protein SCP-2. In addition to a fully functional 13kDa SCP-2 protein, the cleavage of the 58-kDA SCP-x also produces a 46-kDa
protein. SCP-x and SCP-2 are highly expressed in tissues involved in cholesterol
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trafficking and oxidation, notably the liver, intestine, adrenal glands, testis, and
ovary. While SCP-x is almost exclusively localized to peroxisomes, SCP-2 is also
found in cytoplasm, ER, mitochondria, and lysosomes (Gallegos et al., 2001). The
58 kDa SCP-x and its 46 kDa cleavage product are 3-ketoacyl-CoA thiolases that
oxidize straight and branched-chain lipids, and play an essential role in
detoxification and bile acid synthesis (Gallegos et al., 2001; Seedorf et al., 2000).
Mice lacking SCP-x have defects in branched chain fatty acid catabolism, due to
the lack of peroxisomal thiolase activity (Seedorf et al., 1998). Furthermore, SCP2 knockout mice have impairments in biliary lipid and hepatic cholesterol
metabolism (Fuchs et al., 2001).
SCP-2 has also been called the non-specific lipid transfer protein (nsLTP),
because it binds many lipids, including cholesterol, phospholipids, fatty acids, fatty
acyl CoAs, lysophosphatidic acid, phosphatidylinositol, and sphingolipids, and in
vitro has been shown capable of transferring these lipids between membranes
(Gallegos et al., 2001; Prinz, 2007). There is no definitive proof that SCP-2 functions
in this manner in vivo. However, over-expression in cell culture suggests SCP-2
may facilitate non-vesicular sterol trafficking. In McA-RH7777 rat hepatoma cells,
over-expression of SCP-2 increases the rate of newly synthesized cholesterol
transfer to the plasma membrane, alters cholesterol uptake and efflux to HDL,
inhibits cholesterol ester synthesis and high density lipoprotein cholesterol
secretion, and alters plasma membrane lipid distribution (Atshaves et al., 2007a;

27

Atshaves et al., 2007b; Atshaves et al., 2007c; Baum et al., 1997; Gallegos et al.,
2001; Moncecchi et al., 1996; Ren et al., 2004a; Schroeder et al., 2007; Schroeder
et al., 2001).
The Role of Caveolins
The precise function of caveolins in non-vesicular/vesicular cholesterol
transport is still being debated (Prinz, 2007). Caveolins are abundant integral
membrane proteins that are essential for the formation of caveolae, a subset of
lipid rafts with a flask-shaped plasma membrane invagination. There are three
caveolins 1, 2, and 3; caveolin-1 and caveolin-2 have multiple isoforms. Caveolins
are located on the cytoplasmic face of caveolae.

They serve as structural

components of caveolae and scaffolding proteins capable of recruiting and
regulating various signaling molecules (Cohen et al., 2004).
Caveolin-1 is a 22 kDa protein that is highly expressed in adipocytes,
endothelial cells, fibroblasts, and type I pneumocytes. In non-muscle cells caveolin1 is necessary and sufficient to drive caveolae formation; wheras in muscle cells
caveolin-3, which is muscle specific, performs the same function (Cohen et al.,
2004).
In cell culture studies caveolin-1 has been shown to affect cholesterol
trafficking and two mechanisms have been proposed whereby caveolin-1 either
regulates the formation of plasma membrane caveolae or caveolin-1 acts in a
chaperone complex (Cohen et al., 2004; Prinz, 2007). Smart has proposed that
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caveolins form a cytosolic cholesterol-caveolin-chaperone macromolecular
complex, representing a novel intracellular lipid-protein particle analogous in
character to plasma lipoproteins (Li et al., 2005; Liu et al., 2002; Smart et al., 1996;
Uittenbogaard and Smart, 2000; Uittenbogaard et al., 1998). In addition to its
plasma membrane localization, in some cell types caveolin-1 is also found as a
soluble cytosolic protein, in secretory vesicles, and/or in mitochondria.
Caveolin-1 knockout mice have been used to infer the function of caveolin1 in vivo. Given the requirement of caveolin-1 for the formation of caveolae in all
non-muscle cells, surprisingly caveolin-1 knockout mice are viable (Razani et al.,
2002) with normal plasma cholesterol levels and intestinal cholesterol absorption.
The caveolin-1 knockout trait has been bred on to the atherosclerosis prone ApoE
knockout background, and the ApoE-Caveolin-1 double knockout mice have less
atherosclerosis than the ApoE single knockouts, despite higher levels of plasma
non-HDL cholesterol and triglycerides. By way of explanation, Frank has suggested
that caveolins play a role in cholesterol uptake by macrophages, and this important
process may be blunted in the absence of Caveolin-1 (Frank et al., 2004). Treating
mice with an caveolin-1 expressing adenovirus was shown to cause a two-fold
elevation in plasma HDL-cholesterol levels, possibly due to disruption of SR-B1
mediated hepatic HDL uptake. If this is not an artifact of non-physiological
Caveolin-1 over-expression, it suggest a role for Caveolin-1 in the regulation of
HDL metabolism (Frank et al., 2001).
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The Role of the Steroidogenic Acute Regulatory–Related Lipid Transfer
Domain Protein Family
The StAR-related lipid transfer (START) domain is a highly conserved ~210
amino acid lipid binding domain (Ponting and Aravind, 1999). The human and
mouse genomes each have 15 genes encoding START domains, and phylogenetic
analysis divides the family into six subfamilies (STAR, PCTP, acyl CoA thioesterase,
RhoGAP, StARD9, and StARD4) (Alpy and Tomasetto, 2005; Soccio and Breslow,
2003; Thompson et al., 1994). The X-ray crystal structure of the START domain
encoded by several of these genes (StARD 2, 3, 4, and 11) shows a highly
conserved helix-grip fold forming a hydrophobic pocket large enough to
accommodate a cholesterol or similarly sized molecule plus a C-terminal alphahelical lid structure (Kudo et al., 2008; Roderick et al., 2002; Romanowski et al.,
2002; Tsujishita and Hurley, 2000). The START domain of each gene varies slightly
in the number of amino acids as well as in lipid binding specificity. The next six
sub-sections present an in-depth discussion of the six START subfamilies. In part
this thesis attempts to understand the physiological role of one of the genes in the
StARD4 subfamily, StARD5.
The StAR Subfamily
StARD1/StAR
StARD1, also known as the steroidogenic acute regulatory protein (StAR),
regulates the limiting step in steroidogenesis in the adrenal cortex and gonads, by
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promoting the translocation of cholesterol from the outer mitochondrial membrane
(OMM) to the inner mitochondrial membrane (IMM), where the first step in steroid
biosynthesis is catalyzed (Clark et al., 1995; Clark and Stocco, 1995; Clark et al.,
1994; Miller, 2007b; Miller and Strauss, 1999; Stocco, 2001; Sugawara et al., 1995).
StAR delivers cholesterol to the cytochrome P450 side chain cleavage (P450scc)
enzyme on the matrix side of the IMM, allowing for the conversion of cholesterol to
pregnenolone (Alpy and Tomasetto, 2005; Miller, 2007a). Normally, pituitary trophic
hormones can induce steroidogenesis acutely by activating pre-existing StAR
through phosphorylation, and by inducing the rapid synthesis of new StAR (Miller
and Strauss, 1999). The functional role of StAR in promoting steroidogenesis was
identified through transfection and mutational studies. When StAR is transfected
in Leydig MA-10 and Cos-1 cells, steroidogenesis increases, and when StAR is
mutated, steroidogenesis is severely impaired (Lin et al., 1995; Stocco, 2002;
Sugawara et al., 1995).
In humans, mutations in StAR cause congenital lipoid adrenal hyperplasia
(lipoid CAH), a rare autosomal recessive disease that results in almost complete
inability to synthesize steroids, leading to deficiencies in mineralocorticoids,
glucocorticoids, and sex steroids (Lin et al., 1995). The condition is also
accompanied by pathological accumulation of cholesterol and cholesterol esters in
the gonads and adrenal glands. Knocking out StAR in mice causes a similar
disorder to that in humans; mice die prematurely from either respiratory distress or
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volume depletion (Caron et al., 1998; Caron et al., 1997). Due to the hormone
synthesis deficiency, these knockout mice all have female external genitalia, as
well as lipid deposits in the adrenal cortex. Alternatively, mice in which StAR was
over-expressed in liver via adenovirus had an elevated rate of bile acid synthesis
(BAS) due to increased delivery of cholesterol to mitochondria. (Ren et al., 2004a;
Ren et al., 2004b).
StAR contains an N-terminal mitochondrial targeting sequence along with
its C-terminal START domain. Deletion mutagenesis studies have shown that StAR
lacking its mitochondrial targeting sequence (62 N-terminal amino acid residues)
(N-62 StAR) is still functional in cells, suggesting that the protein acts on the
cytosolic face of the OMM (Arakane et al., 1998a; Arakane et al., 1998b). The Nterminus appears to simply confine StARs action to the mitochondria and keep the
protein away from other organelles (Miller, 2007a). Consistent with this hypothesis,
StAR remains functionally active when fused to the C-terminus of the mitochondrial
proteins Tom20, Tim9, or Tim40 in vitro and then added to steroidogenic
mitochondria. In cell culture, StAR also remains active when fused to the Cterminus of Tom20, a mitochondrial pore protein found on the OMM. However, in
vivo StAR becomes inactive when fused to the C-terminus of Tim9, a protein found
in the mitochondrial intramembranous space, or Tim40, a protein localized to the
mitochondrial matrix, thereby indicating that it was the localization of the fusion
protein, not the structure, that rendered them inactive in cell culture (Bose et al.,
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2002; Miller, 2007b).
Exactly how StAR assists in transferring cholesterol from the OMM to the
IMM and in stimulating steroidogenesis remains unclear (Prinz, 2007). Mutation
studies suggest these two functions may be separable. For example, the StAR
mutant R182L can bind and transfer cholesterol, but cannot stimulate
steroidogenesis (Miller, 2007a; Tuckey et al., 2002). Recent studies suggest that
StAR stimulation of steroidogenesis requires interaction with the peripheral
benzodiazepine receptor (PBR), a small OMM protein with a cytoplasmic
“cholesterol recognition amino acid consensus” (CRAC) domain (Hauet et al., 2005;
Miller, 2007b; West et al., 2001).
StARD3/MLN64
StARD3, also known as MLN64 (metastatic lymph node 64), is an integral
membrane protein expressed in all tissues and localizes within cells to late
endosomes. The C-terminal START domain is oriented towards the cytosol and
consistent with its X-ray crystal structure is capable of binding cholesterol in a 1:1
manner (Tsujishita, 2003; Tsujishita and Hurley, 2000). The N-terminal region
consists of four transmembrane domains, has been termed the MENTAL domain.
The MENTAL domain is also capable of binding cholesterol, and may play a role in
targeting the protein to the late endosome (Alpy et al., 2002). The MENTAL domain
can mediate homodimerization of StARD3 as well as heterodimerization with
MENTHO (MLN64 N-terminal domain homologue). MENTHO is a product of a
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different gene, but encodes a region highly homologous to the MENTAL domain of
StARD3, but lacks a START domain (Alpy et al., 2002). MENTHO is ubiquitously
expressed and is located in the membrane of late endosomes, with both its N- and
C-termini projecting into the cytoplasm. Alpy has speculated there is a sequential
transfer of cholesterol from the MENTAL domain of MENTHO to the MENTAL
domain of StARD3, to the START domain of StARD3, and finally to an acceptor
membrane or protein (Alpy and Tomasetto, 2006).
The function of StARD3 in vivo is not yet fully understood. StARD3 was
originally identified as a gene over-expressed in breast cancer (Tomasetto et al.,
1995), and was also recently found to be over-expressed in gastric, prostate, and
esophageal cancers. One theory posits that it might play a role in tumorogenesis
by increasing intra-tumoral steroidogenesis. Alternatively, over-expression of
StARD3 in tumors might be attributable to tumoral amplification of a neighboring
oncogene c-erb-B2 (her-2/neu) (Bièche et al., 1996; Dressman et al., 2003; Hyman
et al., 2002; Kauraniemi et al., 2001; Pollack et al., 2002; Tomasetto et al., 1995)
In vitro, the isolated StARD3 START domain is capable of binding and
transferring cholesterol to liposomes and mitochondria. It has been suggested that
in tissues not expressing StAR, such as placenta and brain, StARD3 might play a
role in steroid hormone synthesis (Tuckey et al., 2002; Watari et al., 1997).
However, the mechanism is not straight forward, since as shown for placenta full
length StARD3 is localized to late endosomes, presumably tethered by its N-
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terminal membrane spanning domains. Moreover, in cell culture full length StARD3
is not capable of increasing steroidogenic activity (Watari et al., 1997). However,
in placenta antibodies to the StARD3 START domain detect not only the full length
protein, but smaller bands. These are presumably proteolysis products that contain
the START domain but have lost some or all of the N-terminal region membrane
spanning domains. Thus it is possible that in late endosomes cholesterol is
transferred to intact StARD3, followed by proteolytic separation of the START
domain allowing cholesterol transfer to mitochondria for steroidogenesis. In cell
culture, while the full length StARD3 has no steroidogenic activity, mutant StARD3
containing only the START domain promotes steroidogenesis (Watari et al., 1997).
A competing theory posits that physiologically StARD3 may be involved in
the movement of cholesterol from late endosomes to lysosomes and then to the
plasma membrane, rather than to mitochondria or the ER. Evidence for this comes
from studies in primary rat hepatocytes, where over-expression of StARD3 causes
only a modest increase in the rate of bile acid synthesis, in contrast to the large
increase in bile acid synthesis observed when over-expressing the mitochondrial
sterol transporter StAR or the enzyme that catalyzes the rate-limiting step in the
conversion of cholesterol to bile acids, CYP7A1 (Ren et al., 2004a). The overexpression of StARD3 along with either StAR or CYP7A1 actually inhibits StAR or
CYP7A1 up-regulation of bile acid synthesis, suggesting that StARD3 actually
sequesters cholesterol, rather than transports cholesterol to the mitochondria or
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the ER, where the bile acid synthetic enzymes CYP27A1 and CYP7A1,
respectively, reside(Ren et al., 2004a).
In vivo adenoviral mediated over-expression of StARD3 in mice, which
occurs mainly in liver, was hepatotoxic. Moreover, StARD3 over-expression both
in mouse liver and in CHO cells was shown to cause apoptosis (Tichauer et al.,
2007). The adenoviral studies also showed over-expression of StARD3 leads to
increased biliary bile acid concentration and increased liver cholesterol, mainly free
cholesterol (Tichauer et al., 2007).
Since in late endosomes StARD3 co-localizes with NPC1; Strauss has
hypothesized that NPC2, NPC1, and StARD3 act sequentially to sense cholesterol
and move it to an acceptor protein or membrane (Strauss et al., 2002). Consistent
with this hypothesis, studies tracking GFP-tagged StARD3 and StARD3 mutants
reveal that the N-terminal domain mediates endocytosis of StARD3 from the plasma
membrane to the late endosomes and that StARD3 colocalizes and traffics in the
same dynamic late endosomal tubules as NPC1 (Zhang et al., 2002). Further
research has demonstrated that that the START domain of StARD3 participates in
intracellular sterol transport, moving lysosomal cholesterol; a truncated StARD3
without the START domain acts as a dominant negative mutant, causing extensive
cholesterol accumulation in the lysosomes of CHO cells and COS-7 cells, inhibition
of late endosomal tubular trafficking, and the failure of the use of lysosomal
cholesterol in mitochondria steroidogenesis, similar to the NPC phenotype (Zhang
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et al., 2002). However, to date, no StARD3 mutations have been reported in
Nieman Pick C disease. Furthermore, mice lacking the StARD3 START domain
were normal and did not suffer from an NPC-like disorder (Kishida, 2004). These
knockout mice were viable, neurologically intact, and fertile; they had no significant
changes in plasma lipid levels or liver lipid content and distribution, and showed
only moderate changes in cellular sterol metabolism. These results imply that
StARD3 in mice is dispensable for sterol metabolism and steroidogenesis, thereby
calling into question the importance of StARD3 in whole body cholesterol
homeostasis (Kishida, 2004).
Recent research has indicated that the main function of StARD3 may be in
modulating the interaction of late endosomes and actin, rather than functioning in
cellular sterol balance (Hölttä-Vuori et al., 2005). StARD3 depletion in cell culture
causes a similar phenotype to actin disruption, impairing clustering and fusion of
late endocytic organelles, scattering late endocytic organelles, and delaying cargo
degradation (Hölttä-Vuori et al., 2005). Meanwhile, over-expression of StARD3
leads to an enhanced formation of actin patches on the organelles harboring
StARD3 (Hölttä-Vuori et al., 2005).
The PCTP Subfamily
The genes in this subfamily are not as closely related as the genes in the
other subfamilies, since they do not share the same common exonic organization
or homology outside their START domain and also appear to bind different lipids.
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StARD2/PCTP
StARD2, also known as phosphatidylcholine transfer protein (PCTP) is a
highly specific intracellular lipid binding protein which, through its START domain,
binds exclusively to phosphatidylcholine in a 1:1 stoichiometric manner (Kanno et
al., 2007b; Roderick et al., 2002). The crystal structure of StARD2 in complex with
a phoshatidylcholine (PC) reveals a unique hydrophobic lipid-binding tunnel,
consistent with a START domain able to accommodate a single molecule of PC
(Roderick et al., 2002). However, it appears that a major conformational change in
StARD2 is needed to allow PC to enter and exit the lipid tunnel of StARD2. In vivo
and in vitro results differ on the exact type of phosphatidylcholine bound to StARD2,
with in vitro studies pointing to specific binding to an sn-1 palmitoyl and an sn-2
unsaturated acyl chain, and in vivo studies pointing to specific binding to an sn-1
stearoyl and sn-2 polyunsaturated chain (Kanno et al., 2007a; Wirtz, 1991). StARD2
is thought to promote the transfer of phosphatidylcholine from its site of synthesis
in the ER to the plasma membrane and the mitochondria.
StARD2 is highly expressed in liver, placenta, testis, kidney, and
macrophages. Radioimmunoassay and photo-bleaching studies indicate that
PCTP is highly mobile in the cytoplasm, but is also present in the nucleus and
associates with the mitochondria (de Brouwer et al., 2002). In mice StARD2
expression is increased by fibrates through activation of the trancription factor
PPARalpha and by adenoviral over-expression of the transcription factor
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PPARgamma. Since the nuclear hormone receptor PPAR transcription factors play
a role in controlling lipid and glucose metabolism, these experiments suggest that
StARD2 might also be involved in these processes (de Brouwer et al., 2002).
The precise physiological role of StARD2 is still under investigation. Many
of the proposed functions of StARD2 were found to be normal in StARD2 knockout
mice, including hepatocellular selection and secretion of biliary phospholipids,
production of lung surfactant (the major lipid being PC), and leukotriene
biosynthesis (van Helvoort et al., 1999). Cohen and colleagues have extensively
studied StARD2 knockout mice fed either a chow or a lithogenic diet, (Baez et al.,
2005; Scapa et al., 2008; Wang et al., 2006; Wu and Cohen, 2005a, b; Wu et al.,
2005). On a chow diet, the knockouts had normal biliary phospholipids secretion
and composition. However, on a lithogenic diet, which increases biliary secretion
rates of bile salts, phospholipids, and cholesterol, the knockouts had impaired biliary
secretion of all three, yet maintained normal hepatocellular selection and secretion
of phosphatidylcholine (Wu et al., 2005). The livers of StARD2 knockouts fed a
chow diet exhibited increased esterified cholesterol and ACAT activity, and
decreased free cholesterol and phospholipids. However, the livers of these mice
on a lithogenic diet failed to show up-regulation of ACAT, resulting in an increased
free cholesterol-to-phospholipid ratio (Wu and Cohen, 2005a; Wu et al., 2005). The
knockouts on a chow diet showed accumulation of small alpha-migrating HDL
particles in plasma, whereas those on a lithogenic diet had increased plasma
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cholesterol and phospholipid levels (Wu and Cohen, 2005b). Cholesterol ester
loaded macrophages from these knockouts exhibited decreased ABCA1 expression
and decreased efflux of phospholipids and cholesterol to apoA-I (Baez et al., 2005).
Compatible with this observation, over-expression of StARD2 in cell culture
accelerates apolipoprotein A-I-mediated efflux of phospholipid and cholesterol as
pre-beta-HDL particles (Baez et al., 2002). Thus StARD2 appears to play a role in
vivo in biliary lipid secretion, hepatic cholesterol metabolism in response to a
lithogenic diet, as well as HDL metabolism.
StARD2 was hypothesized to serve an atheroprotective function. StARD2ʼs
role in atherosclerosis was studied by breeding the StARD2 knockout trait on to
the ApoE knockout background.

Compared to ApoE knockouts, the double

knockout male mice had a slight increase in atherosclerosis at 4 months of age
accompanied by increased cholesterol levels; however, at 6 months of age both
male and female mice had a slight reduction in atherosclerosis, which in the male
mice was accompanied by a decrease in plasma cholesterol levels (Wang et al.,
2006). Compared to wild-type mice, free cholesterol loading of macrophages from
StARD2 knockout mice causes markedly increased apoptotic cell death (Baez et
al., 2005).
Recent studies from Cohen and colleagues also indicate that StARD2
knockout mice show increased hepatic insulin sensitivity and reduced hepatic
glucose production, suggesting a role for StARD2 in regulating energy metabolism
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(Scapa et al., 2008). In a quantitative trait locus (QTL) study from the Quebec
Family Study (QFS), StARD2 gene variants were found to be associated with LDL
peak particle size (LDL-PPD), a trait often associated with the Metabolic Syndrome
(Dolley et al., 2007).
StARD7/GTT1
StARD7 (gestation trophoblastic tumor 1 (GTT1), was identified by its overexpression in choriocarcinoma cell lines compared to cell lines derived from normal
trophoblastic tissue and nonmalignant hydatidiform moles (Durand et al., 2004).
Computer mediated homology search of the primary amino acid sequence of
StARD7 revealed homology to StARD2 in its conserved START domain. However,
the precise lipid binding specificity of StARD7 is unknown. Expression patterns of
StARD7 in normal tissues is unknown. StARD7 is expressed in several cancerderived cell lines, and it was suggested it might play a role in phospholipid-mediated
signaling in tumors (Durand et al., 2004). No functional studies of StARD7.have
appeared in the literature.
StARD10/PCTP-like
StARD10 (PCTP-like) was also identified as a protein over-expressed in
breast cancers, and appears to cooperate with ErbB, a member of the epidermal
growth factor (EGF) receptor family and of the receptor tyrosine kinase family (Alpy
and Tomasetto, 2005; Olayioye et al., 2004; Olayioye et al., 2005). Through
electron spin resonance measurement, StARD10 was shown to interact with
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phosphatidylcholine (PC) and phosphatidylethanolamine (PE); mass spectrometry
revealed a preferential selection for lipids containing a palmitoyl or stearoyl chain
in the sn-1 position and an unsaturated fatty acyl chain (18:1 or 18:2) in the sn-2
position (Olayioye et al., 2005). In vitro studies suggest that StARD10 is capable
of transferring PC and PE between membranes.
The StARD10 gene is expressed in several tissues and the regulation of its
expression as well as the cellular location of the protein suggests it participates in
many physiological processes relating to phospholipid metabolism. In germ cells
of the testis the StARD10 protein is found in the sperm flagellum, implying a role in
sperm energy metabolism (Olayioye et al., 2004; Olayioye et al., 2005). In
mammary glands, StARD10 expression increased in late pregnancy and lactation,
implying a role in phospholipid enrichment of milk. Expression in the liver implies
a role in delivery of phospholipids to the canalicular membrane for biliary excretion.
StARD10 is also expressed in the kidney and intestine, as well as many tumor cell
lines. Olayioye hypothesizes that StARD10 over-expression in tumors may by
replenishing membrane PC and PE activating specific phospholipases, thereby
contributing to aberrant lipid signaling and cellular transformation (Olayioye et al.,
2005).
StARD11/CERT
There are two StARD11 transcripts: one encodes a long isoform, the
Goodpasture antigen-binding protein (GPBP) also known as the CERTL, and the
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other a more abundant short isoform, the ceramide transfer protein (CERT)
(Hanada et al., 2003; Raya et al., 2000). Both isoforms are expressed in striated
muscle and brain, but poorly expressed in placenta, lung and liver. The CERT form
is also highly expressed in kidney, pancreas, and a number of cancer cell lines.
StARD11 was originally described as a protein that binds and
phosphorylates serine residues in the non-collagenous C-terminal region of the a3
chain of collagen IV (Good-pasture antigen), which is involved in the dermatologic
autoimmune disease Goodpastureʼs Syndrome (Raya et al., 1999; Raya et al.,
2000). However, StARD11 lacks a protein kinase motif suggesting this may be an
indirect effect due to an associated kinase.
Both isoforms of StARD11 have ceramide transport activity in vitro and in
vivo, thereby leading to the hypothesis that StARD11 is responsible for the delivery
of ceramide from the ER where it is synthesized to the Golgi where conversion to
sphingomyelin (SM), a major plasma membrane component, takes place (Hanada
et al., 2007; Hanada et al., 2003). Studies of GFP-tagged StARD11 indicate both
cytosolic localization as well as enrichment in the Golgi. The N-terminus of
StARD11 contains a phosphoinositide binding pleckstrin homology (PH) domain
that recognizes the Golgi-associated phosphatidylinositol 4-phosphate (PtdIns 4phosphate), and this interaction may be responsible for Golgi targeting. The
N-terminus also contains an FFAT motif that recognizes and binds the ER integral
membrane protein VAMP-associated protein (VAP), and this may be responsible
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for ER targeting (Levine and Munro, 2002; Loewen et al., 2003). Mutations in either
the PH domain of the FFAT motif impair ER-to-Golgi ceramide transport. RNAi
knockdown of VAP decreases SM synthesis, presumably by preventing the proper
loading of ceramides onto StARD11 (Perry and Ridgway, 2006). The N-terminus
also contains a serine-rich motif and a coiled-coil region (Hanada et al., 2007). The
C-terminus of StARD11 contains a ceramide binding START domain. StARD11
binds ceramides in a 1:1 molar ratio and efficiently transfers various types of
naturally occurring ceramides with C(14), C(16), C(18), and C(20) chains, but not
longer acyl chains (Kumagai et al., 2005). StARD11 also mediates efficient transfer
of C(16)-dihydroceramide and C(16)-phyto-ceramide.

The crystal structure

confirms that StARD11 can distinguish ceramide from other lipid types, yet still can
recognize multiple species of ceramides (Kudo et al., 2008).
In cell culture, deletion mutants reveal that only the START domain of
StARD11 mediates the specific exchange of ceramide from donor to acceptor
membranes. Knocking down StARD11 via RNAi in C6 glioma cells showed a
significant but not complete reduction of SM synthesis (Giussani et al., 2008).
Furthermore, in a CHO-K1 cell line where StARD11 is mutated, there is diminished
ABCG-1 mediated cholesterol and SM efflux, and in CHO-K1 cells over-expressing
StARD11, there is enhanced ABCG1 mediated cholesterol and SM efflux (Nagao
et al., 2007; Sano et al., 2007).
Loss of StARD11 appears to be lethal to cells and organisms.
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UVB

irradiation of keratinocytes induces the rapid formation of a stable, but inactive
StARD11 homotrimer complex, leading to accumulation of cellular ceramides and
a reduction in sphingomyelin synthesis. This increase in cellular ceramide causes
what is known as UVB irradiation-induced apoptosis in cultured human
keratinocytes (Charruyer et al., 2008). Inactivation of StARD11 in keratinocytes by
chemical means also increases apoptosis. Knocking out the StARD11 homologue
in Drosophila melanogaster causes premature death, reduced thermal tolerance,
reduced ATP, increased glucose levels, and a reduction in the sphingomyelin
analog, ceramide phosphoethanolamine, which leads to increased plasma
membrane fluidity and heightened susceptibility to damage by ROS (Rao et al.,
2007).
StARD11 activity can be regulated in several ways. Phosphorylation of the
serine-repeat motif of StARD11 down-regulates the ER-to-Golgi transport of
ceramides, by inducing an inhibitory interaction between the PH and START
domains. This inactivates both ceramide transfer activity and the ability of StARD11
to bind phosphoinositides. The ensuing decrease in cellular sphingomyelin and
accompanying cholesterol are hypothesized to cause changes in SM/cholesterol
rafts, which then leads to the dephosphorylation of the serine-repeat motif of
StARD11, thereby resulting in reactivation of StARD11 (Kumagai et al., 2007).
StARD11 can also be dephosphorylated by protein phosphatase 2Cepsilon
(PP2Cepsilon), which negatively regulates the stress-activated protein kinase
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pathways (Saito et al., 2008). PP2Cepsilon dephosphorylation of StARD11 allows
it carry out ceramide transport to the Golgi.

Over-expression of PP2Cepsilon

enhances the association between StARD11 and VAP, while RNAi knock down of
PP2Cepsilon attenuates this interaction and decreases sphingomyelin synthesis
(Saito et al., 2008). Another enzyme that can regulate StARD11 is PI 4-kinase
beta. RNAi knock down of this enzyme decreases StARD11 mediated ceramide
transport to the Golgi (Tóth et al., 2006). Finally, RNAi knock-down of OSBP
decreases StARD11 activity and SM synthesis, suggesting that OSBP might
interact directly or indirectly with shared binding partners of StARD11 at the Golgi
and/or the ER (Perry and Ridgway, 2005, 2006).
The RhoGap Subfamily
Each member of this subfamily contains a Rho GTPase activating protein
(RhoGAP) domain, which appear to act as tumor suppressors. RhoGAPs are
negative regulators of members of the Ras super-family, by stimulating the intrinsic
GTPase activity of the Rho family of small GTPases. The Rho family of small
GTPases control cell growth, morphogenesis, cell motility, cytokinesis, trafficking,
and organization of the cellular cytoskeleton, as well as are involved in malignant
transformation and metastasis of tumors (Moon and Zheng, 2003). In addition to
the RhoGAP and START domains, each family member also contains an N-terminal
sterile alpha motif (SAM), a putative protein interaction domain that can also interact
with RNA and lipids (Kim and Bowie, 2003). To date, studies of these genes have
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mainly focused on their RhoGAP domains.
StARD12/DLC-1
StARD12, also known as the deleted in liver cancer 1 (DLC-1) or the p122RhoGAP gene, was identified as tumor suppressor gene, that is decreased in
expression, and often entirely deleted, in liver, breast, colon, and prostate cancers
(Kim et al., 2003b; Ng et al., 2000; Plaumann et al., 2003; Teramoto et al., 2004;
Wong et al., 2003; Yuan et al., 2003a; Yuan et al., 2004; Yuan et al., 1998; Yuan et
al., 2003b; Zheng et al., 2003; Zhou et al., 2004b). Further evidence of StARD12ʼs
role as a tumor suppressor comes from a study in which adenoviral expression of
StARD12 inhibited the proliferation, invasiveness, and anchorage-independent
growth of PC-3 and C4-2-B2 cells in vitro by inducing cell-cycle arrest. StARD12
has also been shown to inhibit tumorogenicity of PC-3 cells in nude mice (Guan et
al., 2008).
StARD12 appears to have a dual function. First, StARD12 interacts with the
enzyme phospholipase C delta1 (PLC-delta1) activating phosphatidylinositol 4,5bisphosphate (PIP2) hydrolyzing activity, which causes a rapid elevation of
intracellular Ca2+ levels (Homma and Emori, 1995). Second, StARD12 possesses
RhoGAP activity specific for RhoA, enhancing the conversion of RhoA from its GTPbound active state to GDP-bound inactive state (Homma and Emori, 1995).
Over-expression of StARD12 induces the disassembly of stress fibers and
reorganization of the actin cytoskeleton and focal adhesions, causing the
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morphological rounding of various adherent cells (Sekimata et al., 1999).
Meanwhile, cells mutant in the GAP domain of StARD12 fail to undergo these
morphological changes. Studies of GFP-tagged StARD12 localize the protein to
punctate structures at the plasma membrane, in particular to caveolae, where
StARD12 interacts with caveolin-1 (Yamaga et al., 2007; Yamaga et al., 2004). The
GAP domain of StARD12 is sufficient for this localization; cholesterol content of the
membranes also affects this proteinʼs localization (Kawai et al., 2004; Yamaga et
al., 2007; Yamaga et al., 2004).
Mice homozygous for the StARD12 knockout trait undergo embryonic
lethality after embryonic day 10.5, with defects in neural tube, brain, heart, and
placenta (Durkin et al., 2005). Mice heterozygous for the StARD12 knockout are
phenotypically normal. Consistent with a putative role for StARD12 in the
cytoskeleton, cultured embryonic fibroblasts from the homozygous knockout
embryos display alterations in the organization of actin filaments and focal
adhesions (Durkin et al., 2005).
StARD13/DLC-2
StARD13, also known as the deleted in liver cancer 2 (DLC-2) gene, was
identified as a tumor suppressor gene that is decreased in expression and often
absent or deleted in hepatocellular carcinomas (Ching et al., 2003; Leung et al.,
2005). Recent studies have shown a decrease in StARD13 expression in other
solid tumors, including lung, ovarian, renal, breast, uterine, gastric, colon and rectal
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tumors. StARD13 encodes a RhoGAP specific for RhoA and Cdc42 and to some
extent Rac1 (Ching et al., 2003; Nagaraja and Kandpal, 2004). StARD13 exists in
four isoforms. Initial studies localized StARD13 to the cytoplasm; however, recent
studies indicate that it also localizes to mitochondria and lipid droplets (Ng et al.,
2006).
In mouse fibroblast cell culture, over-expression of StARD13 causes a
marked suppression in cell proliferation, motility, and transformation, as well as in
RhoA activity (Leung et al., 2005). Over-expression changes the morphology of
the cells and inhibits Rho-mediated formation of actin stress fibers and suppresses
lysophosphatidic acid-induced stress fiber formation (Leung et al., 2005). Overexpression also inhibits Ras signaling and Ras-induced cellular transformation.
RNAi knock down of StARD13 results in cells with increased levels of active GTPbound

RhoA

and

reduced

C(2)-ceramide

induction

of

mitochondrial

phosphatidylglycerolphosphate (PGP) synthase activity (Hatch et al., 2008).
StARD8/DLC-3
StARD8, also known as the deleted in liver cancer 3 (DLC-3) gene, was
identified as tumor suppressor gene (Durkin et al., 2007a; Durkin et al., 2007b;
Katoh and Katoh, 2004). It is widely expressed in normal tissues, and there is a
decrease or total loss of expression of StARD8 in various cancer cell lines as well
as

in

kidney,

lung,

ovarian,

uterine,

prostate,

and

breast

cancers.

Immunohistochemistry studies reveal that StARD8 localizes intra-cellularly to focal
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adhesions (Kawai et al., 2007). StARD8 has two isoforms, alpha, which is highly
similar in structure to STARD12 and 13, and beta, which lacks the N-terminal SAM
domain. As with other members of this subfamily, StARD8 stimulates PLCdelta1
and has RhoGAP activity for RhoA and Cdc42 (Durkin et al., 2007a). Consistent
with a role as a tumor suppressor, transfection of breast and prostate cancer cells
with StARD8alpha inhibits cell proliferation, colony formation and growth in soft
agar (Durkin et al., 2007a; Kawai et al., 2007).
The Acyl-CoA Thioesterase Subfamily
Both genes in this subfamily contain two N-terminal acyl hydrolase domains
as well as a C-terminal START domain (Alpy and Tomasetto, 2005).
StARD14/BFIT
StARD14, also known as brown fat-inducible thioesterase (BFIT), acyl-coA
thioester hydrolase 11 (ACOT11), or thioesterase adipose-associated (THEA),
appears to play a role in energy metabolism and obesity (Adams et al., 2001).
Humans have two splice variants, which differ in their C-terminus and therefore
have slightly different START domains. However, mice only have one isoform.
Consistent with its thioesterase domain structure, recombinant StARD14 protein
displays hydrolytic acyl-CoA thioester cleavage activity towards medium- (C12) and
long-chain (C14) fatty acyl substrates, and may play a role in altering intracellular
fatty acyl-CoA concentrations (Adams et al., 2001).
The StARD14 gene localizes to a QTL region for the dietary-obese 1(Do1)
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trait; causing Adams and colleagues to speculate this might be the culprit gene at
this locus responsible for body weight regulation in response to a high fat diet
(Adams et al., 2001). Consistent with this hypothesis is the observation that
expression of StARD14 is induced in brown adipose tissue (BAT) in cold challenged
mice, but repressed in BAT of mice at warm temperatures. Also consistent are the
observations that StARD14 is more highly expressed in BAT of obesity-resistant
compared to obesity-prone mice fed high fat diets, and StARD14 expression is
increased in the BAT of control lean mice compared to obese ob/ob mice (Adams
et al., 2001).
StARD15/CACH
StARD15, also known as cytosolic acetyl CoA hydrolase (CACH) or acylCoA thioesterase 12 (ACOT12), has a hydrolase activity for acetyl-CoA and short
chain (C4 and C6) acyl-CoAs, and therefore, may act to maintain the equilibrium
between concentrations of cytosolic acetyl-CoA and the coenzyme A-SH (CoASH).
Through maintaining this equilibrium, StARD15 may therefore function in fatty acid
and cholesterol metabolism (Suematsu and Isohashi, 2006; Suematsu et al., 2001).
StARD15 is enzymatically active only when the protein homodimerizes or
tetramerizes and binds ATP, whereas when bound to ADP activity is inhibited
(Isohashi et al., 1983a, b). StARD15 mRNA is found in liver, spleen, muscle, and
testes, but its enzymatic activity has been only detected in liver and kidney. The
activity of StARD15 appears to be regulated in several metabolic states. Activity
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of the enzyme increases in rats that were starved, fed a fat-free high carbohydrate
diet, fed a high cholesterol diet (reducing de novo hepatic cholesterol synthesis),
treated with cholesterol synthesis inhibitors, treated with PPARalpha agonists, fed
a diet with thyroid powder, containing T3 to stimulate hyperthyroidism, or treated
with streptozotocin to induce insulin deficient diabetes (Ebisuno et al., 1988;
Matsunaga et al., 1985; Nakanishi et al., 1985).
The StARD9 Protein
Very little is known about StARD9, except that the gene contains 11 exons
and encodes an 1820 amino acid protein with a C-terminal START domain but no
other recognizable domains (Halama et al., 2006). StARD9 exists in a full-length
form and an exon 8 deleted form. It is highly expressed in muscle and nervous
tissues. StARD9 maps to a region of the genome linked to limb-girdle muscular
dystrophy type 2A (LGMD2A), an autosomal recessive form of limb-girdle muscular
dystrophy, and StARD9 has been speculated to play a role in this disease (Halama
et al., 2006).
The StARD4 Subfamily
Members of this subfamily contain only a START domain and share
approximately 30% homology (Soccio et al., 2002; Soccio and Breslow, 2003).
StARD4
StARD4 was originally identified in a microarray study as a gene downregulated in the liver by feeding mice a high cholesterol diet (Soccio et al., 2002;
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Soccio and Breslow, 2003). StARD4 was shown to be transcriptionally up-regulated
by SREBP2 and to have an active sterol response element (SREs) in its promoter.
StARD4 can also be up-regulated by ER stress through the transcription factor
ATF6 (Yamada et al., 2006). StARD4 also has an ERSE-like element in its
promoter (Soccio et al., 2005; Soccio et al., 2002; Yamada et al., 2006).
StARD4 may play an important role as a cholesterol transporter in
maintaining cellular cholesterol homeostasis. StARD4 was shown to bind
cholesterol, and increased expression of StARD4 in primary mouse hepatocytes
leads to a marked increase in intracellular cholesterol esters and in the rate of bile
acid synthesis (Rodriguez-Agudo et al., 2008; Romanowski et al., 2002). Forced
expression of StARD4 in cell culture stimulates steroidogenesis by P450scc and
liver X receptor reporter gene activity (Soccio et al., 2005; Soccio et al., 2002).
Miller speculated that StARD4 might aid in transferring cholesterol to the OMM,
where StAR can then transfer cholesterol to the IMM for steroid biosynthesis (Miller,
2007c). To understand the physiological role of StARD4, knockout mice were
developed, and this thesis will describe the design and development of a StARD4
knockout mouse.
StARD5
StarD5 was shown to selectively bind cholesterol and the potent regulatory
oxysterol, 25-hydroxycholesterol (Rodriguez-Agudo et al., 2006; Rodriguez-Agudo
et al., 2005). In human liver initial studies found StARD5 to be in the cytosolic
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fraction. Further studies indicated StARD5 co-localized with CD68 in Kupffer cells,
but not in parenchymal cells (Rodriguez-Agudo et al., 2006). StARD5 was also
shown to be expressed in monocytes, macrophages, mast cells, basophils, and
pro-myelocytic cells, but not in human hepatocytes, endothelial cells, fibroblasts,
osteocytes, astrocytes, or brain tissue. Cell fractionation and immunocytochemical
studies with THP-1 macrophages localized StARD5 to the cytosol and supported
an association with the Golgi (Rodriguez-Agudo et al., 2006).
StARD5 expression is not down-regulated by cholesterol via SREBPs, nor
is it up-regulated by oxy-cholesterol derivatives via liver X receptors (LXRs).
Instead, StARD5 expression is increased by the ER stress response. This has
been observed in free cholesterol-loaded macrophages, or in NIH-3T3 cells treated
with ER stressors (Soccio et al., 2005). Co-transfection of StARD5 and P450scc
expression vectors into Cos-1 cells stimulated steroidogenesis, and co-transfection
of a StARD5 expression vector along with an LXR promoter-reporter vector into
Cos-1 cells augmented reporter expression (Soccio et al., 2005). Furthermore,
transfection of a StARD5 expression vector in primary hepatocytes caused a
marked increase in microsomal free cholesterol (Rodriguez-Agudo et al., 2006;
Rodriguez-Agudo et al., 2005). These experiments suggest StARD5 can move
cholesterol within cells, but do not reveal its specific physiological function. This
thesis will undertake to understand the physiological role of StARD5 by several
methods, including the development and characterization of StARD5 transgenic
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and knockout mice.
StARD6
Initial studies found StARD6 expressed only in male germ cells as they
matured during spermatogenesis. It was speculated that StARD6 regulated sterol
movement within sperm as they matured (Gomes et al., 2005; Soccio and Breslow,
2003). However, recent studies have found StARD6 expression in the rat nervous
system in cerebral cortex (layers V and VI), hippocampus, substantia gelatinosa
of the spinal cord, suggesting a possible role for StARD6 in sterol transport or
sensing in the nervous system (Chang et al., 2007).
Table 1.1 START Domain Proteins
Common
Alternative
Name
STAR Subfamily

Gene
Name

StARD1

STAR

StARD3

MLN64

Mouse
Knockout
Phenotype

Lipid
Specificity

Possible/Suggested Function

transport cholesterol from the
OMM to the IMM; rate-limiting
Cholesterol
step in steroidogenesis; aids
cholesterol to pregnenolone
Normal viability and fertility
mobilize cholesterol from
Cholesterol endosomes/lysosomes; modulate
No obvious phenotype
actin-endosome interaction
congenital lipoid adrenal
hyperplasia (lipoid CAH)

RhoGAP Subfamily

StARD12

DLC-1

StARD13

DLC-2

StARD8

DLC-3

tumor suppressor
posseses GAP activity
embryonic lethal after e10.5 day
with defects in the neural tube, Unknown modifies PLC-delta1 activity
reorganize actin cytoskeleton and
brain, heart, and placenta
focal adhesions
tumor suppressor
posseses GAP activity
modifies PLC-delta1 activity
None Available
Unknown
mediates ceramide activation of
phosphatidylglycerolphosphate
synthase
tumor suppressor
None Available
Unknown posseses GAP activity
modifies PLC-delta1 activity
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Table 1.1 START Domain Proteins (continued)
Common
Alternative
Name
PCTP Subfamily

Gene
Name

StARD2

StARD7

PCTP

GTT1

StARD10 PCTP-2

Mouse
Knockout
Phenotype

Lipid
Specificity

Decrease efflux to ApoAI
Increase macrophage apoptosis
Modulate atherosclerosis
Increase hepatic insulin
sensitivity, Increase hepatic
cholesterol ester, Alter hepatic
FC-phospolipid ratio
Impaired biliary lipid secretion
None available

None Available

None Available
GPBP

acyl CoA Thioesterase Subfamily
ACOT11
None Available
StARD14 THEA
BFIT
ACOT12
StARD15
None Available
CACH
StARD9 Subfamily
StARD9
StARD4 Subfamily
StARD4

StARD5

StARD6

promote the intermembrane
transfer of phosphatidylcholine
(PC) from the site of synthesis
(ER) to the PM and mitochondria

role in the phospholipid-mediated
signalling; mediates transplacental
Unknown
lipid transport;
role in syncytialization
transfers phosphatidyl-choline(PC)
and ethanolamine (PE) between
PC, PE membranes; cooperates with the
ErbB family of receptor tyrosine
kinases
associated with Goodpasture's
non-vesicular ceramide-carrier
Ceramides
protein aiding sphingomyelin
synthesis

CERT
StARD11

PC

Possible/Suggested Function

energy metabolism and obesity,
Unknown alter intracellular fatty acyl-CoA
concentration
maintain equilibrium between
Unknown concentrationsof cytosolic acetylCoA and the coenzyme A-SH

None Available

Unknown role in modifying LGMD2A

SREBP and ER Stress target gene
Cholesterol stimulates steroidogenesis
directional cholesterol transporter
ER Stress target gene
Cholesterol
stimulates steroidogenesis
embryonic lethal before e9.5
25OH- directional cholesterol transporter
cholesterol role in embryogenesis
lipid sensing in germ cells
None Available
Unknown
lipid sensing of the nervous sytsem
preliminary: viable
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A Disintegrin and Metalloprotease (ADAM) Family
Amongst the dietary cholesterol responsive genes in the liver was ADAM11.
This gene was up-regulated by dietary cholesterol, and encodes a trans-membrane
protein that bears no relationship to the START-domain family of proteins. This
thesis also includes experiments to determine the physiological function(s) of
ADAM11. This section will review the background information on ADAM11 and the
ADAM gene family.
ADAM Family
A disintegrin and metalloproteinase (ADAM) proteins are multi-domain, type
I transmembrane proteins. They possess an N-terminal pro-peptide domain, a
metalloprotease domain, a disintegrin domain, a cysteine-rich region, an epidermal
growth factor (EGF)-like sequence, a trans-membrane domain, and a C-terminal
cytoplasmic tail (Seals and Courtneidge, 2003). Previous literature referred to this
family as the MDC family, indicating the presence of Metalloprotease, Disintegrin,
and Cysteine-rich domains. The ADAMs belong to the metzincin super-family,
which also includes ADAMs with Thrombospondin motifs (ADAM-TS), Matrix
Metalloproteinases (MMP), Serralysins, Leishmanolysins, and Snapalysin. In this
super-family only the ADAMs and ADAM-TSs contain an integrin-binding
(disintegrin) domain. Individual ADAM family members are regulators of cell-cell
and cell-matrix interactions, as well as processors of growth factors, cytokines, and
receptors (Seals and Courtneidge, 2003).
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To date, approximately 40 members of the ADAM family have been reported.
ADAMs have been identified in Schizosaccharomyces pombe, Caenorhabditis
elegans, Drosophila, Xenopus, and in vertebrates, but not in Escherichia coli,
Saccharomyces cerevisiae or plants (Seals and Courtneidge, 2003). It was recently
shown that ADAM18 and ADAM27 are the same gene and likewise for ADAM21
and ADAM31, leaving 38 novel ADAM family members. Of these ADAMs 13, 14,
16, and 35 are not expressed in mammals. The remaining 34 ADAMs are
expressed, but only 25 are expressed in humans.
Although all ADAMs contain a metalloprotease domain, only two-thirds of
these have an active or predicted active catalytic domain, represented by the
conserved sequence HEXGHXXGXXHD; (ADAMs 1, 8, 9, 10, 12, 13, 15, 16, 17,
19, 20, 21, 24, 25, 26, 28, 30, 33-40). The remaining ADAMs have one or more
residues in this sequence incompatible with protease activity. The 34 mammalian
ADAMs can be divided into four groups based on their expression patterns and
whether or not they have or are predicted to have catalytic activity. Nineteen
ADAMs are exclusively or predominantly expressed in the testis; of these 11 are
catalytically active ADAMs 20, 24, 25, 26, 30, 34, 36-40, and 8 catalytically inactive
ADAMs 2, 3, 4, 5, 6, 18, 29, 32.

The remaining 15 ADAMs have somatic

expression; of these 11 are catalytically active ADAMs 1, 8, 9, 10, 12, 15, 17, 19,
21, 28, 33, and 4 catalytically inactive ADAMs 7, 11, 22, 23. Although this review
categorizes ADAMs 2, 3, 4, 5, 21 as exclusively or predominantly expressed in the
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testis, these ADAMs are also expressed in the nervous system (Yang, 2006).
Humans and mice express 25 and 34 ADAMs, respectively, and the difference is in
the number of testis-specific catalytically active ADAMs expressed in mice and not
in humans, including ADAMs 24, 25, 26, 34, 36-40).
A web site maintained by Judith White at the University of Virginia contains
the up-to-date list of all ADAMs:
(http://www.people.virginia.edu/~jw7g/Table_of_the_ADAMs.html
The Roles of the Multi-Domains of the ADAMs
The N-terminal region of ADAMs contains a pro-domain that acts as a
chaperone, directing ADAMs into the secretory pathway. This serves to allow
proper ADAM folding and maintains the protease domain in an inactive state. The
pro-domain of most ADAMs are thought to be cleaved by a furin-type pro-protein
convertase, although some like ADAM8 and ADAM28 may undergo autocatalytic
cleavage (Seals and Courtneidge, 2003; Blobel, 2005).
Twenty-two of 24 ADAMs possess a metalloprotease catalytic site in an
active configuration. The active metalloprotease sites contain zinc and water
molecules, which are necessary for the hydrolytic processing of protein substrates.
Some substrates for the catalytically active ADAMS are known. Tissue inhibitors
of metalloproteases (TIMPs) are endogenous regulators of MMPs, and these can
inhibit the metalloprotease catalytic activity of ADAMs as well (Seals and
Courtneidge, 2003; Blobel, 2005).
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The disintegrin domain is named due to its homology to short soluble
proteins in snake venom that bind and inhibit platelet integrins. Many of these
snake venom proteins contain an RGD consensus motif that form the disintegrin
loop and which bind integrins. Although only human ADAM15 has an RGD
sequence, the other ADAMs appear to have a generalized disintegrin loop
(CRX5CDX2EXC) or an ECD motif, which are also capable of binding integrins
(Seals and Courtneidge, 2003; Blobel, 2005).
The cysteine-rich domain and the EGF-like domains are poorly understood.
The cysteine-rich domain appears to play a role in assisting or determining
specificity of binding by the disintegrin domain. The EGF-like domain may mediate
signaling (Seals and Courtneidge, 2003; Blobel, 2005).
The trans-membrane domain anchors the protein to the cell, and most
ADAMs are found at the plasma membrane. The cytoplasmic tails of ADAMs are
highly variable both in length and sequence, often containing proline-rich SH3binding sites, and serine-threonine and tyrosine kinase phosphorylation sites.
Alternative splicing of ADAMs is common and as a result an ADAM can have
alternative cytoplasmic tails. These cytoplasmic tails might be involved in insideout regulation of metalloprotease activity, outside-in regulation of cell signaling,
regulation of ADAM expression and localization, and mediating protein-protein
interactions (Seals and Courtneidge, 2003; Blobel, 2005).
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The Functional Role of ADAMs:
Somatically Expressed, Catalytically Active ADAMs
To date, most studies have focused on the somatically expressed,
catalytically active ADAMs 1, 8, 9, 10, 12, 15, 17, 19, 21, 28, 33.
ADAM1, also known as fertilin alpha, is found in male germ cells as well as
in somatic tissues, such as the hippocampus (Evans et al., 1997; Kim et al., 2003a;
Nishimura et al., 2002). In mice there are two different isoforms, ADAM1a localizes
to the endoplasmic reticulum of testicular germ cells, and ADAM1b localizes to the
plasma membrane of epididymal sperm. Knockout of ADAM1a results in male
infertility due to severely impaired sperm migration from the uterus through the
uterotubal junction into the oviduct (Nishimura et al., 2004). In vitro, epididymal
sperm of ADAM1a-deficient mice are capable of fertilizing cumulus-intact, zona
pellucida-intact eggs. ADAM1a knockout mice appear normal in other respects,
suggesting ADAM1a does not play a significant somatic functional role. Knockout
of ADAM1b results in fertile mice with no significant defect in sperm migration or
egg penetration (Kim et al., 2006). Of unknown significance, sperm from ADAM1b
knockout mice show a severe reduction of ADAM2 on the epididymal sperm cell
surface, despite the normal presence of ADAM2 in testicular germ cells (Kim et al.,
2006).
ADAM8 is expressed in immune, neuronal, and bone progenitor cells and
has been implicated in a variety of processes, including tissue-remodeling (Ainola
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et al., 2008; Amour et al., 2002; Fourie et al., 2003; King et al., 2004; Matsuno et
al., 2006; Mochizuki and Okada, 2007; Sriraman et al., 2008; Valkovskaya et al.,
2007). ADAM8 is hormonally regulated by progesterone. The ADAM8 knockout
has normal viability and fertility with no obvious pathology (Kelly et al., 2005).
ADAM9, also known as meltrin gamma, is ubiquitously expressed and has
been implicated in cleaving the ecto-domain of heparin-binding epidermal growth
factor-like growth factor (HB-EGF) and cleaving by alpha secretase activity the
amyloid precursor protein (Seals and Courtneidge, 2003). The ADAM9 knockout
appears to be fertile, develop normally, and have no major pathological phenotype.
In the knockouts there is normal ectodomain shedding of HB-EGF implying another
protein performs this function in vivo either primarily or as a back-up to ADAM9
(Weskamp et al., 2002). Over-expression of ADAM9 in HT29 human colon cancer
cells results in growth factor-induced endocytosis, dynamic recycling of E-cadherin,
and prevention of E-cadherin degradation (Hirao et al., 2006).
ADAM10, also known as kuzbanian, can act on many type I and type II
single membrane-spanning proteins causing shedding of their ectodomians (Blobel,
2005). Such proteins include Notch, EGF receptor ligands, Ephrins, and amyloid
precursor protein. The ADAM10 knockout mice die in utero at embryonic day 9.5
as a result of multiple major defects in development of the central nervous system
and the cardiovascular system. The ADAM10 knockouts also have cadherin
processing defects and aberrant expression of Notch target genes (Hartmann et
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al., 2002).
ADAM12, also known as meltrin alpha, has been implicated in multiple
cellular processes, including cell differentiation, proliferation, migration, and
invasion. ADAM12 may act by cleaving IGF-binding proteins and in this manner
trigger insulin-like growth factor (IGF) receptor signaling. ADAM12 can also
cleaving the ectodomain of the epidermal growth factor receptor (EGFR) causing
shedding of membrane-tethered EGFR ligands and EGFR activation. Due to its
expression pattern during development, ADAM12 was thought to play a role in
myogenesis, adipogenesis, and organ development; however, ADAM12 knockout
mice have no recognizable muscle pathology (Kurisaki et al., 2003; Masaki et al.,
2005). ADAM12 knockout mice exhibit low penetrance perinatal lethality, brown
adipose tissue loss, and neck and inter-scapular muscle defects. ADAM12
knockouts mice are resistant to high-fat feeding induced weight gain perhaps
because they fail to increase the number of adipocytes (Kurisaki et al., 2003;
Masaki et al., 2005). Over-expression of ADAM12 increases muscle regeneration
and significantly reduces muscle loss in mdx, dystrophin deficient mice (Guo et al.,
2005).
ADAM15, also known as metargidin, is the only ADAM that possesses an
RGD integrin-binding sequence in the disintegrin loop and may play a role in
mediating inflammation and neovascularization (Seals and Courtneidge, 2003).
ADAM15 knockout mice have no major developmental defects or pathological
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phenotypes. However, they do exhibit a reduction in ischemia-induced retinal
neovascularization, choroidal neovascularization at rupture sites in Bruchʼs
membrane, and VEGF-induced subretinal neovascularization (Horiuchi et al.,
2003).
ADAM17, also known as tumor necrosis factor-alpha converting enzyme
(TACE), cleaves and mobilizes receptor-ligands that are initially synthesized as
membrane-tethered precursors, including TNFalpha, heparin-binding EGF,
TGFalpha, amyloid precursor protein, and many others (Blobel, 2005; Seals and
Courtneidge, 2003). ADAM17 knockout mice have a neonatal lethal phenotype
with multiple defects in heart, lung, and skin (Peschon et al., 1998). This is similar
to the phenotype of EGF receptor and TGFalpha knockouts, consistent with
ADAM17ʼs role in cleavage-dependent activation EGF receptor and TGFalpha.
ADAM19, also known as meltrin beta, is necessary for the proper
morphogenesis of the conotruncus and the endocardial cushion, structures that
give rise to the heart valves and the membranous ventricular septum. ADAM19
knockout mice have a neonatal lethal phenotype with severe defects in cardiac
morphogenesis, including ventricular septal defect (VSD), abnormal formation of
the aortic and pulmonary valves leading to valvular stenosis, and abnormal cardiac
vasculature (Zhou et al., 2004a). ADAM19 is highly expressed in the osteoblastlike cells of the bone, but does not appear to be essential for bone growth and
skeletal development. Mouse embryonic fibroblasts from ADAM19 knockout mice
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exhibit decreased ectodomain shedding of type I Neuregulin, one of the ErbB
ligands expressed in endocardial cells.

This suggests ADAM19-mediated

proteolytic cleavage of ErbB ligands is required for proper heart development
(Kurohara et al., 2004; Yokozeki et al., 2007; Zhou et al., 2004a).
The location of ADAM21 expression is disputed with some studies
suggesting testis specificity, whereas others indicating expression in the nervous
system. The function of ADAM21 is not yet determined, but Yang has speculated
that ADAM21 may regulate neurogenesis through guiding neuroblast migration
through cleavage-dependent protein activation and/or integrin binding (Yang et al.,
2005, 2006).
ADAM28, also known as MDC-L, has its highest expression in epididymis,
suggesting a role in sperm maturation. ADAM28 is also present at lower levels in
lungs and leukocytes (Howard et al., 2000; Mochizuki et al., 2004; Oh et al., 2005;
Shimoda et al., 2007). ADAM28 knockout mice have not yet been reported and
ADAM28 function in vivo is still unclear.
ADAM33 is expressed in lung, heart, testis, and brain, and was identified in
linkage studies as a putative asthma and bronchial hyper-responsiveness gene
(Del Mastro et al., 2007; Holgate et al., 2006; Van Eerdewegh et al., 2002).
ADAM33 knockout mice are viable and fertile, develop normally, and have no
morphological abnormalities (Chen et al., 2006). These mice have normal allergeninduced airway hyper-reactivity, immunoglobulin E production, mucus metaplasia,

65

and airway inflammation. Therefore, ADAM33 is not essential for growth or
reproduction, nor does it modulate baseline or allergen-induced airway
responsiveness. The precise physiological role of ADAM33 is unknown, and the
link of ADAM33 to asthma needs further elucidation.
Somatically Expressed, Catalytically Inactive ADAMs
ADAM7 is found solely in epididymis and in anterior pituitary gonadotropes
and its expression requires androgens and testicular factors (Cornwall and Hsia,
1997). ADAM7 is transferred from the epididymis to the sperm surface and
redistributed on the sperm head during the acrosome reaction, indicating it may
play a role in fertilization (Oh et al., 2005). ADAM7 knockout mice have not been
reported.
The other three somatically expressed, catalytically inactive ADAMs
(ADAM11, 22, 23) belong to an ADAM subfamily that is highly expressed in the
nervous system. These proteins share ~50% identity and have been previously
described by Sagane as predominantly “CNS-expressed brain” ADAMs (Sagane
et al., 1998; Sagane et al., 1999). Uniquely amongst the ADAMs, ADAM22 and
ADAM23 are expressed predominantly in the nervous system, whereas ADAM11
is expressed in the brain and other tissues.
ADAM22 is expressed throughout the brain, but most strongly in neurons of
the basal ganglia and cerebellum. ADAM22 is localized to the plasma membrane
of post-synaptic neurons where it interacts with LGI1 secreted by pre-synaptic
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neurons. LGI1 binds to the extra-cellular disintegrin domain of ADAM22 enhancing
AMPA receptor-mediated synaptic transmission (Fukata et al., 2006). A single
amino acid substitution in the ADAM22 disintegrin domain can prevent this
interaction. In the postsynaptic density the intra-cellular cytoplasmic tail of ADAM22
interacts with PSD95 and in this manner anchors ADAM22 to the cytoskeletal
scaffold, which contains stargazin (Fukata et al., 2006). ADAM22 knockout mice
are normal at birth, however, by postnatal day 10 they display progressive weight
loss and severe ataxia and die by 25 days of age (Sagane et al., 2005). At autopsy
ADAM22 knockout mice have marked hypomyelination of peripheral nerves, but
no major structural abnormalities in the cerebral cortex or cerebellum (Sagane et
al., 2005). The cytoplasmic tail of ADAM22 also interact with 14-3-3zeta and may
in this manner regulate cell adhesion and spreading, which suggests a potential
role in neural development (Zhu et al., 2005).
The pattern of ADAM23 expression is similar to that of ADAM22. As with
ADAM22 knockouts, ADAM23 knockout mice are normal at birth, however, soon
afterwards exhibit tremors, and ataxia and die by 14 days of age (Mitchell et al.,
2001). No detailed analysis of the nervous system in the ADAM23 knockout mouse
has been reported. It was speculated that through its disintegrin-like domain
ADAM23 might function as an adhesion molecule involved in alphavbeta3-mediated
cell interactions, including progression of malignant tumors of neural origin (Cal et
al., 2000).
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Table 1.2 ADAM Family Proteins
Common
Mouse
Alternative
Knockout
Possible/Suggested Function
Name
Phenotype
somatically expressed, catalytically active (HEXGHXXGXXHD)
1a-expressed in testicular germ
Role in fertility
cells, infertile males due to
ADAM1 fertilin alpha
sperm immotility
1b-expressed in epididymal
Role in fertility
sperm, fertile
Normal viability and fertility
ADAM8
Role in tissue-remodeling
No obvious phenotype
mediates growth factor-induced
Normal viability and fertility
ADAM9 meltrin gamma
endocytosis and dynamic
No obvious phenotype
recycling of E-cadherin
embryonic development
embryonic lethal at e9.5 days
involved in Notch pathway,
alpha-secretases for amyloid precursor
ADAM10 kuzbanian Multiple defects in nervous and
protein and ErbB ligands, involved in the
shedding of many type I and type II
cardiovascular system
single membrane-spanning proteins
low penetrance perinatal lethality cleaves IGF-binding proteins,
trigger IGF receptor signaling
brown adispose defect,
ADAM12 meltrin alpha
resistance to high-fat
cleaves ectodomain of EGFR ligands
induced obesity
trigger EGFR pathways
Normal viability
homeostatic role in neovascularization
ADAM15 metargidin
Reduced neovascularization
and cartilage remodeling
Neonatal lethal
processes TNFalpha, heparin-binding
TGFalpha, amyloid precursor protein,
ADAM17
TACE
Multiuple defects in
lung and cardiac development
among many others
proteolytic regulation of ErbB ligands
Neonatal lethal
ADAM19 meltrin beta
cardiovascular development
Cardiac septal and valve defects
guide neuroblast migration, neurogenesis
ADAM21 ADAM31
None available
and axonal growth in CNS
ADAM28 MDC-L
None available
role in sperm maturation
Normal viability and fertility
No obvious phenotype
role in asthma and bronchial
ADAM33
hyperresponsiveness
Normal allergen-induced airway
responsiveness
somatically expressed, catalytically inactive
ADAM7
None available
role in fertility
Normal viability and fertility,
Defects in spatial learning
role in Nervous System
Defects in motor coordination
ADAM11
MDC
Absence-like epilepsy
Normal cholesterol homeostasis
role in Reverse Cholesterol Transport
postnatal lethality
role in Nervous system;
ADAM22
MDC2
ataxia and tremors
binds LGI1, stabilizes PSD95 and
AMPA receptors in neurons
postnatal lethality,
ADAM23
MDC3
role in Nervous system;
ataxia and tremors

Gene
Name
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This thesis will undertake several different methods to understand the
physiological role of ADAM11, including the development and characterization of a
knockout mouse. A thorough review of the literature pertaining to ADAM11 will be
included in Chapter 3.
Primarily Testis Specific ADAMs, Catalytically Active and Inactive
Very little is known about these ADAMs. As mentioned earlier, of the 19
testis specific ADAMs, eleven are catalytically active (ADAM20, 24, 25, 26, 30, 34,
36, 37, 38, 39, 40), while the other eight are catalytically inactive (ADAM2, 3, 4, 5,
6, 18, 29, 32). These catalytically active and inactive ADAMs are thought to play
roles in fertility due to their testes-specific expression, but specific studies are only
available for ADAM2 and ADAM3.
ADAM2, also known as fertilin beta, plays a role in sperm function, as
ADAM2 knockout male mice are infertile. Sperm from these mice are present in
normal numbers, with normal motility, and undergo the normal acrosome reaction
and activation, however, they are deficient in migration from the uterus to the
oviduct, and adhesion to and fusion with the egg membrane (Cho et al., 1998).
ADAM2 knockout mouse sperm also lack ADAM1 and ADAM3, indicating ADAM2
may play a role in stabilizing these other ADAMs (Nishimura et al., 2007; Stein et
al., 2005). It is possible that the infertility-related phenotypes might in part be due
to the loss of these proteins. A recent finding suggests ADAM2 might also play a
role in promoting rostral migration of neuroblasts to the olfactory bulb (Murase et
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Table 1.2 ADAM Family Proteins (continued)
Common
Mouse
Alternative
Knockout
Name
Phenotype
testis specific (primarily), catalytically inactive
ADAM2 fertilin beta Normal viability, male infertility

Gene
Name

ADAM3

cyritestin

Normal viability, male infertility

Possible/Suggested Function
stabilizes Adam1 and Adam3 on sperm
crucial in the fertilization process
sperm-zona pellucida interaction

ADAM4
None available
ADAM5
None available
ADAM6
None available
ADAM18 ADAM27
None available
ADAM29
None available
ADAM32
None available
testis specific (primarily), catalytically active (HEXGHXXGXXHD)
ADAM20
None available
ADAM24
testase1
None available
ADAM25
testase2
None available
ADAM26
testase3
None available
ADAM30
None available
ADAM34
testase4
None available
ADAM36 testase 6
None available
ADAM37
testase7
None available
ADAM38
testase8
None available
ADAM39
testase9
None available
ADAM40 testase10
None available
not expressed in mammallian cells
ADAM13
ADAM14
ADAM16
ADAM35

al., 2008).
Reminiscent of ADAM2, ADAM3, also known as cyritestin, plays a role in
sperm function, as ADAM3 knockout male mice are infertile. Sperm from these
mice are present in normal numbers with normal motility, and undergo the normal
acrosome reaction and activation. However, unlike the ADAM2 knockouts, sperm
from these mice migrate normally from the to the oviduct (Shamsadin et al., 1999).
The sperm defect in these mice appears due to an inability to bind to the zona
pellucida. If the zona pellucida is removed, sperm from ADAM3 knockout mice can
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fertilize eggs (Shamsadin et al., 1999).
The Role of ADAM Family Members in Atherosclerosis
Three ADAMs (ADAM9, ADAM15 and ADAM17) have been shown to
modulate atherosclerosis. ADAM17 is present in atherosclerotic lesions of ApoE
knockout mice. ADAM17 was implicated as the culprit gene at the proximal
chromosome 12 atherosclerosis susceptibility locus identified by quantitative trait
locus (QTL) mapping in an intercross between C57BL/6J and FVB/N mice on the
LDL receptor knockout background (Canault et al., 2006; Canault et al., 2008; Holdt
et al., 2008). ADAM17 presumably acts by cleaving and mobilizing receptor-ligands
that play a role in atherogenesis, which are initially synthesized as membranetethered precursors, including TNFalpha, heparin-binding EGF, TGFalpha, amyloid
precursor protein, and many others (Holdt et al., 2008). Consistent with the finding
that increased ADAM17 expression is associated with atherosclerotic resistance,
knocking out genes that are targets for the ADAM17 metalloprotease, such as
intercellular adhesion molecule-1 (ICAM- 1), VCAM-1, interleukin (IL)-1 receptor,
CX3CL1 (fractalkine), is also associated with decreased atherosclerosis (Holdt et
al., 2008). HDL is protective against atherosclerosis and it is perhaps relevant that
HDL can alter the lipid raft structure of cells in a manner that activates ADAM17dependent processing of trans-membrane substrates (Tellier et al., 2008).
ADAM15 and ADAM9 have been detected in atherosclerotic lesions, but not
in normal aorta (Al-Fakhri et al., 2003; Charrier-Hisamuddin et al., 2008; Herren et
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al., 1997). ADAM15 was detected in foam cells of smooth muscle cell (SMC) origin
and in SMCs surrounding the necrotic lipid core. The integrin binding partners of
ADAM15 and ADAM9, alpha5beta1 and alphavbeta3, respectively, are also found
in atherosclerotic lesions (Al-Fakhri et al., 2003). It is possible that ADAM15 and
ADAM9 expression and interactions with their integrin-binding partners might
modulate SMC-matrix interactions in a manner that alters SMC migration within the
atherosclerotic plaque. Other studies have suggested that ADAM15 might play a
role in atherosclerosis by activating platelets and in this manner augment
inflammation (Charrier-Hisamuddin et al., 2008).
This thesis investigates a possible role for the novel cholesterol up-regulated
gene ADAM11 in cholesterol homeostasis and atherosclerosis susceptibility through
creation and study of ADAM11 knockout mice.
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Chapter 2: Characterization of StARD5
Background
In order to better understand responsiveness to dietary cholesterol, Soccio
and colleagues fed 6-week-old C57Bl/6 mice a semi-synthetic modified AIN76A
diet containing 4.5% fat and either 0.02% or 0.5% cholesterol for three weeks
(Soccio et al., 2002). RNA was isolated from the livers of these mice, and gene
expression on low and high cholesterol diets compared using a cDNA microarray
representing several thousand genes. Dietary cholesterol down-regulated six
genes on the microarray; one of these was novel and subsequently named StARD4
(Soccio et al., 2002). Homology searching led to the discovery of StARD5 and
StARD6. These genes were shown to comprise a novel START-domain containing
subfamily, likely cholesterol binders consisting solely of the ~210 amino acid
START-domain itself. As mentioned earlier, StARD5 expression was not affected
by cholesterol feeding, over expression of truncated nuclear SREBP, LXR agonists,
oxysterols, or statins.

However, StARD5 was shown to be up-regulated in

macrophages by free-cholesterol loading and in NIH-3T3 cells by drugs known to
induce ER stress (UPR) (Soccio et al., 2005; Soccio et al., 2002). Rodriguez and
colleagues showed that in liver StARD5 is localized to Kuppfer rather than
parenchymal cells where StARD4 is expressed. They also showed StARD5
expression in monocytes and macrophages (Rodriguez-Agudo et al., 2006).
StARD5 selectively binds cholesterol and the potent regulatory oxysterol, 25-
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hydroxycholesterol (Rodriguez-Agudo et al., 2005).

These findings suggest

StARD5 is an intra-cellular sterol transporter that might be involved in removing
excess free-cholesterol from the ER; possible destinations include transporting freecholesterol from the ER to other cellular compartments or to the PM for excretion.
It is also possible that StARD5 facilitates the conversion of free-cholesterol to
cholesterol-ester by the ER enzyme ACAT. However, the precise in vivo role of
StARD5 is unknown, and this thesis attempts to understand StARD5 function by
generating and studying StARD5 knockout as well as StARD5 transgenic mice.
The Targeted Disruption of StARD5
In order to allow the gene to be inactivated in a tissue- or temporal-specific
fashion, a strategy was undertaken to create a StARD5 conditional knockout mouse
(cKO mouse). Traditionally through homologous recombination loxP sites are
inserted into two introns of a gene bracketing one or more exons with subsequent
expression of Cre recombinase catalyzing recombination between the loxP sites
eliminating the sandwiched exons and inactivating the gene. Cre recombinase
expression using a tissue-specific promoter can inactive the gene in a cell-typespecific fashion, whereas using an inducible Cre expression systems or a viral
delivery systems (such as adenovirus or lentivirus) can inactivate the gene in a
temporal-specific fashion.
StARD5 is a 213 amino acid protein encoded by 6 exons on mouse
chromosome 7. Based on databases from the Sanger Institute and Ensembl, no

74

5’UTR

~41

596

99
A-1

344

50
2

3488

133

735

118

3-B-C-4 5-6-7

2724

3’UTR

94

148

8-9

10-D

~1-2kb

Figure 2.1. Exonic structure of mStARD5 and secondary structure of protein encoded by
each exon. StARD5 is a 213 amino acid protein encoded by 6 exons. Exons are represented as
boxes with lengths in nucleotides, as determined by alignment of cDNA with genomic DNA. Coding
sequences are white and untranslated regions (UTR) are gray. Lines connecting the boxes
represent introns, with lengths in nucleotides indicated just above. Below the exon structure are
the secondary structural elements aligned to each exon.

other genes or miRNA are known to overlap the region encompassing the StARD5
gene (location: 90,780,510-90,789,625). Directly 5ʼ upstream of the StARD5 gene
in the mouse is the Tmc3 gene, whose 3ʼ UTR ends approximataly 6kb before the
5ʼUTR of StARD5. Directly 3ʼdownstream of the StARD5 gene in the mouse is the
IL16 gene, whose 5ʼUTR begins approximately 2kb after the 3ʼ UTR of StARD5.
A BAC clone encompassing the StARD5 locus was obtained from a C57BL/6
genomic library (BacPac Resources, RP24-252B21). A strategy was devised to
flank the 133bp long exon 3 with loxP sites and then to knock it out using Crerecombinase, thereby removing 44 amino acids that includes critical regions that
form the StARD5 hydrophobic pocket (beta-pleated sheets 3, 4, and 5, and alphahelices B and C) (Figure 2.1). Alternative splicing from exon 2 to exon 4 would be
also out-of-frame and would create several termination codons.

Using the

recombineering techniques described by Copeland and colleagues (Liu et al.,
2003), a targeting vector was constructed in the MC1-TK-containing plasmid that
introduced a loxP site into StARD5 intron 2 and an Frt-Pgk-em7-Neo-Frt-loxP
cassette into StARD5 intron 3 (Figure 2.2). The loxP site was placed 152bp after
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Figure 2.2. Gene targeting and generation of a conditional knockout (floxed) allele of the
StARD5 gene. A) Targeting strategy to flank exon 3 of StARD5 with loxP sites. The targeting vector
was constructed by placing a Neo selectable marker flanked by Frt sites with a loxP site in intron
3. A second loxP site was introduced in intron 2. B) A southern blot (BamHI) using the external 3ʼ
probe was used to monitor homologous recombination. C) A southern blot (BsrGI) using the
external 5ʼ probe was used to monitor homologous recombination D) PCR analysis in order to
determine the presence of the wildtype (bottom band) and/or floxed (top band) alleles in
heterozygous (fl/+) as well as wildtype (+/+) controls D) PCR analysis in order to determine the
presence of the wildtype(top band) and/or null allele (bottom band) in heterozygous (+/-) as well as
wildtype (+/+) controls.
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exon 2 within the 344bp intron 2, and the cassette placed 1606bp after exon 3
within the 3488bp intron 3. The MC1-TK cassette was used for negative selection
against random integration events, while the Neo cassette allowed for positive
selection. The Neo floxed allele of the StARD5 gene was generated through
homologous recombination in isogenic mouse embryonic stem (ES) cells. Thirteen
correctly targeted ES clones were identified by Southern blotting using BamHI or
EcoRV restriction digests of genomic DNA, and external 5ʼ or 3ʼ probes,
respectively, that were not part of the targeting vector. Five ES cell clones were
expanded and injected into blastocysts to produce chimeras, but only one (#118)
led to germ-line transmission.
Viability, Fertility, and Fecundity in the StARD5 Mice
After detection of germ-line transmission of the targeted allele, an attempt
was made to breed the Neo floxed gene to homozygosity. Brother-sister mating of
Neo floxed heterozygous mice failed to yield homozygous offspring. This failure to
achieve the expected Mendelian ratios indicated the genetically altered StARD5
allele was not able to encode functional StARD5, perhaps by interfering with
splicing. It also suggested that the loss of StARD5 might cause embryonic lethality.
Since it was possible that the large Neo cassette in intron 3 might have
interfered with proper splicing of StARD5, an attempt was made to remove it by
breeding StARD5 Neo floxed heterozygous mice to C57BL/6 ACT-FLPe transgenic
mice.

The latter express FLP1 recombinase, an enzyme derived from
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Saccharomyces cerevisiae that recognizes a 34bp FLP1 recombinase target (FRT)
sequence. This enzyme efficiently excises DNA located between similarly oriented
FRT sites and recombines the DNA ends. This leaves a single FRT site in place of
the intervening sequence. The promoter of the FLPe transgene drives expression
in germ-line cells and many other tissues, essentially completely removing the Neo
cassette from the StARD5 gene of targeted mice. After the loss of the Neo cassette,
the result was a targeted allele with 2 loxP sites flanking StARD5 exon 3, which is
referred to as the floxed allele. Brother-sister mating of floxed heterozygous mice
again failed to yield homozygous offspring (33% wild-type, 67% heterozygotes)
(Figure 2.2).

This strongly suggests that the loxP sites in introns 2 and 3

themselves interfere with proper splicing of the StARD5 mRNA and in this manner
prevent StARD5 protein expression.

In other experiments, bone marrow

macrophages from these StARD5 heterozygous floxed mice expressed only ~50%
of normal StARD5 protein, supporting the hypothesis that the placement of the loxP
sites in the targeted allele interferes with proper protein expression.
The floxed allele was converted to a null allele by crossing StARD5 floxed
Table 2.1. Fertility and Fecundity of StARD5cKO Mice
Deleted
Male +/- x Female +/Floxed
Male +/fl x Female +/fl

wt:het:homo
29:56:0

litter size (mean +/- SD)
5.9 +/- 2.3

36:73:0

6.6 +/- 2.5

Deleted
Male +/+ x Female +/Male +/- x Female +/+

# pregnancies
15
5

litter size (mean +/- SD)
6.0 +/- 1.5
6.6 +/- 1.5
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heterozygous mice with C57BL/6 CMV-Cre transgenic mice. Cre-recombinase, an
enzyme derived from the bacteriophage P1, recognizes adjacent loxP sites and
efficiently mediates the excision of DNA located between them. This enzyme also
recombines the DNA ends, leaving a single loxP site in place of the intervening
sequence. The promoter of the Cre transgene drives expression in germ-line cells
and many other tissues, essentially completely removing exon 3 from the StARD5
gene of targeted mice (Figure 2.2). Again, brother-sister mating of StARD5 null
heterozygous mice failed to yield homozygous offspring (34% wild-type, 66%
heterozygotes) (Table 2.1). As with the floxed allele, bone marrow macrophages
from StARD5 heterozygous null mice expressed only ~50% of normal StARD5
protein (Figure 2.3). Together with the breeding experiments, these results indicate
that the loss of StARD5 is embryonic lethal in C57BL/6 mice (Figure 2.4).

StARD5
beta actin
Het Het WT WT
Figure 2.3. Expression of StARD5 in bone marrow macrophages of StARD5 heterozygous
mice. Bone marrow macrophages from StARD5 heterozygous mice and wild-type mice were
extracted and grown in culture. Protein lysates were collected and Western blot performed for
StARD5. Het: Heterozygote, WT: Wild-type.
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Figure 2.4. Mating strategy in generation of the StARD5 knockout.
Chimera mice were mated to C57Bl6 to generate Neo heterozygotes. These Neo heterozygotes
were brother-sister mated in an attempt to generate Neo homozygotes. The Neo heterozygotes
were also mated to the ACT-FLPe transgenic mice to remove the FrtNeoFrt cassette and to
generate Flox heterozygotes. These Flox heterozygotes were brother-sister mated in an attempt
to generate Flox homozgotes. The Flox heterozygotes were mated to CMV-Cre transgenic mice
to remove exon 3 and to generate Null/Deleted heterozygotes. These Null heterozygotes were
brother-sister mated in an attempt to generate Null homozygotes. Results of the brother-sister
matings are indicated on the right; the order is wildtype:heterozygotes:homozygotes. No
homozygote Neo, floxed, or null mice have been identified. Rectangles represent exons, triangles
represents loxP sites, cross represents the FrtNeoFrt cassette, line vertical line represents Frt site
after Flp recombinase, thick arrows represent matings.
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Embryonic Lethality of StARD5 Homozygous Knockouts
Both males and female heterozygous null mice were capable of breeding
the null trait when crossed to wild-type mice, indicating that sperm and oocyte
carrying the StARD5 knockout trait are viable and capable of fertilization and that
lethality of the homozygosity must occur between fertilization and birth. Timed
matings of StARD5 heterozygous intercrosses were performed to determine at what
stage of gestation embryonic lethality occurs. Embryos were collected on days
E16.5, E15.5, E14.5, E13.5, E12.5, E11.5, E10.5 and E9.5, and genotyping
revealed that none were homozygous null mutants (Table 2.2). Thus it appears
that the lack of StARD5 leads to embryonic lethality before the E9.5 stage of
development. Potential causes for the lethality of the StARD5 homozygous embryo
at this early stage include a failure of cleavage, compaction, hatching, implantation,
gastrulation, hematopoeisis, or cardiovascular development.

Table 2.2. Genotypes of Embryos from Intercross of StARD5+/- Mice
Age
E16.5
E14.5
E13.5
E11.5
E10.5
E9.5

WT
3
3
3
2
1
12

Het
4
11
13
6
4
14
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KO
0
0
0
0
0
0

Undetermined
1
2

5

Pathology of StARD5 Heterozygous Knockouts
A small significant decrease (approximately 6%) in weight was observed
between wild-type and StARD5 heterozygous floxed mice at 12 weeks of age, in
both males and females on a chow diet (Table 2.3), as was a corresponding
decrease in liver weight. This was also found between female wild-type and
StARD5 heterozygous null mice, however, not between male wild-type and StARD5
heterozygous null mice (Table 2.3). In the experiment with the wild-type and
StARD5 heterozygous null mice weights were measured from weaning at 4 weeks
until sacrifice at 12 weeks of age and the difference between the genotypes did not
become significant until week 12 (Figure 2.5). Upon sacrifice at 12 weeks of age a
complete pathological examination was performed on StARD5 heterozygous null

Table 2.3. Body composition of StARD5 mice at 12 weeks old
Male

Null Mice
Mouse Weight (g)

n=

Liver Weight (g)

n=

Wt
24.3 +/- 0.6
6
1.04 +/- 0.02
6

Het
24.8 +/- 0.4
12
1.00 +/- 0.03
12

Female
Wt
Het
21.2 +/- 0.6 19.3 +/- 0.3*
6
15
0.98 +/- 0.04 0.85 +/- 0.02*
6
15

Floxed Mice
25.7 +/- 0.3 24.3 +/- 0.4* 19.6 +/- 0.6 18.3 +/- 0.2*
10
14
8
16
1.12 +/- 0.04 1.06 +/- 0.05 0.88 +/- 0.03 0.79 +/- 0.03*
Liver Weight (g)
n=
6
7
3
7
All values are means +/- SEM, number of mice (N) is given for each value,
Mouse Weight (g)

n=

* indicates p values < 0.05
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A

B

Figure 2.5. Growth curve of StARD5 mice.
A) Males B) Females. The cross of StARD5 heterozygous null mice were weaned at 4 weeks and
fed a chow diet until sacrfice at 12 weeks. Weight of mice were taken each week. Blue points
represent values for StARD5 heterozygous null mice; red points represent wild-type siblings. Mean
weight (g) plus or minus SEM at each time point are indicated in graph Each data point represents
5-15 mice.

mice and their wild-type litter-mates by the Tri-Institutional Core Facility located in
the MSKCC Pathology Department.

No apparent anatomical-histological

differences were observed in heart, lungs, esophagus, thymus, tongue, kidneys,
pancreas, renal lymph nodes, spleen, salivary glands, stomach, duodenum,
jejunum, ileum, colon, cecum, pancreas, brown fat, urinary bladder, thyroid glands,
trachea, adrenal glands, liver, sciatic nerve, spinal cord, gallbladder, or brain.
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Plasma Cholesterol, Triglycerides, and Glucose levels
Comparison of wild-type and StARD5 heterozygous null or floxed mice at
12 weeks of age on a chow diet revealed no significant differences in plasma total
and free cholesterol, HDL, and LDL cholesterol, triglycerides, and glucose levels
(Table 2.4).
Table 2.4. Plasma levels of StARD5 mice at 12 weeks old
Male

Null Mice
Triglycerides
n=
(mg/dL)
Total Cholesterol
n=
(mg/dL)
HDL (mg/dL)

n=

LDL (mg/dL)

n=

non-HDL
n=
(calculated)
Free Cholesterol
n=
(mg/dL)
Glucose
(mg/dL)
n=

Wt
31 +/- 3
6
71 +/- 3
6
51 +/- 2
6
21 +/- 1
6
20 +/- 2
6
6 +/- 1
6
116 +/- 9
5

Female
Het
31 +/- 2
12
69 +/- 2
12
49 +/- 1
12
22 +/- 3
12
20 +/- 2
12
10 +/- 1
12
126 +/- 8
10

Wt
37 +/- 5
4
67 +/- 4
4
41 +/- 3
4
24 +/- 3
4
26 +/- 4
4
9 +/- 1
4
109 +/- 7
3

Het
30 +/- 7
14
63 +/- 4
14
40 +/- 1
14
24 +/- 2
14
23 +/- 3
14
9 +/- 1
14
122 +/- 11
7

Floxed Mice
31 +/- 2
30 +/- 2
25 +/- 2
6
9
7
92 +/- 4
89 +/- 5
73 +/- 3
7
12
7
64 +/- 6
62 +/- 3
48 +/- 2
HDL (mg/dL)
n=
5
10
7
24 +/- 3
21 +/- 2
23 +/- 2
LDL (mg/dL)
n=
5
10
7
27 +/- 1
29 +/- 3
24 +/- 3
non-HDL
n=
5
10
7
(calculated)
All values are means +/- SEM, number of mice (N) is given for each value
Triglycerides
n=
(mg/dL)
Total Cholesterol
n=
(mg/dL)
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28 +/- 2
14
80 +/- 4
14
50 +/- 2
14
23 +/- 2
14
31 +/- 3
14

Hepatic Cholesterol Levels
Similarly, there were no significant differences between wild-type and
StARD5 heterozygous null or floxed mice at 12 weeks of age on a chow diet in
hepatic total cholesterol (Table 2.5).
Table 2.5. Hepatic levels of StARD5 male mice at 12 weeks old
Wt
Het
Null Mice
2.4 +/- 0.4
2.4 +/- 0.1
Total Cholesterol
n=
3
3

Floxed Mice
2.5 +/- 0.3
2.7 +/- 0.2
n=
3
3
Values are in mg/g liver, all values are means +/- SEM,
number of mice (N) is given for each value
Total Cholesterol

Gallbladder Bile Composition
There were no significant differences between wild-type and StARD5
heterozygous null or floxed mice at 12 weeks of age on a chow diet in gallbladder
bile concentrations of cholesterol, bile acids, or phospholipids (Table 2.6).
Table 2.6. Gallbladder bile levels of StARD5 mice at 12 weeks old
Male
Female
Wt
Het
Wt
Het
Null Mice
133 +/- 17
155 +/- 20
182 +/- 23
231 +/- 17
Cholesterol
n=
5
9
3
12
(mg/dL)
Phospholipids
1304 +/- 313 1504 +/- 145 1946 +/- 177 1907 +/- 208
(mg/dL)
n=
3
7
3
10
Bile Acids
71 +/- 11
75 +/- 6
100 +/- 10
89 +/- 6
(mM)
n=
5
9
3
12

Floxed Mice
160 +/- 13
157 +/- 11
200 +/- 22
237 +/- 12
Cholesterol
n=
6
6
7
10
(mg/dL)
Phospholipids
2045 +/- 118 1902 +/- 141 1928 +/- 195 2105 +/- 106
n=
6
6
7
10
(mg/dL)
All values are means +/- SEM, number of mice (N) is given for each value
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Glucose Tolerance
The same mice were subjected to an intra-peritoneal glucose tolerance test
(IPGTT) a few days before sacrifice, with glucose measurements made 0, 15, 30,
60, and 120 minutes after injecting a glucose bolus of 2g/kg. Again, there was no
significant differences between wild-type and StARD5 heterozygous null mice
(Figure 2.6).
A

B

Figure 2.6. Intraperitoneal Glucose Tolerance Test (IPGTT) of StARD5 mice. 11.5 week old
StARD5 heterozygous null mice were tested by injecting a bolus of 2g glucose/kg body weight;
mean blood glucose values are indicated with SEM for error bars.
AUC, area under curve, for IPGTT is also provided.
A) Male (n=5 WT, 10 Het); AUC: wt: 24,408 +/- 1074; het: 24,808 +/- 2495
B) Female (n=3 WT, 7 Het) AUC: wt: 22,159 +/- 4534; het: 21,243 +/- 2059

86

Macrophage Cholesterol Efflux
Bone marrow macrophages from wild-type and StARD5 heterozygous null
male mice were isolated and then loaded with 3H-cholesterol. Measuring efflux of
radiolabeled cholesterol to ApoAI or HDL, testing the ABCA1 and ABCG1
pathways, respectively, over 4 and 8 hours showed no differences between
genotypes (Figure 2.7).
A

B

Figure 2.7. Bone marrow macrophage cholesterol efflux of StARD5 male mice. Bone marrow
macrophages fromStARD5 heterozygous null mice were extracted and grown in culture. 3Hcholesterol was added to the medium for 24 hours; acLDL and 3H Cholesterol was added for an
additional 24 hours. Media was removed. Cells were washed and placed with media containing No
Acceptor (NA), HDL (50ug/ml) or ApoAI (10ug/ml) as the cholesterol acceptor. Cells and media
were counted (cpm) after (A) 4 or (B) 8 hours, and percent efflux was calculated as counts in media
divided by the total counts in the media and cells. (n=3 for each genotype, efflux from each mouse
is measured for each acceptor and time point in triplicate). Mean values plus or minus SEM are
indicated.

87

Crossing the StARD5 Knockout Trait onto the LDLR Knockout Background
To identify a possible effect of StARD5 on atherosclerosis susceptibility,
StARD5 heterozygous null mice were crossed onto the atherosclerosis-susceptible
B6.LDLR KO background. After weaning at 4 weeks, mice were fed a low-fat lowcholesterol semi-synthetic diet for 16 weeks. The animals were sacrificed at 20
weeks of age and aortic root cross sectional lesion area compared between wildtype and heterozygous StARD5 null mice.

No significant differences were

observed for either gender between the genotypes (Figure 2.8). Comparison of

Female
Het

Female
WT

Male
Het

Male
WT

Figure 2.8. Atherosclerotic lesion size at the aortic root of StARD5 mice on LDLR KO
background. Average lesion size (um2) at the aortic root was measured in each
StARD5 null
heterozygous and wild-type mouse after 16 weeks on semi-synthetic AIN76a diet
(n= 6 heterozygote females, 10 wildtype females, 9 heterozygote males, 6 wildtype males).
Mean values (x105) plus or minus SEM for lesion area are indicated.
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wild-type and StARD5 heterozygous null mice on the LDLR KO background did not
show any differences in body weight or liver weight (Table 2.7), total, HDL, LDL and
VLDL cholesterol, triglycerides, glucose or free cholesterol (Table 2.8), gallbladder
bile cholesterol, bile acids and phospholipid concentrations (Table 2.9), and glucose
tolerance as measured by the IPGTT (Figure 2.9).
Table 2.7. Body composition of StARD5 mice on LDLR KO background
Male
Female
Wt
Het
Wt
Het
Null Mice
27.9 +/- 0.8
28.3 +/- 0.5
21.8 +/- 0.6
21.4 +/- 0.9
Mouse Weight (g)
n=
6
9
10
6
1.09 +/- 0.07 1.05 +/- 0.04 0.97 +/- 0.04 0.93 +/- 0.03
Liver Weight (g)
n=
6
8
10
6
All values are means +/- SEM, number of mice (N) is given for each value

Table 2.8. Plasma levels of StARD5 mice on LDLR KO background
Male
Female
Wt
Het
Wt
Het
Null Mice
Triglycerides
148 +/- 27
98 +/- 10
99 +/- 15
113 +/- 21
(mg/dL)
n=
6
9
10
6
Total Cholesterol
521 +/- 41
556 +/- 35
617 +/- 42
671 +/- 83
(mg/dL)
n=
6
9
10
6
Free Cholesterol
147 +/- 18
125 +/- 26
136 +/- 11
155 +/- 18
(mg/dL)
n=
6
9
10
6
HDL
76 +/- 2
73 +/- 3
55 +/- 4
46 +/- 5
(mg/dL)
n=
6
9
10
6
LDL
379 +/- 47
409 +/- 36
410 +/- 33
407 +/- 51
(mg/dL)
n=
6
9
10
6
VLDL
45 +/- 15
49 +/- 10
97 +/- 14
117 +/- 29
(mg/dL)
n=
6
9
10
6
Glucose
146 +/- 11
160 +/- 11
131 +/- 8
119 +/- 10
(mg/dL)
n=
6
7
9
4
All values are means +/- SEM, number of mice (N) is given for each value
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Table 2.9. Gallbladder bile levels of StARD5cko on LDLR KO background
Male
Female
Wt
Het
Wt
Het
Null Mice
Cholesterol
175 +/- 23
166 +/- 29
186 +/- 36
163 +/- 39
(mg/dL)
n=
4
6
6
4
Phospholipids
1471 +/- 351 1684 +/- 161 2352 +/- 379 1355 +/- 194
(mg/dL)
n=
3
4
4
3
127 +/- 19
85 +/- 13
55 +/- 14
70 +/- 21
Bile Acids (mM)
n=
3
6
3
3
All values are means +/- SEM, number of mice (N) is given for each value

A

B

Figure 2.9. Intraperitoneal Glucose Tolerance Test (IPGTT) of StARD5 mice on the LDLR KO
background. 19.5 week old mice were tested after 15.5 weeks on diet, by injecting a bolus of 2g
glucose/kg body weight; mean blood glucose values plus or minus SEM are indicated.
AUC, area under curve, for IPGTT is also provided.
A) Male (n=6 WT, 7 Het); AUC: wt: 36,160 +/- 4227; het: 42,147 +/- 5149
B) Female (n=9 WT, 4 Het); AUC: wt: 33,262 +/- 1745; het: 28,909 +/- 4843
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Development of Transgenic Mice Over-Expressing Human StARD5 in
Macrophages Using the Scavenger Receptor A Enhancer and Promoter
In another attempt to probe the function of the StARD5, transgenic mice
were created expressing human StARD5 only in macrophages. This also involved
utilizing the Copelandʼs recombineering techniques. Human genomic StARD5 DNA
was obtained from a BAC clone (BacPac Resources RP11-770M20), placed under
control of the promoter and enhancer regions of Scavenger Receptor A (SR-A) (a
gift from DʼArmiento and Glass) (Liu et al., 2003), and injected into C57BL/6 ES
cells. Using human StARD5 sequences allowed transgene expression to be easily
distinguished from endogenous StARD5 expression.

Transgenic mice were

identified by PCR and 2 founder lines were obtained. In both cases, bone marrow
macrophages expressed StARD5 mRNA at low levels; approximately half the levels
of mouse StARD5 mRNA in the same cells (Figure 2.10). To help assess the

Figure 2.10. Expression of hStARD5 in bone marrow macrophages of SR-A-hStARD5
transgenics. Bone marrow macrophages were extracted and grown in culture. Blue bars represent
expression levels of mStARD5, while red bars represent expression levels of hStARD5. Values are
in copy number of transcript per 1000 copies of cyclophilin A transcript. Expression levels of
hStARD5 in both transgenic lines are approximately one-third the expression levels of mStARD5.
All values are means +/- SEM.
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possible physiological significance of this relatively small amount of human StARD5
expression, wild-type and hStARD5 transgenic mice at 6 weeks of age were placed
on the AIN76a diet free of cholesterol for one week. After this the mice were
switched to the AIN76a diet containing 0.5% cholesterol for one week and then
sacrificed at 8 weeks of age.

Comparison of wild-type and both hStARD5

transgenic mouse lines failed to reveal significant differences in body weight or liver
weight (Table 2.10), total, HDL, LDL and VLDL cholesterol and triglycerides (Table

Table 2.10. Body composition, plasma, liver and gallbladder bile
levels of SR-A-hStARD5 transgenic mice on high 0.5%
cholesterol diet
Male
Wt
Transgenic-11 Transgenic-4
Body Weight
22.8 +/- 0.5
23.1 +/- 0.4
21.8 +/- 0.9
n=
14
14
11
(g)
1.10 +/- 0.04 1.25 +/- 0.06 1.07 +/- 0.07
Liver Weight
n=
13
14
11
(g)
Plasma
91 +/- 5
96 +/- 5
106 +/- 10
Cholesterol (mg/dl) n=
15
14
11
54 +/- 4
60 +/- 2
61 +/- 5
HDL (mg/dL)
n=
15
14
11
32 +/- 2
36 +/- 2
42 +/- 3
LDL (mg/dL)
n=
15
14
11
7 +/- 1
7 +/- 1
7 +/- 1
VLDL (mg/dL)
n=
15
14
11
37 +/- 2
37 +/- 3
36 +/- 3
Triglycerides (mg/dL)
n=
15
14
11
Liver Total
14.0 +/- 0.8
15.2 +/- 0.8
13.8 +/- 1.1
Cholesterol (mg/g) n=
15
14
11
Bile
365 +/- 36
298 +/- 25
341 +/- 27
Cholesterol (mg/dL) n=
12
12
8
1653 +/- 107
1769 +/- 141 1708 +/- 139
Phospholipids(mg/dL)
n=
12
12
8
All values are means +/- SEM, number of mice (N) is given for each value;
Liver cholesterol values are in mg/g liver
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Table 2.10. Continued. Body composition, plasma, liver and
gallbladder bile levels of SR-A-hStARD5 transgenic Mice on
high 0.5% cholesterol diet
Female
Wt
Transgenic-11 Transgenic-4
Body Weight
18.2 +/- 0.3
18.7 +/- 1.0
17.4 +/- 0.3
n=
16
8
11
(g)
0.94 +/- 0.02 0.94 +/- 0.06 0.90 +/- 0.03
Liver Weight
n=
16
9
11
(g)
Plasma
82 +/- 5
73 +/- 11
92 +/- 9
Cholesterol (mg/dl) n=
16
8
11
41 +/- 2
35 +/- 2
41 +/- 3
HDL (mg/dL)
n=
16
8
11
36 +/- 2
36 +/- 3
45 +/- 7
LDL (mg/dL)
n=
16
8
11
7 +/- 1
7 +/- 3
9 +/- 1
VLDL (mg/dL)
n=
16
8
11
27 +/- 2
26 +/- 4
29 +/- 3
Triglycerides (mg/dL)
n=
16
8
11
Liver Total
21.6 +/- 1
22.8 +/- 1.5
25.8 +/- 4.5
Cholesterol (mg/g) n=
16
8
11
Bile
288 +/- 25
328 +/- 25
360 +/- 60
Cholesterol (mg/dL) n=
12
6
9
1950 +/- 197 2121 +/- 158 1910 +/- 294
Phospholipids(mg/dL)
n=
12
6
9
All values are means +/- SEM, number of mice (N) is given for each value;
Liver cholesterol values are in mg/g liver
2.10), hepatic cholesterol content (Table 2.10), and gallbladder bile cholesterol and
phospholipid concentrations (Table 2.10).
Crossing the hStARD5 Macrophage-Specific Transgenic Lines onto the
LDLR Knockout Background
To identify a possible effect of StARD5 over-expression (albeit low level) on
atherosclerosis susceptibility, the hStARD5 macrophage-specific transgenic trait
was crossed onto the atherosclerosis-susceptible B6.LDLR KO background. After
weaning at 4 weeks, mice were fed a low-fat low-cholesterol semi-synthetic diet
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for 16 weeks. The animals were sacrificed at 20 weeks of age and aortic root cross
sectional lesion area compared between wild-type and hStARD5 macrophagespecific transgenic lines. No significant differences were observed in for either
gender between the genotypes (Figure 2.11). Comparison of wild-type and
A

Female
WT

Female
TG(4)

Male
WT

Male
TG(4)

B

Female
WT

Female
TG(11)

Male
WT

Male
TG(11)

Figure 2.11. Atherosclerotic lesion size at the aortic root of SR-A-hStARD5 transgenic mice
on LDLR KO background. A) Trangenic-4; B) Transgenic-11
Average lesion size (um2) at the aortic root was measured in each transgenic and wild-type mouse
after 16 weeks on semi-synthetic AIN76a diet (8-12 per gender and genotype). Mean values (x105)
plus or minus SEM for lesion area are indicated.
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hStARD5 macrophage-specific transgenic lines on the LDLR KO background did
not show any differences in body weight, liver weight, total, HDL, LDL and VLDL
cholesterol, or triglyceride levels (Table 2.11); nor was there a difference in the
ability of bone marrow macrophages from wild-type and hStARD5 transgenic mice
on the LDLR knockout background loaded with 3H-cholesterol to efflux radiolabeled
cholesterol to ApoAI or HDL (Figure 2.12).
A

B

Figure 2.12. Bone marrow macrophage cholesterol efflux of SR-A-hStARD5 transgenic male
mice on LDLR KO background. (n=3 for each genotype, efflux from each mouse is measured for
each acceptor and time point in triplicate) 3H Cholesterol was added to the medium for 24 hours,
acLDL and 3H Cholesterol was added for an additional 24 hours. Media was removed. Cells were
washed and placed with media containing No Acceptor (NA), HDL (50ug/ml) or ApoAI (10ug/ml) as
the cholesterol acceptor. Cells and media were counted (cpm) after 4 hours, and percent efflux was
calculated as counts in media divided by the total counts in the media and cells. A) Transgenic-4,
B) Transgenic-11. Mean values plus or minus SEM are indicated.
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Table 2.11. Body composition and plasma levels of SR-A StARD5
transgenic mice on LDLR KO background
Male
Wt
TG
Transgenic 11
Body Weight
26.1 +/- 0.5
26.1 +/- 1.1
n=
21
13
(g)
1.01 +/- 0.04 1.08 +/- 0.05
Liver Weight
n=
21
13
(g)
Plasma
593 +/- 42
487 +/- 56
Cholesterol (mg/dl) n=
21
13
63 +/- 4
65 +/- 3
HDL (mg/dL)
n=
15
11
413 +/- 32
378 +/- 32
LDL (mg/dL)
n=
15
11
74 +/- 7
69 +/- 13
VLDL (mg/dL)
n=
15
11
136 +/- 18
94 +/- 14
Triglycerides
n=
12
8
(mg/dL)
148 +/- 12
121 +/- 12
Glucose (mg/dL)
n=
7
7
Male

Transgenic 4

Female
Wt
TG
20.9 +/- 0.3
20.6 +/- 0.5
11
11
0.96 +/- 0.03 0.90 +/- 0.02
11
11
801 +/- 50
688 +/- 51
11
11
40 +/- 5
47 +/- 6
8
6
508 +/- 28
440 +/- 28
8
6
226 +/- 31
164 +/- 28
8
6
99 +/- 17
91 +/- 14
6
9
107 +/- 7
116 +/- 8
4
5
Female

Wt
TG
Wt
TG
Body Weight
25.3 +/- 0.8
23.5 +/- 1.0
19.2 +/- 0.4
19.5 +/- 0.3
n=
9
8
11
8
(g)
1.01 +/- 0.05 0.98 +/- 0.06 0.81 +/- 0.04 0.87 +/- 0.04
Liver Weight
n=
9
8
11
8
(g)
631 +/- 28
677 +/- 52
641 +/- 32
733 +/- 52
Plasma
8
8
11
8
Cholesterol (mg/dl) n=
64 +/- 8
55 +/- 4
43 +/- 4
49 +/- 4
HDL (mg/dL)
n=
5
7
11
7
438 +/- 27
449 +/- 36
392 +/- 22
467 +/- 25
LDL (mg/dL)
n=
5
7
11
7
62 +/- 10
124 +/- 10
134 +/- 10
159 +/- 25
VLDL (mg/dL)
n=
5
7
11
7
66 +/- 21
110 +/- 7
116 +/- 20
110 +/- 21
Triglycerides
n=
8
8
11
8
(mg/dL)
132 +/- 9
125 +/- 7
111 +/- 4
119 +/- 11
Glucose (mg/dL)
n=
4
7
11
8
All values are means +/- SEM, number of mice (N) is given for each value
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Development of Transgenic Mice Over-Expressing Human StARD5 in Liver
Using the ApoE Promoter
StARD5 was originally described as a liver expressed gene and it was
assumed this meant parenchymal cell expression. Therefore, early in my thesis
work I cloned the human StARD5 gene into the pLIV.7 vector so that expression
was driven by the human ApoE enhancer/promoter which was known to produce
high levels of transgene expression in liver parenchymal cells.

I used this

construction to create 4 transgenic founder lines. After I had begun to characterize
them, Rodriguez and colleagues published convincing evidence for liver StARD5
expression in Kuppfer cells and not in parenchymal cells. Since I wanted to
characterize the physiological functions of StARD5, I decided that the transgenic
lines with liver parenchymal cell expression were not germane, so I abandoned
these studies.
Preliminary work had been done on one of these transgenic lines
(ApoEhStARD5-1). Quantitative PCR was used to show liver expression of human
StARD5 (data not shown). The effect of the transgene was assessed on 3 different
diets, the AIN76a diet containing 0.0% or 0.5% cholesterol and a chow diet. The
protocol used was similar to the one described for the hStARD5 macrophagespecific transgenic mice. Wild-type and hStARD5 liver-parenchymal-cellexpressing transgenic mice at 6 weeks of age were placed on the AIN76a 0.0%
cholesterol diet for one week. After this mice were either kept on the AIN76a 0.0%
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cholesterol diet or switched to the AIN76a diet containing 0.5% cholesterol for one
week and then sacrificed at 8 weeks of age. The chow diet group was kept on
chow from weaning to 8 weeks of age. Comparison of wild-type and hStARD5
liver-parenchymal-cell-expressing transgenic mice showed little effect of the
transgene on plasma cholesterol levels (Table 2.12). In males the transgene
lowered triglyceride levels by 30% and 40% on the 0.0% and 0.5% cholesterol diets,
respectively, without change on the chow diet. In females the transgene had no
effect on triglyceride levels on any of the diets (Table 2.12). In addition, there were
no changes in liver total, free or esterified cholesterol levels on the AIN76a 0.5%
cholesterol and the chow diets of males (the livers of mice on the AIN76a 0.0%
cholesterol diet were not analyzed). In males the transgene decreased gallbladder
bile cholesterol concentration 43% on the AIN76a 0.5% cholesterol diet, with no
change on the AIN76a 0.0% cholesterol diet and a 48% reduction on the chow diet
(Table 2.12). In females the transgene decreased gallbladder bile cholesterol
concentration 30% on the AIN76a 0.5% cholesterol diet, with no change on the
AIN76a 0.0% cholesterol diet and a 38% reduction on the chow diet. Both males
and females had a 31% reduction in gallbladder bile phospholipid concentrations
on the AIN76a 0.5% cholesterol diet, but no change on the chow diet (the
phospholipids levels of mice on the AIN76a 0.0% cholesterol diet were not
analyzed) (Table 2.12). On a chow diet, the transgene decreased gallbladder bile
acid concentration 28% in males, but had no change in females (the bile acid
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concentrations of mice on the AIN76a 0.0% or 0.5% cholesterol diet were not
analyzed). In view of the findings of Rodriguez and colleagues (Rodriguez-Agudo
et al., 2006), the findings in this one founder family were not followed up in the
other founder families. Therefore, we do not know if they are gene-specific or due
to off-target transgene insertional effects. With this caveat, the data suggest ectopic
StARD5 expression in parenchymal cells is capable of sequestering cholesterol
and preventing its movement into the bile.

Table 2.12. Plasma, hepatic, and gallbladder bile levels of
ApoEhStARD5-1 transgenic mice fed the indicated diets
Male
Female
ApoEhD5-1
Wt
TG
Wt
TG
0.5% Cholesterol
84 +/- 8
85 +/- 9
66 +/- 4
65 +/- 2
Plasma
n=
7
7
8
7
0.0% Cholesterol
74 +/- 5
83 +/- 7
68 +/- 4
59 +/- 4
Cholesterol
n=
5
6
3
3
Chow
78 +/- 4
89 +/- 7
63 +/- 5
65 +/- 4
(mg/dl)
n=
9
7
6
13
0.5% Cholesterol
41 +/- 4
40 +/- 4
28 +/- 1
25 +/- 1
n=
7
7
8
7
0.0% Cholesterol
47 +/- 5
51 +/- 4
38 +/- 1
32 +/- 4
HDL (mg/dL)
n=
5
6
3
3
Chow
36 +/- 2
37 +/- 2
25 +/- 2
25 +/- 2
n=
9
7
6
12
45 +/- 5
27 +/- 1*
28 +/- 2
26 +/- 2
Triglycerides 0.5% Cholesterol
n=
7
7
8
7
0.0% Cholesterol
55 +/- 2
38 +/- 4*
23 +/- 3
25 +/- 3
n=
5
6
3
3
Chow
51 +/- 5
44 +/- 5
45 +/- 6
36 +/- 3
(mg/dL) n=
9
7
6
13
All values are means +/- SEM, number of mice (N) is given for each
* indicates p values < 0.05, ND indicates values not determined
99

Table 2.12. Plasma, hepatic, and gallbladder bile levels of
ApoEhStARD5-1 transgenic mice fed the indicated diets
Male
Female
ApoEhD5-1
Wt
TG
Wt
TG
Liver Total 0.5% Cholesterol 10.3 +/- 0.4 10.3 +/- 0.4
Cholesterol n=
3
3
Chow
3.7 +/- 0.2
3.8 +/- 0.5
(mg/g)
n=
3
3
8.1 +/- 0.6
Liver Free 0.5% Cholesterol 6.9+/-0.5
Cholesterol n=
3
3
Chow
3.2 +/- 0.3
3.1 +/- 0.4
(mg/g)
n=
3
3
Liver
0.5% Cholesterol 3.5 +/- 0.2
2.3 +/- 0.7
Cholesterol n=
3
3
Ester
Chow
0.6 +/- 0.3
0.7 +/- 0.3
(mg/g)
n=
3
3
Liver
0.5% Cholesterol
42 +/- 5
55 +/- 6
Triglycerides n=
3
3
Chow
130 +/- 9
113 +/- 4
n=
3
3
(mg/g)
0.5% Cholesterol 320 +/- 35
181 +/- 19*
Bile
n=
6
7
0.0% Cholesterol
66 +/- 11
80 +/- 18
Cholesterol
n=
5
4
Chow
129 +/- 14
68 +/- 7*
(mg/dL) n=
8
7
0.5% Cholesterol 2048 +/- 170 1396 +/- 189*
Bile
n=
6
7
Phospholipid

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

271 +/- 20
7
110 +/- 13
3
156 +/- 15
6

189 +/- 14*
6
77 +/- 18
3
98 +/- 4*
13

2692 +/- 142 1856 +/- 258*

7

6

0.0% Cholesterol
ND
ND
ND
ND
n=
Chow
1933+/- 203 1403 +/- 124 1988 +/-241 1704 +/- 134
n=
8
7
6
13
Chow
75 +/- 8
54 +/- 6*
67 +/- 7
68 +/- 4
n=
8
7
6
13

(mg/dL)
Bile Acids
(mM)
All values are means +/- SEM, number of mice (N) is given for each
liver values are in mg/g liver
* indicates p values < 0.05, ND indicates values not determined
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Expression of StARD5 in Saccharomyces cerevisiae
and Complementation Assays
The yeast is an excellent model organism for studying cell autonomous
functions like intra-cellular lipid transport. Although the yeast genome does not
encode START-domain containing proteins, yeast have been used to discover and
characterize many genes for other types of lipid transporters. Yeast mutants
deficient in many of these have been established, and we endeavored to determine
if any of those deficient in sterol transport might be complemented by StARD5. If
successful this would have been a powerful way to gain insight into StARD5
function. This work was done in collaboration with Steve Sturleyʼs laboratory at
Columbia University. A plasmid was constructed containing human StARD5 cDNA
with an N-terminal GFP under the control of an inducible galactose promoter
(pRS426) (gift from Sturley). This StARD5 expression vector was transfected into
wild-type yeast grown in galactose and inducible expression of StARD5 was
confirmed both by GFP levels in a fluorescence assay and StARD5 amount by
Western-blotting analysis (Figure 2.13).
This StARD5 expression vector was transfected into the upc2.1 strain, which
is a gain of function mutant for the transcription factor regulating the ATP-binding
cassette transporters AUS1 and PDR11. The expression of these transporters
allows sterol influx to occur under aerobic conditions. If StARD5 was capable of
promoting cholesterol efflux from yeast, we were hoping its expression might
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diminish yeast sterols and alter the lipid profile, but this did not occur. Similarly the
arv1 yeast strain contains a temperature sensitive mutation in a putative sterol
transporter that moves sterols from the ER to the Golgi. At the inactivation
(restrictive) temperature the ER accumulates excess free sterols and the ER stress
response is triggered. If StARD5 was able to move cholesterol from the ER to the
Golgi we might have expected the arv1 strain to be rescued from the ER stress
response. However, transfection of the StARD5 expression plasmid had no effect
as evidenced by continued expression of Hac1, the yeast ATF homolog.
1
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Figure 2.13. Expression of hStARD5-GFP in wildtype yeast. Western blot of yeast showing
galactose-inducible expression of GFP-hStARD5 (anti-GFP antibody). 10ug protein used. Protein
bands are approximately 52kDa, which is the expected size of the fusion of StARD5 and GFP.
Lane 1-4 Control Plasmid; Lane 5-8 hStARD5-GFP transformed cells. Lane1-2, 5-6 cells grown in
glucose; Lane 3-4, 7-8 cells grown in galactose.

We were about to test other yeast mutants for complementation with
StARD5 when Rodriguez and colleagues published a paper showing that StARD5
bound cholesterol and 25-hydroxycholesterol, but not 27-hydoxycholesterol, 24hydroxycholesterol,

24,25-hydroxycholesterol,

7alpha-hydroxycholesterol,

beta-sitosterol, or cholic acid. The unexpected (at least to us) specificity with which
StARD5 bound sterols made us reconsider our work in yeast, which has ergosterol
as its major sterol. Although ergosterol is synthesized, regulated, and esterified
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in yeast in a manner similar to the way cholesterol is metabolized in mammals,
ergosterol is structurally different from cholesterol in that it has two additional
double bonds at C7 and C22, plus an additional methyl group at C24 (Figure 2.14).
These differences would most likely prevent StARD5 from binding ergosterol. This
would explain our negative complementation results with the upc2.1 and arv1 yeast
strains, and strongly suggest that any similar effort to complement other yeast
mutants with defective ergosterol transport would also be fruitless. This realization
caused us to abandon our efforts to determine StARD5 function by yeast
complementation studies.

Figure 2.14 Structure of ergosterol and cholesterol.
Ergosterol (left) differs structurally from cholesterol (right) with two additional double bonds at C7
and C22, along with an additional methyl group at C24.
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Summary
This chapter describes our studies attempting to determine the physiological
functions of StARD5 in vivo through the creation and study of a knockout mouse
and two different transgenic mice. With the knockout, we demonstrated that
StARD5 is essential for the early development of mouse embryos, but that
haploinsufficiency does not alter plasma cholesterol or triglyceride levels, liver
cholesterol levels, gallbladder bile composition, glucose tolerance, cholesterol efflux
from macrophages or atherosclerosis susceptibility. In addition, tissue-specific
transgenic over-expression of human StARD5 in macrophages had no effect on
plasma cholesterol or triglyceride levels, liver cholesterol levels, gallbladder bile
composition, cholesterol efflux from macrophages or atherosclerosis susceptibility.
Moreover, although StARD5 is normally expressed in liver Kuppfer cells,
inappropriate transgenic over expression in liver parenchymal cells lowered plasma
triglyceride levels and decreased gallbladder bile cholesterol, phospholipids, and
bile acids concentration. Finally, in yeast complementation assays human StARD5
failed to complement two mutant yeast strains with defects in sterol transport,
probably because StARD5 fails to transport ergosterol.
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Chapter 3: Characterization of ADAM11
Background
One of the goals of our laboratory is to understand diet responsiveness. In
this regard, Soccio and colleagues undertook an experiment to feed low and high
cholesterol diets to C57BL/6J mice to determine which genes were regulated by
dietary cholesterol. At the time of his experiments the only gene expression array
available to our laboratory was a cDNA array displaying a few thousand genes.
Several years later with availability of commercial oligonucleotide microarrays
displaying sequences corresponding to most genes, this experiment was repeated
with minor modifications by Maxwell and colleagues (Maxwell et al., 2003).
C57BL/6 mice at 6 weeks of age were placed on the AIN76a 0.0% cholesterol diet
for one week. After this, mice were either kept on the AIN76a 0.0% cholesterol diet
or switched to the AIN76a diet containing 0.5% cholesterol for one week and then
all of the mice were sacrificed at 8 weeks of age. Under these conditions compared
to the AIN76a 0.0% cholesterol diet the AIN76a 0.5% cholesterol diet increased
liver total, free and esterified cholesterol. Liver RNA was isolated and gene
expression assessed by Affymetrix microarrays MGU74v2. There were 69 dietary
cholesterol regulated gens, 39 down-regulated (including StARD4 as seen in the
earlier study by Soccio) and 32 up-regulated. One of the relatively novel upregulated genes was ADAM11, and this is the second gene studied in depth as part
of this thesis.
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Figure 3.1. ADAM11 mRNA is regulated by sterol levels. (From K.Maxwell) Northen blot of RNA
from multiple tissues pooled from male C57Bl6 mice fed a Low Cholesterol (L) (0.0%) diet or a high
cholesterol (H) (0.5%) cholesterol diet. Blots were probed with ADAM11A 3ʼutr.

In previous work Maxwell had shown that ADAM11 up-regulation by dietary
cholesterol was only in liver and not in other tissues (Figure 3.1). In vivo she
showed that injection into mice of the LXR agonist T0901317 increased ADAM11
mRNA, confirming ADAM11 as an LXR target gene. Rybnikova and colleagues
had previously shown ADAM11 expression in liver parenchymal cells of mice
(Rybnikova et al., 2002). The role of ADAM11 in the liver is unknown, although it
is tempting to speculate it might be involved in reverse cholesterol transport, since
it is up-regulated by cholesterol feeding and is an LXR target gene as are many
others in this pathway. This thesis attempts to understand ADAM11 function by
generating an ADAM11 conditional knockout (cKO) mouse and characterizing it
metabolically, as well as creating an ADAM11 adenovirus to study the
consequences of over-expression of ADAM11 in the liver in vivo.
The Targeted Disruption of ADAM11
In order to allow the gene to be inactivated in a tissue- or temporal-specific
fashion, a strategy was undertaken to create an ADAM11 cKO mouse. The
ADAM11 gene contains 26 or 27 exons (see next paragraph) and is located on
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mouse chromosome 11. A BAC clone encompassing the ADAM11 locus was
obtained from a C57BL/6 genomic library (BacPac Resources, RP24-166M9).
Utilizing the recombineering techniques described by Copeland and colleagues
(Liu et al., 2003), a targeting vector was constructed in the MC1-TK-containing
plasmid with a loxP site in ADAM11 intron 11 and an Frt-Pgk-em7-Neo-Frt-loxP
cassette in ADAM11 intron 18 (Figure 3.2). The MC1-TK cassette was used for
negative selection against random integration events, while the Neo cassette
allowed for positive selection. The Neo floxed allele of the ADAM11 gene was
generated through homologous recombination in isogenic mouse ES cells. Twelve
correctly targeted ES clones were identified by Southern blotting using BamHI or
EcoRV restriction digest of genomic DNA and external 5ʼor 3ʼprobes, respectively,
that were not part of the targeting vector. Five ES cell clones were expanded and
injected into blastocysts to produce chimeras, but only one (#138) led to germ-line
transmission.
Like other members of the ADAM family, ADAM11 is a multi-domain protein
(see Chapter 1)(Figure 3.3). Two alternatively spliced isoforms of ADAMm11 mRNA
exist: one expressed primarily in brain, and the other predominantly in liver. These
isoforms share the first 25 exons and differ only in their C-terminal cytoplasmic tails.
The liver form of ADAM11, ADAM11a, is a 778 amino acid protein encoded by 26
exons, whereas the brain form of ADAM11, ADAM11b, is a 773 amino acid protein
encoded by 27 exons. ADAM11 exons 1-7 encode the prodomain, exons 8-15

107

A

C

B

fl/fl

fl/+ +/+
+/- +/+ -/-

Figure 3.2. Gene targeting and generation of a conditional knockout (floxed) allele of the
ADAM11 gene. A) Targeting strategy to flank exon 12 through exon 18 of ADAM11 with loxP sites.
The targeting vector was constructed by placing a Neo selectable marker flanked by Frt sites with
a loxP site. A second loxP site was introduced in intron 11. B) PCR analysis in order to determine
the presence of the wildtype and/or floxed alleles in heterozygous (fl/+), homozygous mutants (fl/fl)
as well as wildtype controls. C) PCR analysis in order to determine the presence of the wildtype
(top) and/or null allele(bottom) in in heterozygous (+/-), homozygous mutants (-/-) as well as
wildtype (+/+) controls.
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encode the inactive metalloprotease domain, exons 15-18 encode the disintegrin
domain, exons 18-23 encode the cysteine-rich domain, exons 23-24 encode the
EGF-like domain, exons 24-25 encode the transmembrane domain, and exons 2526 (ADAM11a) or exons 25-27 (ADAM11b) encode the cytoplasmic tail. We
undertook to knockout exons 12 to 18 by flanking these exons with loxP sites and
using Cre-recombinase to remove them, thus deleting coding sequences for much
of the metalloprotease domain and the entire disintegrin domain. In addition,
splicing of exon 11 to either exons 19, 20 or 21 would be out of frame and result in

Figure 3.3. Domain structure of ADAM11. Mouse ADAM11 protein is made up of a signal peptide
(SP), a pro-domain, a metalloprotease domain, a disintegrin domain, a cysteine-rich domain, an
EGF-like domain, a single transmembrane domain, and a cytoplasmic C-terminal domain (CTD).
ADAM11 (along with its subfamily members ADAM22 and ADAM23) does not contain the
conserved histine residues (H) within the metalloprotease domain that are necessary for protease
activity. ADAM11 contains a similar potential integrin binding loop as ADAM22 and ADAM23.
There are two transcripts of ADAM11: A and B, which differ at their C-terminal ends. Exons 1-7
encode the signal peptide and pro-domain; exons 8-15 encode the metalloprotease domain; exons
15-18 encode the disintegrin domain; exons 18-23 encode the cysteine-rich domain, exons 23-24
encode the EGF-like domain, exons 24-25 encode the transmembrane domain, and exons 2526(A) or 25-27(B) encode the cytoplasmic domain.
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termination codons. The possible splicing of exon 11 to either exons 22 or 23 would
be in frame, however, the proteins encoded would also be missing the cysteinerich domain, which is thought to provide protein stability.
Viability, Fertility, and Fecundity in the ADAM11 cKO Mice
After detection of germ-line transmission of the targeted allele, brother-sister
mating of ADAM11 heterozygous cKOs with the Neo floxed allele was carried out
and yielded offspring with genotypes compatible with the expected Mendelian
pattern of inheritance. The ADAM11 homozygous Neo floxed cKO mice produced
were viable, grew normally. Next, the ADAM11 cKO mice heterozygous for the Neo
floxed allele were bred to C57BL/6 ACT-FLPe transgenic mice, which efficiently
removed the Neo cassette from the ADAM11 gene (Figure 3.2). Again, brothersister mating of ADAM11 heterozygous cKOs with the floxed allele was carried out
and yielded offspring with genotypes compatible with the expected Mendelian
pattern of inheritance. The ADAM11 homozygous floxed cKO mice produced were
viable, grew normally, and were fertile.

Finally, the ADAM11 cKO mice

heterozygous for the floxed allele were bred to C57BL/6 CMV-Cre transgenic mice,
which efficiently removed exons 12-18 from the ADAM11 gene leaving in their place
a single loxP site (Figure 3.2).

Again, brother-sister mating of ADAM11

heterozygous cKOs with the null allele was carried out and yielded offspring with
genotypes compatible with the expected Mendelian pattern of inheritance (Table
3.1). The ADAM11 homozygous null cKO mice produced were viable, grew
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Table 3.1. Fertility and Fecundity of ADAM11cKO Mice
Floxed
Male +/fl x Female +/fl
Deleted
Male +/- x Female +/-

wt:het:homo
14:23:14

litter size (mean +/- SD)
6.4 +/- 2.0

17:28:15

6.6 +/- 1.5

normally, and were fertile, indicating that the ADAM11 gene is not essential for
survival or normal development.
ADAM11 protein levels were examined by Western-blotting in the brain of
ADAM11 heterozygous and homozygous cKO null mice and compared to wild-type
mice found to be about half normal in the former and absent in the latter. A similar
analysis of ADAM11 heterozygous and homozygous cKO floxed mice showed
normal levels of ADAM11 protein; the latter indicating that the loxP sites in introns
11 and 18 do not interfere with proper splicing and protein synthesis (Figure 3.4)
(Figure 3.5).
1

2

3

4

5

6

7

8

9

10 11 12 13

Figure 3.4. Western blot of brains of ADAM11 mice.
Absence of ADAM11 protein in the knockout brain was shown using anti-ADAM11 monoclonal
antibody. Comparison of the Takahashi null mutant and the full knockout developed in our lab.
Expression is detected in our homozygous floxed allele, but not in the full knockout or in the
Takahashi null mutant. Expression of ADAM11 in the heterozygote KO is approximately half the
levels of wildtype mice,
Lane 1) Homozygous Floxed, 2) Takahashi null mutant, 3) Takahashi heterozygote mutant,
4) Takahashi null mutant, 5) Empty, 6) ADAM11 recombinant protein,
7) Wildtype, 8) Heterozygote KO, 9) Homozygote KO, 10) Heterozygote KO, 11) Wildtype,
12) Heterozygote Floxed, 13) Homozygote Floxed.
Brain homogenate was processed via ConA Sepharose 4B treatment. 25ug of protein from brain
was was added in each lane, equal and proper transfer was confirmed by Ponceau staining.
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Chimera
Mate to
C57Bl6
Exon 11

Exon
12-18

Exon 19

Brother-Sister
Mating

Neo Hets

6:9:3
loxP

loxP
FrtNeoFrt

Mate to
ACT-FLPe
Exon 11

Exon
12-18

Exon 19

Brother-Sister
Mating
14:23:14

Flox Hets
loxP

loxP
Frt

Mate to
CMV-Cre
Exon 11

Exon
12-18

Exon 19

Brother-Sister
Mating
17:28:15

Null/Deleted
Hets
loxP

Figure 3.5. Mating strategy in generation of the ADAM11 knockout.
Chimera mice were mated to C57Bl6 to generate Neo heterozygotes. These Neo heterozygotes
were brother-sister mated in an attempt to generate Neo homozygotes. The Neo heterozygotes
were also mated to the ACT-FLPe transgenic mice to remove the FrtNeoFrt cassette and to
generate Flox heterozygotes. These Flox heterozygotes were brother-sister mated in an attempt
to generate Flox homozgotes. The Flox heterozygotes were mated to CMV-Cre transgenic mice
to remove exon 12-18 and to generate Null/Deleted heterozygotes. These Null heterozygotes were
brother-sister mated in an attempt to generate Null homozygotes. Results of the brother-sister
matings are indicated on the right; the order is wildtype:heterozygotes:homozygotes. Results of
the matings followed Mendellian laws. Rectangles represent exons, triangles represents loxP sites,
cross represents the FrtNeoFrt cassette, line vertical line represents Frt site, arrows represent
matings.
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Full Knockout of ADAM11 has a Neurologic Phenotype
ADAM11 was originally identified as a gene highly expressed in the CNS of
the adult mouse by Sagane and colleagues (Sagane et al., 1998; Sagane et al.,
1999). Rybnikova and colleagues further showed the spatiotemporal expression
pattern of the ADAM11 gene in adult mice and during development, and identified
the cells expressing the gene (Rybnikova et al., 2002). In the adult CNS, ADAM11
mRNA was present throughout the forebrain, including different cortical fields and
diencephalic nuclei (Rybnikova et al., 2002). In brainstem, low to moderate
expression was detected in certain midbrain nuclei, while several pontine and
medullary nuclei showed a very strong signal (Rybnikova et al., 2002). High
expression was observed in the cerebellar cortex and spinal cord. In addition,
ADAM11 was expressed in ganglia of the peripheral nervous system (PNS), retina,
testes, liver, and at lower levels in epidermal and mucosal epithelia, kidney, and
salivary gland (Rybnikova et al., 2002). Expression occurred only in neurons in all
examined CNS and PNS subfields.
In parallel with our work, Takahashi and colleagues also developed an
ADAM11 knockout mouse.

Their main objective was to understand the

physiological role of ADAM11 in the brain. Their knockout strategy consisted of
introducing a stop codon in exon 5 and replacing exon 6 with a Neo cassette by
homologous recombination, thereby creating a null gene (Takahashi et al., 2006a;
Takahashi et al., 2006b). In agreement with our findings, they found ADAM11
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homozygous knockout mice to be viable, grow normally, and be fertile. They also
showed that at autopsy ADAM11 homozygous knockout mice had no anatomical
or histological abnormalities (Takahashi et al., 2006a; Takahashi et al., 2006b).
Because ADAM11 is highly expressed in the hippocampus and cerebellum,
Takahashi and colleagues examined ADAM11 homozygous knockout mice for
learning using visual and hidden water maze tasks, and motor coordination using
a rotating rod task (Takahashi et al., 2006a; Takahashi et al., 2006b). They showed
that while the mice performed normally in the visual water maze task, they had
deficits in the hidden water maze, suggesting a deficit in spatial learning (Takahashi
et al., 2006a; Takahashi et al., 2006b). The mice also had impairments in the
rotating rod task, while exhibiting normal grip strength, suspension from a wire, and
walking, suggesting ADAM11 knockout mice have a CNS deficit in motor
coordination, but not muscle weakness or other PNS deficits. Further testing
showed these mice to have normal responses to stimuli in the von Frey and hot
plate tests, but reduced responses to the formalin paw test and acetic acid writhing
test, suggesting ADAM11 may also play a role in pain transmission and perception
(Takahashi et al., 2006a; Takahashi et al., 2006b).
The mice created by Takahashi and colleagues were available for study prior
to our ADAM11 cKO mice, and they generously provided them to us. It is their mice
that were used for the functional studies presented in this thesis. When we received
them, their mice, originally created using strain 129 ES cells, had undergone 14
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generations of backcrossing to the C57BL/6 background. However, to ensure a
pure C57BL/6 background, especially necessary for atherosclerosis studies, the
mice were backcrossed to C57BL/6 another 4 times, and then genotyped by
microsatellite and SNP analysis and confirmed to be (over 99.5% C57BL/6).
ADAM11 Knockout has Absence-like Seizures
As described in Chapter 1, ADAM11 is the closest paralog of ADAM22 and
ADAM23. Deletion of either ADAM22 or ADAM23 results in severe seizures and
peri-natal death, but ADAM11 null mice appear to develop normally and do not
exhibit an overt seizure phenotype. However, because of structural similarity
between these genes a more careful examination for seizure activity was
performed by doing an electroencephalograph (EEG) on ADAM11 knockout mice.
In collaboration with Dr. Noebels at Baylor University, 3 ADAM11 knockout males
and 2 wild-type male siblings at approximately 20 weeks of age were examined.
The EEG results showed a major change in background rhythms of the knockout
mice, with most of the power in the 5-6Hz or theta range, while no faster activity
(beta or alpha) was detected. This could explain the impairments in memory and
exploration-related behaviors. ADAM11 knockout mice also exhibited constant
cortical discharges and frequent (approximately 1/hour) non-convulsive seizures,
indicative of absence-like epilepsy (Figure 3.6).
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Figure 3.6. EEG Analysis of ADAM11 mice.
ADAM11 mutant mice display absence-like epilepsy and altered brain
wave activity. Power is in the 5-6Hz or theta range, with no fasterr
activity (alpha or beta waves). Mice also exhibited constant cotical
discharges and frequent (1/hour) non-convulsive seizures.
(J.Noebels, Baylor, Texas).

116

Fear Conditioning Testing
The hippocampus and amygdala are responsible for regulating the bodyʼs
responses to stress. Contextual fear depends on hippocampus and amygdale,
whereas cued fear depends on the amygdala. ADAM11 knockout and wild-type
mice (eight to twelve mice of each gender and each genotype) were tested in a
fear conditioning assay. As measured by the time the mouse spends frozen after
a given stimulus, ADAM11 mice showed normal baseline fear, learned fear,
contextual fear, and cued fear (Figure 3.7).
A

C

B

D

Figure 3.7. Fear Conditioning of ADAM11 Mice. (n=8-12 mice per gender and genotype).
A) Initial baseline percent freezing over 2-minute interval, B) Learning Phase, percent freezing over
30-second interval after initial tone and before shock, C) Contextual Freezing, percent freezing
over 2-minute interval after placement of mice in same context (same cage, same scent), D) Cued
Freezing, percent baseline freezing (Before Cue) in new context (new cage, new scent) over 1minute interval, and then percent freezing after cue (Cued) (same tone) over 1-minute interval.
Values are means of percent freezing plus or minus SEM.
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The Dietary Feeding Paradigms of ADAM11 Knockout Mice
Experiments were undertaken to determine the effect of ADAM11 deficiency
on lipid and glucose homeostasis. Wild-type and ADAM11 heterozygous and
ADAM11 homozygous knockout mice at 6 weeks of age were placed on the AIN76a
0.0% cholesterol diet for one week. These mice were then either kept on the
AIN76a 0.0% cholesterol diet or switched to either the AIN76a diet containing 0.5%
cholesterol or the AIN76a diet containing 0.5% cholic acid for one week. At 8 weeks
of age measurements were made and the mice sacrificed. In confirmation of the
previous study by Maxwell, wild-type mice did respond to one week of high
cholesterol feeding by increasing liver levels of ADAM11 mRNA.
Pathology of ADAM11 Knockout Mice on the High Cholesterol Diet
There was no difference in body or liver weight between wild-type and
ADAM11 heterozygous and homozygous knockout mice fed the three diets at 8
weeks of age (Table 3.2). The ADAM11 knockout mice on the AIN76a 0.5%
cholesterol diet were autopsied by the Tri-Institutional Core Facility located at the
MSKCC Pathology Department. Compared to wild-type litter-mates there were no
apparent anatomical-histological differences observed in heart, lungs, esophagus,
thymus, tongue, kidneys, pancreas, renal lymph nodes, spleen, salivary glands,
stomach, duodenum, jejunum, ileum, colon, cecum, pancreas, brown fat, urinary
bladder, thyroid glands, trachea, adrenal glands, liver, sciatic nerve, spinal cord,
gallbladder, or brain.
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Table 3.2. Body composition of ADAM11 mice fed the indicated diets

Male

Wt
Het
Ko
0.0% Cholesterol
21.6 +/- 0.6
21.1 +/- 0.3
21.5 +/- 0.3
n=
18
36
10
0.5% Cholesterol
22.4 +/- 0.3
22.7 +/- 0.2
21.8 +/- 0.5
Mouse Weight (g)
n=
38
61
28
0.5% Cholic Acid
20.6 +/- 0.4
21.7 +/- 0.4
20.4 +/- 0.4
n=
10
17
14
0.0% Cholesterol
1.07 +/- 0.04 1.02 +/- 0.02 1.10 +/- 0.04
n=
18
36
10
0.5% Cholesterol
1.15 +/- 0.02 1.19 +/- 0.02 1.17 +/- 0.03
Liver Weight (g)
n=
38
61
28
0.5% Cholic Acid
1.08 +/- 0.04 1.09 +/- 0.02 1.02 +/- 0.03
n=
10
17
14
Female
Wt
Het
Ko
0.0% Cholesterol
16.7 +/- 0/4
16.7 +/- 0.3
17.7 +/- 0.6
n=
16
22
6
0.5% Cholesterol
17.2 +/- 0.2
17.4 +/- 0.2
17.6 +/- 0.3
Mouse Weight (g)
n=
25
75
25
0.5% Cholic Acid
17.7 +/- 0.3
16.7 +/- 0.4
16.9 +/-0.5
n=
8
21
6
0.0% Cholesterol
0.83 +/- 0.03 0.83 +/- 0.03 0.85 +/- 0.06
n=
16
22
6
0.5% Cholesterol
0.94 +/- 0.02 0.94 +/- 0.01 0.98 +/- 0.02
Liver Weight (g)
n=
25
75
25
0.5% Cholic Acid
0.92 +/- 0.04 0.87 +/- 0.03 0.90 +/- 0.05
n=
8
21
6
All values are means +/- SEM, number of mice (N) is given for each value
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Effect of ADAM11 Deficiency on Plasma Total, HDL and LDL Cholesterol,
Free Cholesterol, Triglycerides, Glucose, ALT and Plant Sterol Levels
There were no differences between wild-type, ADAM11 heterozygous
knockout, and ADAM11 homozygous knockout mice of each gender fed the three
diets in plasma total, HDL and LDL cholesterol, free cholesterol, triglycerides,
glucose, and ALT levels (Table 3.3).
Levels of plant sterols were compared in wild-type and ADAM11
homozygous knockout mice fed the AIN76a 0.5% cholesterol diet. ADAM11
deficiency in mice of each gender had no effect on plasma levels of total, free or
esterified brassicasterol, campesterol, or sitosterol, with the exception in male mice
of a 20% decrease in free campesterol. ADAM11 deficiency had no effect on total
lathosterol levels (Table 3.4).
Mice fed the AIN76a 0.5% cholic acid diet had a modest increase in plasma
levels of ALT, but this was independent of genotype (data not shown).
Blood Amino Acid Levels
Blood levels of the amino acids alanine, arginine, asparagine, aspartic acid,
glutamic acid, glutamine, histidine, isoleucine, leucine, methionine, phenylalanine,
proline, serine, threonine, tryptophan, tyrosine, valine, as well as ornithine and
citrulline did not differ between wild-type and ADAM11 homozygous knockout mice
fed the AIN76a 0.5% cholesterol diet (data not shown).
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Table 3.3. Plasma levels of ADAM11 mice fed the indicated diets
Male
Wt
Het
Ko
42 +/- 3
29 +/- 3
45 +/- 3
Triglycerides 0.0% Cholesterol
n=
16
31
8
0.5% Cholesterol
33 +/- 2
32 +/- 1
34 +/- 2
n=
27
50
21
0.5% Cholic Acid
31 +/- 9
38 +/- 12
29 +/- 5
(mg/dL)
n=
3
3
5
84 +/- 4
85 +/- 3
79 +/- 8
Total Cholesterol 0.0% Cholesterol
n=
18
36
9
0.5% Cholesterol
89 +/- 3
87 +/- 2
91 +/- 4
n=
27
50
21
0.5% Cholic Acid
73 +/- 6
88 +/- 8
77 +/- 4
(mg/dL)
n=
5
7
9
0.0% Cholesterol
54 +/- 3
55 +/- 2
55 +/- 6
n=
18
36
9
0.5% Cholesterol
47 +/- 2
48 +/- 1
48 +/- 2
HDL (mg/dL)
n=
27
50
21
0.5% Cholic Acid
28 +/- 4
34 +/- 2
28 +/- 2
n=
5
7
9
0.0% Cholesterol
23 +/- 1
23 +/- 1
20 +/- 2
n=
18
36
9
0.5% Cholesterol
30 +/- 2
30 +/- 2
30 +/- 2
LDL (mg/dL)
n=
27
49
21
0.5% Cholic Acid
36 +/- 1
42 +/- 6
36 +/- 3
n=
5
7
9
0.0% Cholesterol
2 +/- 1
3 +/- 1
3 +/- 1
n=
12
19
6
0.5% Cholesterol
7 +/-2
6 +/- 1
7 +/- 1
VLDL (mg/dL)
n=
9
14
5
0.5% Cholic Acid
8 +/- 1
7 +/- 1
7 +/- 1
n=
5
7
9
0.0% Cholesterol
30 +/- 2
30 +/- 2
25 +/- 2
non-HDL
n=
18
36
9
0.5% Cholesterol
45 +/- 3
39 +/- 2
43 +/- 3
(calculated)
n=
27
50
21
0.5% Cholic Acid
43 +/- 3
53 +/- 7
48 +/- 5
(mg/dL)
n=
5
7
9
Free Cholesterol 0.5% Cholesterol
14.9 +/- 0.5
15.0 +/- 0.7
ND
n=
16
16
(mg/dL)
Glucose
0.5% Cholesterol
177 +/- 16
182 +/- 11
ND
mg/dL
n=
4
5
All values are means +/- SEM, number of mice (N) is given for each value
ND indicates not determined
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Table 3.3. (cont.) Plasma levels of ADAM11 mice fed the indicated diets
Female
Wt
Het
Ko
0.0%
Cholesterol
32
+/2
32
+/3
33
+/- 3
Triglycerides
n=
13
18
4
0.5% Cholesterol
25 +/- 2
26 +/- 1
26 +/- 2
n=
14
44
15
0.5% Cholic Acid
35 +/- 6
30 +/- 4
30 +/- 5
(mg/dL)
n=
4
6
3
0.0%
Cholesterol
67
+/-3
68
+/3
70
+/6
Total Cholesterol
n=
16
22
6
0.5% Cholesterol
69 +/- 3
76 +/- 3
79 +/- 4
n=
14
46
15
0.5% Cholic Acid
57 +/- 6
72 +/- 11
52 +/- 4
(mg/dL)
n=
5
10
3
0.0% Cholesterol
43 +/- 2
43 +/- 2
45 +/- 3
n=
15
22
6
0.5% Cholesterol
33 +/- 2
34 +/- 1
33 +/-2
HDL (mg/dL)
n=
14
46
14
0.5% Cholic Acid
25 +/- 2
23 +/- 2
23 +/- 2
n=
5
10
3
0.0% Cholesterol
19 +/- 2
22 +/- 2
21 +/- 2
n=
15
22
6
0.5% Cholesterol
24 +/- 3
29 +/- 2
26 +/- 4
LDL (mg/dL)
n=
14
45
14
0.5% Cholic Acid
25 +/- 2
33 +/- 6
22 +/- 4
n=
5
10
3
0.0% Cholesterol
2 +/- 1
2 +/- 1
2 +/- 1
n=
7
10
3
0.5% Cholesterol
13 +/- 2
16 +/- 3
14 +/- 3
VLDL (mg/dL)
n=
5
11
7
0.5% Cholic Acid
6 +/- 1
10 +/-4
6 +/- 1
n=
5
10
3
0.0% Cholesterol
26 +/- 2
24 +/- 2
24 +/- 3
non-HDL
n=
15
22
6
0.5% Cholesterol
37 +/- 3
42 +/- 3
45 +/- 4
(calculated)
n=
14
46
14
0.5% Cholic Acid
32 +/- 3
34 +/- 10
28 +/- 3
(mg/dL)
n=
5
10
3
10.4 +/- 0.5
11.9 +/- 1.3
Free Cholesterol 0.5% Cholesterol
ND
n=
16
16
(mg/dL)
Glucose
0.5% Cholesterol
131 +/- 7
130 +/- 10
ND
mg/dL
n=
4
4
All values are means +/- SEM, number of mice (N) is given for each value
ND indicates not determined
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Table 3.4. Plasma phytosterol levels of ADAM11 mice on
0.5% cholesterol diet

Male

Wt
Ko
Total Brassicasterol/cholesterol
1.18 +/- 0.14
1.15 +/- 0/17
Free Brassicasterol/cholesterol
0.23 +/- 0.05
0.21 +/- 0.05
Ester Brassicasterol/cholesterol
0.95 +/- 0.10
0.95 +/- 0.13
Total Campesterol/cholesterol
17.43 +/- 1.16 15.91 +/- 1.10
Free Campesterol/cholesterol
5.03 +/- 0.30
3.98 +/- 0.27*
Ester Campesterol/cholesterol
12.41 +/- 0.88 11.93 +/- 0.85
Total Sitosterol/cholesterol
0.80 +/- 0.14
0.55 +/- 0.11
Free Sitosterol/cholesterol
0.63 +/- 0.08
0.52 +/- 0.10
Ester Sitosterol/cholesterol
0.16 +/- 0.08
0.04 +/- 0.03
Total Lathosterol/cholesterol
0.17 +/- 0.02
0.19 +/- 0.02
Female
Wt
Ko
Total Brassicasterol/cholesterol
1.95 +/- 0.17
1.77+/- 0.11
Free Brassicasterol/cholesterol
0.28 +/- 0.03
0.32 +/- 0.05
Ester Brassicasterol/cholesterol
1.67 +/- 0.15
1.45 +/- 0.09
Total Campesterol/cholesterol
22.99 +/- 1.07 21.07 +/- 0.89
Free Campesterol/cholesterol
5.14 +/- 0.35
4.13 +/- 0.45
Ester Campesterol/cholesterol
17.85 +/- 0.76 16.94 +/- 0.86
Total Sitosterol/cholesterol
0.68 +/- 0.17
1.33 +/- 0.31
Free Sitosterol/cholesterol
0.58 +/- 0.13
0.81 +/- 0.21
Ester Sitosterol/cholesterol
0.10 +/- 0.07
0.52 +/- 0.23
Total Lathosterol/cholesterol
0.22 +/- 0.03
0.23 +/- 0.03
(n= 16 for each gender and genotype); All values are means +/- SEM
All values are multiplied by a factor of 10,000.
(* is for values p<0.05)
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Hepatic Cholesterol and Triglyceride Levels on the High Cholesterol Diet
There were no differences between wild-type and ADAM11 homozygous
knockout mice of each gender fed the AIN76a 0.5% cholesterol diet in hepatic free
and esterified cholesterol as well as triglyceride levels (Table 3.5).

Table 3.5. Hepatic levels of ADAM11 mice on 0.5% cholesterol diet
Male

Female

Wt
Ko
Wt
10.6 +/- 0.8
10.5 +/- 0.7
14.7 +/- 1.2
Total Cholesterol
n=
14
11
8
4.0 +/- 0.2
3.7 +/- 0.2
4.1 +/- 0.3
Free Cholesterol
n=
14
11
8
36.5 +/- 3.6
35.6 +/- 2.5
47.2 +/- 3.6
Triglycerides
n=
14
11
8
All values are in mg/g liver, all values are means +/- SEM,
number of mice (N) is given for each value
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Ko
14.8 +/- 0.7
5
4.3 +/- 0.4
5
53.3 +/- 6.0
5

Gallbladder Bile Composition
There were no differences between wild-type, ADAM11 heterozygous
knockout, and ADAM11 homozygous knockout mice of each gender fed the three
diets in gallbladder bile concentrations of cholesterol, phospholipids, and bile acids
(Table 3.6).
Table 3.6. Gallbladder bile levels of ADAM11 mice fed the indicated diets
Male
Wt
Het
Ko
0.0% Cholesterol
120 +/- 11
108 +/- 9
126 +/- 13
Cholesterol
n=
12
8
4
0.5% Cholesterol
253 +/- 17
310 +/- 20
287 +/- 21
n=
24
27
16
0.5% Cholic Acid
184 +/- 20
231 +/- 55
225 +/- 14
(mg/dL)
n=
10
3
13
1532 +/- 113 1521 +/- 125 1406 +/- 250
Phospholipids 0.0% Cholesterol
n=
12
8
4
0.5% Cholesterol
1370 +/- 75
1480 +/- 92
1539 +/- 82
n=
24
27
16
0.5% Cholic Acid
1342 +/- 90
1345 +/- 152
1529 +/- 90
(mg/dL)
n=
10
3
13
56 +/- 5
57 +/- 3
65 +/- 7
Bile Acids (mM) 0.5% Cholesterol
n=
11
22
6
Female
Wt
Het
Ko
0.0% Cholesterol
117 +/- 4
126 +/- 7
115 +/- 10
Cholesterol
n=
10
9
4
0.5% Cholesterol
272 +/- 21
307 +/- 15
296 +/- 21
n=
11
28
17
0.5% Cholic Acid
223 +/- 11
206 +/- 24
ND
(mg/dL)
n=
6
5
2013 +/- 78
2198 +/- 101 1936 +/- 214
Phospholipids 0.0% Cholesterol
n=
10
9
4
0.5% Cholesterol
2173 +/- 97
2356 +/- 82
2180 +/- 102
n=
11
28
17
0.5% Cholic Acid
1755 +/- 132
1742 +/- 154
ND
(mg/dL)
n=
6
5
78 +/- 13
80 +/- 4
85 +/- 13
Bile Acids (mM) 0.5% Cholesterol
n=
4
24
4
All values are means +/- SEM, number of mice (N) is given for each value,
ND indicates not determined
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Glucose Tolerance
Wild-type, ADAM11 heterozygous knockout, and ADAM11 homozygous
knockout mice of each gender fed the AIN76a 0.5% cholesterol diet were subjected
to an IPGTT. The mice were given a bolus of glucose (2g/kg) intraperitoneally and
glucose measurements made at 0, 15, 30, 60, and 120 minutes. No differences
were observed in glucose tolerance between the genotypes (Figure 3.8).
A

B

Figure 3.8. Intraperitoneal Glucose Tolerance Test (IPGTT) of ADAM11 mice on 0.5%
cholesterol diet. 7.5 week old mice were tested after 4 days on high cholesterol diet, by injecting
a bolus of 2 mg glucose/g body weight; mean blood glucose values are indicated plus or minus
SEM. AUC, area under curve, for IPGTT is also provided.
A) Male (n=4wt, 9 het, 5 ko); AUC: wt: 30,038 +/- 1630, het: 32,159 +/- 2417, ko: 32,590 +/- 3669
B) Female (n=5wt, 7 het, 4 ko); AUC: wt: 26,759 +/- 1652, het: 27,819 +/- 3078, ko: 23,966 +/- 3661
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Global Transcript Profiling of Liver
In view of dietary cholesterol up-regulation of liver ADAM11 mRNA levels,
the lack of a phenotype related to plasma and liver lipids, gallbladder bile
composition, and glucose tolerance was puzzling. Therefore, we undertook
assessment of global liver gene expression analysis with hope that it might lead us
to the true function of ADAM11 in the liver. Utilizing the feeding paradigm outlined
previously, wild-type and ADAM11 homozygous knockout mice were fed AIN76a
0.0% or 0.5% cholesterol diets. As controls quantitative PCR was used to show
that wild-type mice on the AIN76a 0.5% cholesterol diet had higher levels of liver
ADAM11 mRNA than on the AIN76a 0.0% cholesterol diet, and in the ADAM11
homozygous knockout mice liver ADAM11 mRNA levels were undetectable on both
diets. Affymetrix gene expression arrays (MOE 430) were probed with liver RNA
as follows: three different pools of five male wild-type mice and three different pools
of five male ADAM11 homozygous knockout mice fed the AIN76a 0.5% cholesterol
diet, and two different pools of five male wild-type mice and two different pools of
five male ADAM11 homozygous knockout mice fed the AIN76a 0% cholesterol diet.
On the AIN76a 0.5% cholesterol diet compared to wild-type, in liver from ADAM11
homozygous knockouts only 8 genes were down-regulated and 10 up-regulated
by a 2-fold change. Not surprisingly, ADAM11 was the most highly down-regulated
gene (Table 3.7). All 17 of the other regulated genes were expressed at low or
marginal levels, and none had a known function related to sterol metabolism.
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Therefore, we have elected not to further investigate these genes. A third array
with pools of male mice (knockout and wild-type) fed the AIN76a 0% cholesterol
diet was not peformed, because none of the genes regulated by a 2-fold change
detected in the two prior arrays intersected with the 17 regulated genes on the
AIN76a 0.5% cholesterol diet, and again none of these genes had a known function
related to sterol metabolism either; statistics were not performed on this data set.
Table 3.7. Affymetrix list of genes regulated two-fold in the liver of
ADAM11 mice fed the 0.5% cholesterol diet
Affy

Mean Fold

Extension

Change

1443610_at

7.6

1446596_at
1440771_at

7.4
4.2

1440729_at

3.5

1433277_at
1459984_at

3.1
2.5
2.4

1423597_at

2.2

1442540_at

2.1

1425686_at

2.0

1440565_at

Affy

Mean Fold

Extension

Change

Gene Name

Fold Change in 3 arrays
1

5' of steroid 5 {alpha} -reductase 2-like

2.34
Protein kinase C mu
21.56
Zinc finger with KRAB and SCAN domains 1
1.93
epidermal growth factor receptor pathway
1.88
substrate 15
gephyrin
1.74
zinc finger and BTB domain containin 20
2.33
melanoma inhibitory activity 3
2.46
ATPase, aminophospholipid transporter (APLT),
2.91
class I, type 8A, member 1
Transcribed sequences
1.95
caspase 8 and FADD-like apoptosis regulator
1.81
Gene Name

2

3

17.47

10.54

3.61
2.35

5.27
16.42

2.16

10.27

6.55
2.31
2.2

2.54
2.88
2.48

1.86

1.99

2.53

1.98

1.74

2.54

Fold Change in 3 arrays
1

2

3

1450248_at

-3.0

a disintegrin and metalloprotease domain 11

-2.96

-2.4

-3.68

1444240_at

1451771_at

-2.9
-2.7
-2.6
-2.6
-2.4
-2.1

-2.43
-1.9
-1.87
-3.38
-1.81
-1.9

-1.83
-2.13
-3.52
-3
-2.26
-2.54

-5.38
-4.72
-2.75
-1.76
-3.44
-1.95

1436213_a_at

-2.0

Shank1 (SH3 ankyrin domain gene 1)
inhibitor of DNA binding 4
Transcribed sequences
asparagine synthetase
Sam68/Khdrbs1
two pore channel 1
ribulose-5-phosphate-3-epimerase

-1.71

-1.81

-2.61

1455298_at
1442808_at
1451095_at
1437389_x_at

Experiments 1-3 each compared liver gene expression of pools of five mice that were either ADAM11
KO or their wildtype siblings; each mouse was fed a one week high 0.5% cholesterol diet.
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Crossing the ADAM11 Knockout Trait onto the LDLR Knockout Background
To identify a possible effect of ADAM11 on atherosclerosis susceptibility, the
ADAM11 knockout trait was crossed on to the atherosclerosis-susceptible B6.LDLR
KO background. Brother-sister mating of LDLR KO ADAM11 heterozygous
knockout mice was carried out to produce wild-type and ADAM11 homozygous
knockout mice on the LDLR KO background for atherosclerosis studies. After
weaning at 4 weeks, these mice were fed the AIN76a 0.02% cholesterol diet for 16
weeks. The mice were sacrificed at 20 weeks of age and aortic root cross sectional
lesion areas measured. No significant differences were observed for either gender
between the genotypes (Figure 3.9).

Comparisons of wild-type, ADAM11

heterozygous knockout, and ADAM11 homozygous knockout mice on the LDLR
KO background did not show any differences in body weight or liver weight (Table
3.8), total, HDL, LDL and VLDL cholesterol, triglycerides, glucose or free cholesterol
(Table 3.9), gallbladder bile cholesterol and phospholipid concentrations (Table
3.10), and glucose tolerance as measured by the IPGTT (Figure 3.10).
Table 3.8. Body composition of ADAM11 mice on LDLR KO background
Male
Wt
Het
Ko
30.3 +/- 0.7
29.6 +/- 0.5
29.2 +/- 0.5
Mouse Weight (g)
n=
23
32
19
1.18 +/- 0.25
1.24 +/- 0.12
1.18 +/- 0.10
Liver Weight (g)
n=
3
3
6
Female
Wt
Het
Ko
22.8 +/- 0.8
21.2 +/- 0.4
20.5 +/- 0.6
Mouse Weight (g)
n=
16
26
19
1.05 +/- 0.05
0.92 +/- 0.07
1.09 +/- 0.07
Liver Weight (g)
n=
4
3
3
All values are means +/- SEM, number of mice (N) is given for each value
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Table 3.9. Plasma levels of ADAM11 mice on LDLR KO background
Male
Wt
Het
Ko
Triglycerides
155 +/- 14
175 +/- 20
162 +/- 17
mg/dL
n=
13
19
10
Total Cholesterol
417 +/- 29
515 +/- 37
474 +/- 42
mg/dL
n=
22
28
17
HDL
57 +/- 3
62 +/- 3
58 +/- 3
mg/dL
n=
21
23
17
LDL
260 +/- 19
303 +/- 21
282 +/- 27
mg/dL
n=
21
23
16
VLDL
59 +/- 8
54 +/- 7
63 +/- 9
mg/dL
n=
21
23
17
Glucose
142 +/- 7
152 +/- 6
135 +/- 11
mg/dL
n=
21
29
15
Female
Wt
Het
Ko
Triglycerides
177 +/- 27
189 +/- 20
167 +/- 22
mg/dL
n=
10
29
15
Total Cholesterol
671 +/- 51
695 +/- 34
731 +/- 63
mg/dL
n=
16
36
17
HDL
38 +/- 3
48 +/- 8
38 +/- 2
mg/dL
n=
16
31
17
LDL
374 +/- 28
364 +/- 17
385 +/- 22
mg/dL
n=
16
31
17
VLDL
177 +/- 23
157 +/- 15
177 +/- 17
mg/dL
n=
16
31
17
Glucose
131 +/- 11
124 +/- 5
117 +/- 10
mg/dL
n=
12
35
17
All values are means +/- SEM, number of mice (N) is given for each value
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Female
KO

Female
WT

Male
KO

Male
WT

Figure 3.9. Atherosclerotic lesion size at the aortic root of ADAM11 mice on LDLR KO
background. Average lesion size (um2) at the aortic root was measured in each ADAM11 knockout
and wild-type mouse after 16 weeks on semi-synthetic AIN76a diet (18-22 per gender and
genotype). Mean values (x105) plus or minus SEM for lesion area are indicated.
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A

B

Figure 3.10. Intraperitoneal Glucose Tolerance Test (IPGTT) of ADAM11 mice on LDLR KO
background. 19.5 week old mice were tested after 15.5 weeks on diet, by injecting a bolus of 2 mg
glucose/g body weight; mean blood glucose values are indicated plus or minus SEM. AUC, area
under curve, for IPGTT is also provided..
A) Male (n= 9wt, 12 het, 7 ko); AUC: wt: 41,105 +/- 4410, het: 44,998 +/- 3561, ko: 38,285 +/- 4551
B) Female (n= 7wt, 10 het, 5 ko); AUC: wt: 28,179 +/- 2657, het: 29,679 +/- 2004, ko: 30,624 +/2210
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Over-Expression of ADAM11 in Liver by Injection of ADAM11-Adenovirus
An adenovirus capable of expressing the liver isoform of ADAM11 (AdADAM11a) designed by Maxwell (Maxwell Thesis 2006) and produced by Viraquest
at a dose of 1e9 pfu was injected retro-orbitally into chow fed 8-week old male
C57Bl/6 mice. High levels of ADAM11 expression was detected as early as 17
hours post-infection and through 101 hours when the experiment was terminated
at both the mRNA level by qPCR and the protein level by Western-blotting. At 101
hours post-infection, there were no differences between mice infected with AdADAM11a or an empty control adenovirus (AD-Empty) in plasma total, HDL, and
non-HDL cholesterol levels, or gallbladder bile concentrations of cholesterol,
phospholipids, and bile acids.
The high levels of liver ADAM11 expression achieved without effects on
plasma or gallbladder lipid levels caused us to search deeper for a phenotype.
Therefore, we again undertook assessment of global liver gene expression analysis
with hope that it might lead us to the true function of ADAM11 in the liver. Affymetrix
gene expression arrays (MOE set 430A&B) were probed with pools of liver RNA
from 5 chow fed mice at various times post-infection (5, 17, 29, 53, and 101 hours)
with either Ad-ADAM11a or AD-Empty. Compared to infection with AD-Empty,
infection with Ad-ADAM11a up-regulated several genes involved in liver
regeneration, but did not change expression of genes involved in lipid metabolism.
Since liver enzymes were elevated only in plasma from the Ad-ADAM11a infected
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mice, increased liver regeneration genes may have been a manifestation of a toxic
affect from the extremely high levels of ADAM11 expression and not a clue to the
physiologic function of liver expressed ADAM11. Therefore, this observation was
not pursued further.
A Yeast Two Hybrid Screen for Proteins Interacting with ADAM11
Cytoplasmic Tails
In a collaboration with the Duke Yeast Model Systems Genomics Group, we
made a fusion construct of the Gal4 DNA-binding domain with the liver form of the
cytoplasmic tail of mouse ADAM11. This construct was used as bait for the
screening of a mouse liver yeast two-hybrid cDNA library. One strongly positive
clone was identified that interacted with the cytoplasmic tail of ADAM11a. This
clone encoded 3-hydroxyanthranilic acid oxygenase (3HAO), the most active
enzyme in the kynurenine pathway of tryptophan metabolism. We also made a
similar construction, but with the brain form of the cytoplasmic tail of mouse
ADAM11, and this was also shown to strongly interact with 3HAO (Figure 3.11).
Livers from wild-type and ADAM11 homozygous knockout mice did not differ in
3HAO mRNA levels or in the levels of mRNA of other members of the kynurenic
pathway. Antibodies to mouse 3HAO are not available precluding measurement
of protein levels. Levels of blood tryptophan were also unaltered between ADAM11
homozygous knockout and wild-type mice fed the high cholesterol (AIN76a 0.5%
cholesterol) diet. Whole liver 3HAO functional activity assays did not reveal
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different activity levels between ADAM11 homozygous knockout and wild-type mice
fed the high cholesterol diet (Table 3.11).

A)
ADAM11a: N-terminal- GGTGWGFKNIRRGRYDPTQQGAV (23aa)
ADAM11b: N-terminal- GGTGWGFKNIRRGRSGGA (18aa)
B)

9 11
1

2

2

7

Figure 3.11. Yeast two hybrid of the cytoplasmic tails of ADAM11. A) amino acid sequence of
ADAM11 cytoplasmic tail cloned into DBD of yeast two hybrid screen, ADAM11a is predominantly
the liver splice form, and ADAM11b is predominantly the brain splice form. B) Left Panel: 1) Bait:
ADAM11a, Prey: 3HAO; 2) Bait: Control, Prey: 3HAO; Right Panel: 2) Bait: ADAM11a , Prey: Neg
Control (negative control); 7) Bait: Pos Control, Prey: Pos Control (positive control); 9) Bait:
ADAM11b, Prey: 3HAO; 11) Bait: ADAM11b, Prey: Neg Control (negative control)
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Summary
This chapter describes the development of a conditional knockout of the
ADAM11 gene.

ADAM11 knockout mice were previously shown to have a

neurological phenotype to which we now add absence-like epilepsy. This chapter
also evaluates the role of ADAM11 in cholesterol metabolism. Utilizing low and
high cholesterol and cholic acid containing diets in wild-type and ADAM11
heterozygous and homozygous knockout mice, we failed to find a phenotype for
ADAM11 with respect to plasma cholesterol or triglyceride levels, liver lipid levels,
gallbladder bile lipid concentrations, glucose tolerance, or atherosclerosis
susceptibility. Finally, a previously unsuspected binding partner, 3HAO, for the
cytoplasmic tails of both the liver and brain forms of ADAM11 has been identified.
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Chapter 4: Discussion and Future Directions
Discussion of StARD5
StARD5 is a member of the Steroidogenic Acute Regulatory–Related Lipid
Transfer (START) domain protein family, more specifically the StARD4 subfamily.
In vivo StARD5 expression is restricted to reticuloendothelial (RE) cells, and in vitro
StARD5 was shown capable of binding cholesterol and 25-hydroxycholesterol
(Rodriguez-Agudo et al., 2006; Rodriguez-Agudo et al., 2005). In a variety of cell
types ER stress induces the expression of StARD5; and in macrophages free
cholesterol loading was shown to induce ER stress and StARD5 expression
(Rodriguez-Agudo et al., 2006; Soccio and Breslow, 2003). It is hypothesized that
excess ER free cholesterol triggers the ER stress response in part to increase
StARD5, which then transports excess free cholesterol away from the ER to other
cellular membranes or to facilitate excretion (Soccio and Breslow, 2003). In this
manner StARD5 might allow the cell to restore homeostasis rather than undergo
apoptosis. This thesis describes the first studies to directly examine the role of
StARD5 in vivo. To aid our attempts at elucidating the physiological function(s) of
StARD5, we created StARD5 conditional knockout mice.

We also made a

transgenic line expressing StARD5 in RE cells using the scavenger receptor A
promoter/enhancer, and another expressing StARD5 in liver parenchymal cells
using the apoE promoter.
Brother-sister mating of StARD5 heterozygous knockout mice did not
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produce homozygous offspring. Timed matings and genotyping embryos at various
stages of development indicated lethality prior to day E9.5; suggesting StARD5 is
essential for early embryonic development. It is probable the mechanism involves
some aspect of intracellular cholesterol transport necessary for normal embryonic
development. For example, hedgehog is a PM signaling protein required for
embryo survival. Hedgehog is covalently bound to cholesterol, which anchors it to
the PM. It is possible that intracellular cholesterol transport by StARD5 might
facilitate its covalent attachment to hedgehog; and the lack of StARD5 render
hedgehog functionally defective.
Our planning strategy involved creation of a conditional knockout in
anticipation of the possibility that the total knockout might be an embryonic lethal.
The hope was that tissue-specific knockout mice might be viable under conditions
in which total knockout mice are not. The general method involves flanking one or
more exons with loxP sites and exposure to cre-recombinase driven by a tissue
specific promoter. This then causes elimination of these exons in only that tissue,
resulting in production of mRNA that is either unstable or codes for a non-functional
transcript. We chose to flank StARD5 exon 3 with loxP sites (floxed allele) to
eliminate this exon after subsequent exposure to cre-recombinase, expressed
either globally or in a tissue-specific manner. Unexpectedly, brother-sister mating
of mice heterozygous for the StARD5 floxed allele did not result in any mice
homozygous for the floxed allele (expected in ¼ of offspring). Since these mice

138

have an intact exon 3, we concluded that the mere placement of the loxP sites
caused a non-functional allele. Although we had carefully placed the loxP sites in
the exon 3 flanking introns so as not to disrupt any known intronic sequence related
to splicing, this is probably what occurred. This was unfortunate for 2 reasons.
First, this finding indicated that mice with 2 dysfunctional StARD5 alleles were nonviable and thus our physiological studies would be limited to comparing wild-type
with StARD5 heterozygous knockout mice. Secondly, rather than being inactivated
only after cre-recombinase mediated exon 3 excision, the floxed allele with intact
exon 3 was itself inactive. This precluded tissue specific inactivation of the floxed
allele, which is necessary for the conditional knockout strategy. Therefore, we were
not able to create either global or tissue-specific StARD5 homozygous knockout
mice for study.
StARD5 is the fifth member of the START family to be disrupted in mice; the
others being StARD12, StARD1, StARD2 (PCTP), and StARD3 (MLN64) (Caron
et al., 1998; Caron et al., 1997; Durkin et al., 2005; Kanno et al., 2007b; Kanno et
al., 2007c; Kishida et al., 2004). The StARD12 homozygous knockout mice are
embryonic lethal around day E10.5 with severe defects in the neural tube, brain,
heart, and placenta, as well as alterations in the organization of actin filaments and
focal adhesions (Durkin et al., 2005). The StARD12 heterozygous knockout mice
were phenotypically normal. StAR (StARD1) was the first START family member
to be knocked out, and this knockout mouse provides a model for the human
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disease congenital lipoid adrenal hyperplasia (Caron et al., 1997). Both male and
female StARD1 homozygous knockout mice have female external genitalia due to
a generalized defect in steroid hormone biosynthesis. In addition, knockout mice
fail to thrive and die shortly after birth from adrenocortical insufficiency. The
StARD2 (PCTP) homozygous knockout mice are viable, but show increased
hepatic insulin sensitivity and hepatic esterified cholesterol, and their macrophages
after cholesterol loading have decreased cholesterol efflux to ApoA-I and increased
apoptosis. In addition, on a lithogenic diet StARD2 knockout mice exhibit impaired
excretion of lipids into the bile and increased hepatic free cholesterol-to-phospolipid
ratio (Wu et al., 2005; Kanno et al., 2007a; Kanno et al., 2007b; Kanno et al., 2007c;
Scapa et al., 2008). Finally, the StARD3 (MLN64) knockout mice are viable but
are apparently normal without a recognizable phenotype on chow, high fat, or high
cholesterol diets (Kishida et al., 2004).
Since StARD5 homozygous knockout mice were early embryonic lethal, we
could only compare adult wild-type and StARD5 heterozygous knockout mice.
Careful anatomical and histological examination at autopsy at 12 weeks of age
revealed no differences. Measurements of total body and liver weights, plasma
and liver lipids, biliary composition, fasting glucose and IPGTT, and macrophage
cholesterol efflux to HDL or ApoA-I also showed no differences, except for slightly
diminished total body weight at 12 weeks of age in female but not male StARD5
heterozygous knockout mice. This suggests slightly altered metabolism in these
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mice, but the finding was not deemed robust enough for follow-up. We have
concluded that haploinsufficiency for StARD5 does not compromise a diverse array
of metabolic functions.
The ER stress response is activated at all stages of atherosclerotic lesion
development (Zhou et al., 2005). It is thought that the ER stress response triggers
macrophage apoptosis, which results in further lesion progression. If the ER stress
response gene StARD5 is acting early in this process to protect macrophages and
restore homeostasis, we hypothesized that reduced StARD5 expression might
result in larger atherosclerotic lesions.

To explore this idea we evaluated

atherosclerosis progression on the LDLR knockout background of wild-type and
StARD5 heterozygous knockout mice and found no difference.

Either our

hypothesis is wrong or our measurement of aortic root cross sectional lesion area
is not sensitive or specific enough to pick up a difference. For example, StARD5
haploinsufficiency might have a subtle effect on lesion composition that we might
have missed or alternatively affect processes that were not measured such as
aspects of lesion stability or regression.
There are several possible explanations for the absence of a clearly
observable phenotype in StARD5 heterozygous knockout mice. First, in adult mice
the amount of StARD5 might be in excess of what is needed for function and the
amount produced under haploinsufficiency may be sufficient for meeting meet
organismal needs. Second, functional studies were done with mice fed a chow
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diet. It may be that StARD5 heterozygous knockout mice need to be challenged
with high fat, high cholesterol, or lithogenic diets to bring out a physiologically
relevant phenotype. For example, in StARD2 homozygous knockout mice a
lithogenic diet was used to bring out impairment in bile lipid secretions and
increases in plasma cholesterol and phospholipids levels (Wu et al., 2005). Third,
redundancy is possible and another START gene or a gene of another family might
compensate for decreased StARD5 expression. StARD4 and StARD5 have over
30% amino acid identity and, based on initial in vitro studies, were both shown
capable of promoting intracellular cholesterol transport (Soccio et al., 2002; Soccio
and Breslow, 2003). This certainly suggested that the relative lack of either could
be compensated for by the other subfamily member. When the StARD4 knockout
mice become available, this could be tested by studying StARD5 heterozygous
knockout mice on the StARD4 homozygous knockout background. However, at
least in the liver, it appears that StARD5 is expressed in Kuppfer cells and StARD4
in parenchymal cells, which makes it difficult to conceive how these 2 intra-cellular
proteins could complement each other.

Finally, StARD5 may not play a

demonstrably significant role in the processes that were examined.
In addition to genetically determined decreased StARD5 expression, we also
examined increased expression in transgenic mice. To achieve over expression of
StARD5 in reticuloendothelial cells, we used a StARD5 transgene driven by the
scavenger receptor A promoter/enhancer. Litter-mates without (wild-type) and with
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the transgene were compared for total body and liver weights, plasma and liver
lipids, biliary composition, fasting glucose, and macrophage cholesterol efflux to
HDL or ApoA-I, and no significant differences were found. Expression of the
transgene gave only a ~30% increase in total StARD5 expression, which might not
have been large enough to produce a phenotype. Alternatively, for the parameters
measured, the amount of StARD5 might not have been rate limiting. We also
achieved over-expression of StARD5 using a transgene driven by the apoE
promoter/enhancer. These transgenic mice had high levels of StARD5 expression
in liver and measurements of total body and liver weights, plasma and liver lipids,
and biliary composition were made. Compared to non-transgenic male mice, those
expressing StARD5 in the liver had decreased plasma triglyceride levels, as well
as decreased gallbladder bile acids, cholesterol, and phospholipid concentration.
However, after Rodriguez and colleagues demonstrated that StARD5 is expressed
in Kuppfer but not parenchymal cells (these mice express StARD5 driven by the
ApoE promoter/enhancer in liver parenchymal cells), we abandoned our studies of
these mice because we deemed them unphysiological (Rodriguez-Agudo et al.,
2006).
Finally, the transgenic mice in which StARD5 is driven by the scavenger
receptor A promoter/enhancer were bred to the LDLR knockout background. Nontransgenic and transgenic mice were compared for atherosclerotic lesion
progression and no difference was found. This may have been due to the small
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increase in StARD5 expression achieved using this promoter/enhancer and gene.
However, the scavenger receptor A promoter/enhancer has been used to drive
expression of other transgenes with reasonably high levels of expression achieved
(Yan et al., 2007; Zhao et al., 2007). Therefore, it may be necessary to make
additional StARD5 scavenger receptor A driven transgenic lines capable of higher
expression levels for testing on the LDLR knockout background for effects on
atherosclerosis progression.
Future Directions for StARD5
To get a better idea of the crucial but previously unsuspected, role of StARD5
in embryonic development, the precise day of embryonic lethality in StARD5
homozygous knockout mice must be determined. In general, lethality prior to day
E3.5 indicates difficulty in fertilization, cleavage, and compaction; between days
E3.5 and E6.5 difficulty in implantation and gastrulation; between days E6.5 and
E9.5 difficulty in hematopoeisis and cardiovascular development and placental
insufficiency; and beyond E9.5 through the perinatal period difficulty in
organogenesis. In the case of StARD5 homozygous knockout mice lethality prior
to day E9.5 indicates problems either in implantation or organogenesis. We have
attempted to procure and genotype day E3.5 embryos (at the blastocyst stage),
but have failed thus far we believe due to insufficient starting DNA.

As a

consequence we need to improve the sensitivity of our analysis by nested PCR or
whole genome amplification. However, if this does not work we will have to improve
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our harvesting techniques to get more starting DNA. Another approach to inferring
the role of StARD5 in embryonic development will be to document when and in
what tissues StARD5 expression first occurs. This will be done by timed matings
of wild-type mice to procure and whole mount embryos for in situ expression studies
at the mRNA and/or protein levels. In addition, the Nat Heintz laboratory at
Rockefeller, as part of their GENSAT project, has produced and characterized for
brain expression StARD5-GFP-BAC-transgenic mice. These mice have been
made available to us, and we intend to use them to assess the timing and location
of StARD5 expression by following GFP expression in whole mount embryos of
various ages.
Another issue that needs further study is whether or not challenging StARD5
heterozygous knockout mice with different diets might bring out metabolic
abnormalities. Thus far we have studied mice consuming a chow diet, which is low
in fat (4.5% by weight) and low in cholesterol (0.02%). Future studies might try
high fat (up to 60% by weight) and/or high cholesterol (up to 0.5%) diets from
weaning to ~12 weeks of age and assessing their consequences for weight gain,
plasma and liver lipids, biliary lipid composition, and glucose/insulin homeostasis.
There are many precedents for this; for example, recently in studies of StARD2
knockouts, it was necessary to place the mice on lithogenic diets to bring out
metabolic abnormalities (Wu et al., 2005).
Future studies should evaluate possible effects of StARD5 on the quality of
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atherosclerotic lesions. On the LDLR knockout background, wild-type and StARD5
heterozygous knockout mice showed no difference in atherosclerotic lesion
progression as measured by aortic root cross sectional lesion area determined by
oil-red-O staining. However, this did not exclude possible effects of StARD5
deficiency on lesion morphology. Tabas and colleagues have shown that on the
ApoE knockout background, NPC1 heterozygous knockout mice have normal aortic
root cross sectional lesion area but increased lesion cellularity, diminished necrotic
core, and less TUNEL-staining of lesional macrophages, suggesting decreased
lesional macrophage apoptosois (Feng et al., 2003). In future experiments lesions
from LDLR knockout StARD5 heterozygous knockout mice (and controls) should
be stained with Massonʼs trichrome and H&E to look for differences in cellularity,
extent of the necrotic core, and thickness of the fibrous cap, as well as TUNELstaining to assess lesional macrophage apoptosis. In addition to looking for
possible StARD5 effects on lesion morphology, it could also be argued that the
effects of relative StARD5 deficiency on atherosclerosis might be better observed
at later stages of lesion development. In the current study, LDLR knockout wildtype and StARD5 heterozygous knockout mice were weaned at 4 weeks to a
semi-synthetic AIN76a diet containing 0.02% cholesterol for 16 week and lesion
analysis occurred upon sacrifice at 20 weeks of age. In future experiments it might
be preferable to either accelerate lesion formation by increasing dietary cholesterol
from 0.02% to 0.5%, or sacrifice mice on the 0.02% cholesterol diet at 32 rather
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than 20 weeks of age.
StARD5 is an ER stress response gene and has been hypothesized to act
early in free cholesterol loaded macrophages to transport cholesterol out of the ER
protecting against apoptosis and restoring homeostasis. This thesis reports studies
of bone marrow macrophages derived from wild-type and StARD5 heterozygous
knockout mice loaded with tracer amounts of 3H-cholesterol.

We found no

difference between the genotypes in radiolabeled cholesterol efflux to either ApoAI
or HDL over an 8 hour incubation period. Future studies should examine possible
effects of StARD5 deficiency or excess in free cholesterol loaded macrophages.
Tabas and colleagues have loaded macrophages with free cholesterol by incubation
in AcLDL in the presence of an ACAT inhibitor and showed induction of the ER
stress response pathway leading to apoptosis (Devries-Seimon et al., 2005; Han
et al., 2006). This experiment needs to be done with macrophages from wild-type
and StARD5 heterozygous knockout mice to determine whether StARD5 plays an
anti-apoptotic role in macrophages. Initial attempts at this experiment following the
Tabas protocol have caused sever necrosis rather than apoptosis, possibly due to
the use of too high concentrations of either one or both of these reagents (50ug/ml
AcLDL, 10ug/ml ACAT inhibitor 58035) or too long an incubation period (14 hours);
future titration experiments will be needed to identify the best conditions for this
assay. In the future similar in vitro studies should be carried out with StARD5 over
expressing mice, such as those made with the scavenger receptor A
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promoter/enhancer driving StARD5 expression. The transgenic mice we currently
have exhibit relatively low level StARD5 transgene expression. Therefore, these
studies probably should await the creation of mice with higher transgene
expression. It was recently reported that transgenic mice developed using the
scavenger receptor A promoter/enhancer exhibit higher expression levels when
driving cDNA rather than genomic DNA (Yan et al., 2007; Zhao et al., 2007). Our
current strategy involves this promoter driving a genomic construct, but in the future
it might be wise to make transgenics with the scavenger receptor A
promoter/enhancer driving a StARD5 cDNA construct. Circulating cytokines levels
should also be measured in plasma and compared between StARD5 heterozygous
knockout and wild-type mice and StARD5 transgenic and wild-type mice. Increased
or decreased levels of pro-inflammatory cytokines, such as IL-1b or TNFa, may
indicate compromised or enhanced macrophage function in StARD5 deficiency and
excess, respectively.
It is possible that the major role of StARD5 is to transport sterol precursors
of cholesterol to or within the ER, or preferentially transport newly synthesized
cholesterol away from the ER. In this thesis we found wild-type and StARD5
heterozygous knockout mouse macrophages pre-labeled with 3H-cholesterol did
not differ in efflux of radiolabeled cholesterol to either ApoAI or HDL. To study
whether or not StARD5 transports sterol precursors of cholesterol to or within the
ER, or preferentially transport newly synthesized cholesterol away from the ER, we

148

will do a similar experiment except pre-incubating macrophages with labeled
cholesterol precursors, 14C-acetate or 14C-mevalonate. In addition to efflux of newly
synthesized radiolabeled cholesterol, the movement of labeled cholesterol from ER
to PM and the esterification of labeled cholesterol in the ER by the ACAT reaction
will be quantified over time. If StARD5 is involved in the final stages of ER
cholesterol synthesis of transporting newly synthesized cholesterol away from the
ER as a mechanism for reducing ER stress, decreased expression of StarD5 could
lead to an increase in labeled cholesterol synthesis and secretion or movement to
the PM. It would also be good to do this experiment under conditions of ER stress
where the ability to make StARD5 might be more rate limiting.
We already showed that haploinsufficiency for StARD5 was not sufficient to
cause major metabolic derangement and embryonic lethality of homozygous
knockouts precluded studying adult mice with a total inability to make StARD5.
Future experiments might entail utilizing RNAi to achieve greater than 50%
diminution of StARD5 expression in adult mice. We propose either making
transgenic mice expressing shRNA for StARD5 in RE cells or administering AdStARD5 RNAi to adult mice to knockdown StARD5 between 50 and 90% to
examine how this might affect plasma, liver and biliary lipids, glucose/insulin
metabolism, and macrophage cholesterol transport.
Finally, protein-protein interactions may be essential for the function of
StARD5 and the identification of interacting partners could place StARD5 in a
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known cellular pathway. A co-immunoprecipiation assay or a yeast two hybrid
should be done to identify potential binding partners.
Future Directions of StARD4 after the Targeted Disruption of StARD4
It is also the goal of our laboratory to understand the physiological role of
the cholesterol-regulated, SREBP-regulated StARD4 gene, and one of our main
approaches was to make a StARD4 knockout mouse. Since I was the first one in
our laboratory to use the recombineering technique to generate conditional
knockouts, I designed a conditional knockout strategy for StARD4, very much like
for StARD5 (Figure 4.1). This project was then assigned to another student in the
laboratory, Joshua Riegelhaupt, who started his work 2 years after me. I spent a
lot of time then helping Mr. Rieglhaupt to create the targeting vectors and to troubleshoot in creating the knockout mouse. A BAC clone encompassing the StARD4
locus was isolated from a mouse C57Bl6 genomic library (BacPac Resources).
Our plan was to knockout exon 3 using the Cre-loxP technique. In StARD4 splicing
of exons 2and 4 results in a number of pre-termination codons (PTC). A targeting
vector was created using the MC1-TK-containing plasmid. A loxP site was
introduced into StARD4 intron 2 and an Frt-Pgk-em7-Neo-Frt-loxP cassette placed
in StARD4 intron 3. The StARD4 Neo floxed allele was substituted for the
endogenous gene by homologous recombination in isogenic mouse embryonic
stem (ES) cells. One correctly targeted ES clone was identified by Southern
blotting, expanded, and injected into blastocysts. Chimeras were produced, which
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upon further breeding gave germ-line transmission. After conversion of the StARD4
Neo floxed allele to a null allele missing exon 3, brother-sister mating of
heterozygous knockout mice was undertaken. In the first litter one of eight mice
was a StARD4 homozygous knockout, which appears normal and is thriving after
6 weeks of age. This suggests StARD4 homozygous knockout mice are not
embryonic lethal. Thus future studies will be able to compare the three genotypes,
wild-type, heterozygous knockouts, and homozygous knockouts. We will also
create and characterize conditional knockouts with StARD4 deficiency in liver (AlbCre) and macrophages (LysM-Cre).

In the future StARD4 knockouts will be

characterized for the traits measured in the StARD5 experiments enumerated in
previous section of this thesis. Since StARD4 is a dietary cholesterol downregulated gene, we will have to pay particular attention to studying mice on both
low and high cholesterol diets and perhaps on treatment with cholesterol-lowering
statins as well.
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Figure 4.1. Gene targeting and generation of a conditional knockout (floxed) allele of the
StARD4 gene. A) Targeting strategy to flank exon 3 of StARD4 with loxP sites. The targeting vector
was constructed by placing a Neo selectable marker flanked by Frt sites with a loxP site in intron
3. A second loxP site was introduced in intron 2
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Discussion of ADAM11
ADAM11 homozygous knockout mice are viable and grow and develop
normally. Autopsy at 12 weeks of age did not reveal any gross anatomical or
histological abnormalities.
Functional Role of ADAM11 in the Brain
Takahashi and colleagues showed ADAM11 homozygous knockout mice
have a defect in the hidden water maze test, impairment in the rotating rod task,
and reduced responses to the formalin paw test and acetic acid writhing test. To
these abnormalities we now add altered brain wave activity and absence-like
seizures. Thus it appears that ADAM11 plays roles in learning, motor coordination,
nociception, brain electrical activity, and seizure control.
Since ADAM11 is catalytically inactive, Takahashi and colleagues have
proposed it plays an important signaling or structural role at the synaptic junction
either by integrin-dependent or integrin-independent mechanisms (Cai et al., 1998;
Takahashi et al., 2006a; Takahashi et al., 2006b). In Xenopus, ADAM11 (MDC11a)
is expressed in neural crest cells and is thought to be involved in cell-cell or cellmatrix interactions during neural crest cell migration (Cai et al., 1998). Rybnikova
and colleagues have proposed that ADAM11 may play a role in any one of the many
integrin functions in the adult or developing brain, including neuronal plasticity,
neuronal migration, neuronal differentiation, neuritic outgrowth, and synapse
formation (Rybnikova et al., 2002). Other groups have hypothesized that because
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of strong homology in their integrin binding domains, ADAM11, ADAM22, and
ADAM23 may be partially redundant in the brain (Sagane et al., 1998; Sagane et
al., 1999).
Unlike the ADAM11 homozygous knockout, ADAM22 and ADAM23
homozygous knockout mice have severe ataxia, convulsions, and perinatal death;
both die before the third week post-birth (Mitchell et al., 2001; Sagane et al., 2005).
The post-synaptic PM protein ADAM22 through its cytoplasmic tail anchors to the
scaffolding protein postsynaptic density-95 (PSD-95), and through its extracellular
disintegrin domain serves as a receptor for LGI1 (Fukata et al., 2006). LGI1 is
secreted by pre-synaptic neurons and by binding to the disintegrin domain of
ADAM22 increases AMPA receptor-mediated post-synaptic transmission. The
LGI1-ADAM22 disintegrin domain interaction appears to alter the interaction
between the ADAM22 cytoplasmic tail and the scaffold protein PSD-95, which in
turn promotes the association of PSD-95 with the post-synaptic AMPA glutamate
receptor subtype (Fukata et al., 2006). The amino acid residues in the ADAM22
disintegrin domain that are crucial for LGI1 binding are completely conserved in
both ADAM11 and ADAM23. Utilizing an in vitro assay, Fukata and colleagues
showed both the ADAM22 and ADAM23 disintegrin domains bind LGI1, but did not
examine the ADAM11 disintegrin domain (Fukata et al., 2006). Since the ADAM22
cytoplasmic tail is very different from the ADAM11 and ADAM23 cytoplasmic tails,
it is unlikely that after receiving the LGI1 signal that the latter interact in the same
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way as ADAM22 with PSD-95. Instead, it is more likely that the LGI1 interaction
with ADAM11 and ADAM23 is competitive with the LGI1 interaction with ADAM22,
and may serve to block the latter, as described for dominant negative interactions.
It is also possible that LGI1 interaction with ADAM11 and ADAM23 might modulate
entirely different pathways in post-synaptic neurons.
Although ADAM11 function in the brain was not the main goal of this thesis,
we did perform a few preliminary studies. Since ADAM11 is highly expressed in
hippocampus and amygdala (Rybnikova et al., 2002), we performed a fear
conditioning test, but did not find a difference between ADAM11 homozygous
knockout and wild-type mice. ADAM11 is also expressed in thalamus and cerebral
cortex (Rybnikova et al., 2002), where neuronal defects commonly cause seizures.
Therefore, we performed electroencephalography (EEG) on ~20 week old ADAM11
homozygous knockout mice to test for seizure activity. We found the knockout mice
had a major change in background brain rhythms, with most brain waves in the 56Hz or theta range and no faster beta- or alpha-wave activity observed. ADAM11
knockout mice also exhibited constant cortical discharges and at a rate of 1/hour
non-convulsive seizures indicative of absence-like epilepsy. These preliminary
studies require further work to determine the natural history of these seizures and
to delve more deeply into mechanism. Since this type of work is outside the
expertise of our laboratory, we are actively seeking a laboratory with these interests
to take over this project.
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With regard to mechanisms underlying altered brain electrical activity in
ADAM11 homozygous knockout mice, one clue might be the results of our yeast
two hybrid study that revealed a strong interaction between the cytoplasmic tail of
ADAM11 and 3HAO. 3HAO is in the pathway from tryptophan to the excitotoxin
quinolinic acid (QA). It converts the unstable 3-hydroxyanthranilic acid (3-HA) to
an unstable intermediate 2-amino-3-carboxymuconic acid semialdehyde (ACMS),
which non-enzymatically and spontaneously cyclizes to form QA. Normally, the
enzyme -αamino-β
- carboxymuconate- -εsemialdehyde decarboxylase (ACMSD),
also known as picolinic carboxylase, diverts the unstable ACMS to a benign
catabolite and prevents the accumulation of QA. However, altered activity of either
3HAO or ACMSD can result in QA accumulation. QA is an endogenous agonist of
the NMDA glutamate receptor subtype and a potent neurotoxin. Elevated levels of
QA have been implicated in inflammatory diseases of the CNS, including AIDS and
Lyme disease dementia, Huntingtonʼs disease, Alzheimerʼs disease, and epilepsy
(Eastman et al., 1994; Köhler et al., 1988). Schwarcz and colleagues have shown
that 3HAO activity is markedly increased in both seizure-prone EL and DBA/2 mice
as compared to non-epileptic strains in all brain regions examined, leading them to
hypothesize that enhanced production of QA contributes to seizure susceptibility
in mice (Eastman et al., 1994; Köhler et al., 1988). More studies are needed to
determine whether ADAM11 affects 3HAO activity in neurons and whether the
ADAM11 homozygous knockout mice have altered 3HAO activity or altered QA
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levels as a possible explanation for their altered brain wave activity and nonconvulsive seizures.
Functional Role of ADAM11 in the Liver
ADAM11 is a catalytically inactive member of the A Disintegrin and
Metalloprotease (ADAM) family. It is expressed in the liver only in hepatocytes with
highest expression near the portal triads at the peripheral parts of hepatic lobules
and lowest expression near the central vein at the center of the hepatic lobules
(Rybnikova et al., 2002). There are several reasons to suspect that ADAM11 might
play an important role in liver metabolism, including that cholesterol feeding
increases ADAM11 expression in liver but not other tissues, there is a tissue-specific
mRNA splicing mechanism capable of producing a liver isoform of ADAM11 that
differs in its cytoplasmic tail from the brain form, and ADAM11 up-regulation in liver
by an LXR dependent mechanism is a characteristic shared with many genes
involved in reverse cholesterol transport (RCT); a process whereby excess
cholesterol is transported from peripheral tissues to the liver, for excretion in bile.
ADAM11 is localized to the hepatocyte plasma membrane and depending on
whether it is basolateral or cannalicular it is in a position to influence the uptake or
excretion, respectively, of cholesterol or cholesterol containing particles. ADAM11
could act as a stand-alone receptor or as a co-receptor. Liver ADAM11 with its
distinct cytoplasmic tail could also act as an outside-in signaling molecule.
In general to determine the functional role of ADAM11 in liver, we studied
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cohorts of mice, including wild-type, ADAM11 heterozygous knockouts, and
ADAM11 homozygous knockouts, and used three different diets: 0% cholesterol,
high 0.5% cholesterol; and high 0.5% cholic acid. In general, ADAM11 gene
dosage (i.e. 2, 1, and 0 functional copies in wild-type, ADAM11 heterozygous
knockout mice, and ADAM11 homozygous knockout mice, respectively) had no
effect on liver weight or levels of plasma total, HDL, LDL, and VLDL cholesterol,
total free cholesterol, triglycerides, glucose, ALT, blood amino acids, and plant
sterols (except for free campesterol levels discussed below). There was also no
effect of ADAM11 gene dosage on hepatic cholesterol and triglyceride levels,
gallbladder bile composition, glucose tolerance, and the global liver gene
expression profile.
ADAM11 induction was observed in the livers of wild-type mice fed the 0.5%
cholesterol diet. Consequently, we expected to observe the largest difference in
phenotype between wild-type and knockout mice fed this diet. However, the
absence of ADAM11 had no effect on any of the parameters measured. While liver
function tests (ALT) revealed slight liver toxicity in mice fed the 0.5% cholate diet,
there was no difference in toxicity between wild-type and ADAM11 knockout mice.
Finally, in addition to its role in RCT and cholesterol homeostasis, LXRs in the liver
also modulate glucose homeostasis. However, ADAM11 is apparently not involved
since the loss of ADAM11 does not affect fasting glucose levels or impair glucose
tolerance.
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On a high cholesterol diet, the loss of ADAM11 resulted in a slight, but
statistically significant, decrease in free campesterol levels in male mice, and a
similar, but not statistically significant, decrease in females. However, there was
no alteration in total campesterol levels, or total and free sitosterol and
brassicasterol levels. Plant sterols cannot be synthesized endogenously and are
thus completely derived from the diet and their absorption is regulated by intestinal
ABCG5/8 and NPC1L1 (Sehayek and Breslow, 2005). Phytosterol levels, in
particular levels of total campesterol, correlate positively with dietary cholesterol
absorption and inversely with markers of whole body cholesterol synthesis, and
elevated phytosterol levels may be pro-atherogenic and a risk factor for coronary
heart disease (Sehayek and Breslow, 2005). A role for ADAM11 in specifically
regulating free campesterol is unlikely, since ADAM11 has not been detected in
intestine. In addition, the decrease in free campesterol but not free sitosterol or
brassicasterol levels is peculiar because no known physiological process
distinguishes them. Also, total campesterol is normal suggesting this is not a major
physiological alteration. It is doubtful that isolated low levels of free campesterol
indicates a role for ADAM11 in some novel metabolic pathway, rather the
observation is probably a false positive. Moreover, the modest size of the difference
observed in free campesterol levels leads us to think it is not biologically significant
and not worth following up.
The process of RCT is thought to be anti-atherogenic. To examine whether
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the putative RCT gene ADAM11 plays a role in atherosclerosis progression, we
evaluated aortic cross sectional lesion area in ADAM11 knockout mice on the LDLR
knockout background. We found total loss of ADAM11 has no effect on plasma
lipids or atherosclerosis. However, there are two potential drawbacks of this study.
First, we employed the AIN76a 0.02% cholesterol diet to induce atherosclerosis in
these mice. Since the induction of ADAM11 in wild-type mice is highest on a 0.5%
cholesterol diet, it is possible that the effect of ADAM11 loss on atherosclerosis
could only be observed after a long-term feeding using a high cholesterol diet.
Additionally, we only analyzed atherosclerosis on the LDLR knockout background.
There may be phenotypic differences between the LDLR and ApoE knockout
backgrounds, especially if there is an interaction of the LDLR with ADAM11.
Many members of the ADAM family have been demonstrated to serve as
signal transducers, playing a role in the transferring of information between the cell
and its extracellular milieu. We performed a microarray of total RNA from mouse
livers in order to explore whether the loss of ADAM11 in the liver has an effect on
gene expression and gene pathways. While we did identify 17 genes whose
expression was greater than two-fold changed, all of these genes were expressed
at low or marginal levels in the liver, and none of the genes has a known function
related to sterol, triglyceride, or glucose metabolism. Since none of these genes
share a known common pathway, we have not further investigated the relationship
of these genes with ADAM11.
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There are several possible reasons for the lack of a clearly observable,
phenotype for liver expressed ADAM11, as studied with the ADAM11 knockout
mouse model. First, it is possible that ADAM11 does not play a significant role in
the processes that were examined. It is also possible that ADAM11ʼs expression in
mouse livers and its regulation by cholesterol and LXRs are vestigial (too low), in
which case the loss of ADAM11 would have little or no effect on the liver, plasma
or gallbladder bile. Alternatively, compensatory mechanisms may exist. Another
gene, possible even another ADAM family member, could compensate for the loss
of ADAM11. The extent of the redundancy that exists among ADAM family
members remains unclear, but is hypothesized to be significant given that ADAMs
often share over 30% sequence similarity. In fact, ADAM11 has over a 50%
sequence similarity to its subfamily members ADAM22 and ADAM23, with over
70% similarity among the three different disintegrin domains (Sagane et al., 1998;
Sagane et al., 1999). While these two genes, ADAM22 and ADAM23, are highly
expressed in the brains of mice, ADAM23 was shown to be expressed at low levels
in the liver; ADAM22 has not been found in the liver.

If the compensatory

mechanism involves increased gene expression, this would likely be detected by
the microarray; however, it is also possible that a redundant mechanism alters
protein stability, rather than RNA expression. In this case, proteomic studies, such
as a two-dimensional difference gel electrophoresis, could be revealing. It is
possible that a double knock-out of ADAM11 and its compensatory gene would
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result in an observable phenotype. Unfortunately, the ADAM22 knockout dies
shortly after birth, and therefore analysis of sterol metabolism and the process of
RCT in the double knockout of ADAM11 and ADAM23 is not feasible at this time.
However, the eventual creation of a liver-specific conditional knockout of ADAM23,
along with our conditional knockout of ADAM11 may allow this study to be
performed.
In order to elucidate the function of the two ADAM11 splice forms, we
attempted to identify novel binding partners of the two different cytoplasmic tails of
ADAM11 by performing a yeast two-hybrid screen. Only one gene, 3HAO (3hydroxyanthranilic acid 3,4-dioxygenase), was identified in this analysis and was
shown to interact with both ADAM11 cytoplasmic tails. 3HAO is an enzyme that
plays an important role in the metabolic transformation of tryptophan to nicotinamide
in the kynurenine pathway, the main route of metabolism of the essential amino
acid tryptophan. 3-HAO has been shown to be widely expressed in numerous
tissues including brain, inflammatory cells, lung, stomach, intestine, and epididymis.
The gene is also highly expressed in the liver, the major site of the systemic
kynurenine pathway metabolism, which is likely related to high uptake and transport
capacity of hepatocytes for tryptophan and kynurenine. However, mRNA levels of
3HAO and plasma levels of tryptophan were unaltered in the knockout mice. In
addition, the interaction with 3HAO was with both cytoplasmic tails questioning the
specificity of the interaction and making it hard to know if this interaction is functional

162

in brain and/or liver or in neither.
Future Directions for ADAM11 in the brain
Many questions need to be addressed to gain a better understanding of the
physiological role of ADAM11 in the brain. To date, due to logistical constraints only
three male ADAM11 homozygous knockout mice, aged 20 weeks, have undergone
EEG testing. More mice of both genders and a variety of ages need to be studied
to determine the natural history of the seizures observed. For example, absence
seizures in humans have specific age-related expression patterns, and this
information might have pathophysiological significance as well as make the
ADAM11 homozygous knockout mouse a more attractive model for a human
disease with a similar expression pattern.
It will also be necessary to develop a new antibody to ADAM11, so that we
can carefully document the brain regions and cells that express ADAM11 by
immunohistochemical staining. This would complement previous RNA in situ
hybridization studies by Rybnikova, and allow identification of brain regions and
cells that actually express ADAM11 protein, which may not always correspond to
ADAM11 mRNA expression. In addition, seizures are often associated with
complex seizure-induced histological changes in cerebral cortex, hippocampus and
thalamus; so a thorough histological study of brains from knockout mice, beyond
H&E stains, should be performed. Many seizure disorders have a derangement or
alteration in the number of excitatory and/or inhibitory neurons; therefore all
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interneurons in ADAM11 knockout mouse brain sections should be stained and
counted. This will require immunohistochemical analysis with antibodies that
identify various types of inhibitory neurons, such as antibodies to GABA alpha and
beta receptors, neuropeptide Y (NPY), calbindin, calretinin, reelin, Gad,
somatostatin, and parvalbumin, and antibodies that identify excitatory neurons,
such as antibodies to zinc transporter 3 (znt3) and acetylcholinesterase. Other
potentially useful antibodies are to c-Fos, an indirect marker of neuronal activity,
iba1, a microglial marker, and GFAP an astrocyte marker. Timmʼs stain should also
be used as it is a zinc detecting histological marker found in mossy fiber projections,
which are often altered after seizures. Finally, since seizures can induce neuronal
cell death, knockout mouse brains should also be examined for markers of
apoptosis.
Since ADAM11 knockout mice exhibit seizures, along with spatial learning
impairment and motor coordination problems, the question arises as to whether or
not ADAM11 affects synaptic transmission and plasticity? Electrophysiological
studies of slices of the hippocampus and cerebellum of ADAM11 knockout mice
would be useful in this regard.
We have also established a conditional floxed allele of ADAM11, which allow
for engineering mice with cell-specific or tissue-specific loss of ADAM11. Using
transgenics that express Cre in various regions or cells of the brain, the region in
the brain in which loss of ADAM11 is most essential for the seizure phenotype could
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be identified. Currently there are only a few brain cell-specific Cre transgenic lines,
but some might be useful, including emx1-Cre, expressed in cerebral cortex and
hippocampus, camK2a-Cre, expressed in cortex, amygdale, and hippocampal CA1
neurons, c-kit-Cre, expressed in hippocampal CA1, CA2 and CA3 neurons, anterior
dentate gyrus, and the ganglion cell layer of the retina, and grik4-Cre, expressed
in hippocampal CA3 neurons. Utilizing these cell- and tissue-specific expressing
Cre transgenics to create cell- and tissue-specific ADAM11 knockout mice coupled
with careful histological examination would be an essential element in explaining
the brain phenotypes in ADAM11 knockout mice.
Future Directions for ADAM11 in the Liver
Is the expression of ADAM11 on the hepatocyte surface polarized?
Hepatocytes are polarized with a basolateral side facing the liver sinusoids and the
blood, and an apical side facing the bile canaliculi and the bile. ADAM11 expression
on the basolateral membrane would suggest it plays a role in cholesterol
uptake/efflux from/to the blood; alternatively, ADAM11 expression on the
cannalicular membrane suggests a role in biliary lipid efflux. Development of a
better antibody is needed to address this question, since my previous attempts with
existing antibodies have failed to elucidate endogenous levels of ADAM11 protein
expression in the liver.
Which proteins interact with ADAM11? To gain better insight into the function
of ADAM11, we need to determine which proteins interact with ADAM11. We have
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already reported the interaction of the cytoplasmic tails of ADAM11 with the enzyme
3HAO using yeast two-hybrid strategy. Using another technique, such as GSTfusions, we want to identify other novel cytoplasmic interactions, and using either
GST-fusions or yeast two hybrid screens we would also hope to identify novel
extracellular interactions, in particular proteins that interact with the disintegrin
domain of ADAM11. To fully cover the ADAM11 interacting proteome we will need
to use homogenates or prey from liver and brain tissue.
Does the loss of ADAM11 cause changes in protein expression in the liver?
The microarrays did detect RNA expression changes in several genes in the livers
of ADAM11 knockout mice on a high cholesterol diet, but did not suggest an obvious
pathway for study that might be affected by ADAM11. Proteomic studies, such as
a two-dimensional difference gel electrophoresis, are needed to determine which
proteins are differentially affected in the livers of these knockout mice.
Does the loss of ADAM11 cause changes in plant sterol absorption? Since
levels of free campesterol were reduced in the ADAM11 knockout mice on a high
cholesterol diet, plasma measurements of the knockout mice should be repeated
on a low cholesterol diet. Biliary plant sterols should also be measured under both
conditions. Radiolabeled sterol absorption studies are needed to determine whether
these mice have altered ability to take up phytosterols.
Although ADAM11 does not appear to affect cholesterol homeostasis or
atherosclerotic development in our studies, new techniques by Rader and
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colleagues on how to examine the in vivo role of genes in the process of RCT could
help give us a more direct answer as to whether the LXR-regulated gene ADAM11
plays role in RCT. Raderʼs techniques involve tracing the movement of cholesterol
from 3H-cholesterol–labeled J774 macrophages injected intraperitoneally into
plasma, then liver, and ultimately into the bile and feces as free cholesterol or bile
acids (Zhang et al., 2003).
Other questions that should be addressed in determining ADAM11ʼs nonneural function as it pertains to its regulation in the liver by cholesterol and LXRs
are whether the loss of ADAM11 affects atherosclerosis in the ApoE knockout
background. In future experiments it might be preferable to either accelerate lesion
formation by increasing dietary cholesterol from 0.02% to 0.5%, or sacrifice mice
on the 0.02% cholesterol diet at 32 rather than 20 weeks of age.
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Chapter 5: Materials and Methods
Animals and Diets:
All animal protocols were approved by The Rockefeller University Animal
Care and Use Committee. All mice were bred and housed at the Rockefeller
University Laboratory Animal Research Center in a single humidity- and
temperature-controlled room with a 12h dark-light cycle.
Mice: Wild-type C57BL/6 male mice were obtained from The Jackson
Laboratory (stock no. 00664). LDLR–/– mice on the C57BL/6 background were
obtained from The Jackson Laboratory (B6.129S7-Ldlrtm1Her/J, stock no. 002207,
henceforth called LDLR–/–).

ACTFLPe transgenic mice on the C57BL/6

background were obtained from The Jackson Laboratory (B6.Cg-Tg (ACTFLPe)
9205Dym/J, stock no. 005703, henceforth called Flp). These mice have active
flippase expression in all mouse tissues. CMV-Cre transgenic on the C57BL/6
background were obtained from The European Mutant Mouse Arhcive (EMMA)
(B6.129P2-Tg(CMV-cre)1Cgn/CgnIbcm, stock no. 01149, henceforth called CMVCre) These mice have active Cre recombinase expression in all mouse tissues.
Alb-Cre transgenic on the C57BL/6 background were obtained from The Jackson
Laboratory (B6.Cg-Tg(Alb-cre)21Mgn/J, stock no. 003574, henceforth called AlbCre). These mice have active Cre recombinase expression mainly in hepatocytes.
LysM-Cre transgenic on the C57BL/6 background were obtained from Ira Tabas.
These mice have active Cre recombinase expression mainly in the
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reticuloendothelial system (particularly macrophages). Albino mice on the C57BL/6
background were obtained from The Jackson Laboratory (B6(Cg)-Tyrc-2J/J, stock
no. 000058, henceforth called albino).
To assess fertility and fecundity, littermate males (>6 weeks old) were placed
in cages with two mature wild-type females for 1 month or more. Littermate females
were caged with a wild-type male for a similar period. The number of mice achieving
a pregnancy and the number of offspring from each mating set or pregnancy were
recorded.
Dietary Studies: For dietary studies involving the ADAM11 knockout mice,
6-week old mice were fed a semi-synthetic modified AIN76a diet containing 10%
kcal as fat, added with 0.00% cholesterol (wt/wt) ((Clinton/Cybulsky Rodent Diet),
Research Diets D12102N), which was fed to the mice for one week before the start
of each experiment. Mice were then split into three groups and then fed either this
control 0.00% cholesterol diet or this diet supplemented with either 0.50%
cholesterol (wt/wt) (Research Diets D00083101) or 0.50% cholic acid (wt/wt)
(Research Diets D07040901) for one week, before sacrifice.
For dietary studies involving scanvenger receptor A-hStARD5 transgenic
mice and ApoE-hD5 transgenic mice, 6-week old mice were fed a semisynthetic
modified AIN76a diet containing 10%kcal as fat, added with 0.00% cholesterol
(Clinton/Cybulsky Rodent Diet), Research Diets D12102N), which was fed to the
mice for one week before the start of each experiment. Mice were then split into
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two groups and fed either this control 0.00% cholesterol diet or this diet
supplemented with 0.50% cholesterol (wt/wt) (Research Diets D00083101) for one
week, before sacrifice.
For dietary studies involving StARD5 knockout mice, 4-week old mice were
split into two groups and fed either a normal chow diet or a high fat diet containing
60% kcal as fat from lard with 0.03% cholesterol (Research Diets D12492)(these
mice are currently still under analysis) . Mice were fed either diet until sacrifice at
12 weeks.
For all atherosclerosis studies, mice were crossed onto the LDLR-/background. Mice were weaned at 4-weeks and then fed a semisynthetic modified
AIN76a diet containing 10% kcal as fat, supplemented with 0.02% cholesterol
(Clinton/Cybulsky Rodent Diet), Research Diets D00110804). Mice were fed this
diet for 16 weeks prior to sacrifice.
Adenovirus: For adenovirus injections, eight week old male C57Bl/6
animals were anesthetized with ketamine/xylazine and were injected via the retroorbital plexus with 1x109 pfu of ADAM11 adenovirus(designed by Kara Maxwell and
made by Viraquest) in PBS per mouse. Mice were sacrificed after 5, 17, 29, 53,
and 101 hours after injection.
Sacrifice of Animals
At the end of all dietary mouse experiments, food was removed from the
cage early in the light cycle (9am). Mice were fasted for 6 hours, but with full access
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to water. Prior to sedation, blood glucose levels were measured from tail blood
using a glucometer (Bayer). For all dietary studies, mice were sedated with
ketamine/xylazine and sacrificed. The gallbladder bile was aspirated, and blood
was drawn through heart puncture. The animals were exsanguinated with
heparinized PBS. Harvested tissues were frozen in liquid nitrogen and stored at 80C or stored in RNAlater (Ambion) according to the manufactuere instructions.
The animals were perfused with formalin and the heart was removed by cutting
halfway between the aortic root and the brachiocephalic artery. The tissue was
frozen in Tissue-Tek OCT compound. The brachiocephalic artery was cut at the
point where it branches from the aorta and 1mm distal to its bifurcation into the
subclavian and carotid arteries. For all neurologic studies, mice were sedated with
Avertin and sacrificed, prior to the removal of the brain.
Creation of Transgenic Mice
To generate transgenic mice overexpressing StARD5 in liver, human
StARD5 ORF was PCR amplified. The human sequence was used so that
transgene mRNA exprssion could be distinguished from the endogenous mouse
genes. This ORF was cloned into the KpnI/Xho1 sites of the pLIV.7, a transgene
construct in which liver expression is driven by the human ApoE promoter and
enhancer. SacII and SpeI digestion isolated the linear ~6.5kb transgene fragment
from the vector. The fragments were purified by ethanol precipitation. Pronuclear
injection of the transgene was carried out at The Rockefeller University, potential
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founders were screened by PCR using the gene specific primers, and 4 founder
mice were generated. These founders were mated with C57Bl/6 animals to
generate transgenic and wildtype littermates.
To generate transgenic mice overexpressing StARD5 in macrophages, the
full length human StARD5 gene (BAC RP11-770M20) was inserted using
techniques by Copeland and into the J900 expression vector, which encodes the
scavenger receptor promoter-enhancer A (SREP) [gift by Chris Glass (UCSD, La
Jolla, California, USA) and Jeanine DʼArmiento (Columbia, NY, NY, USA)]. The
translational initiation codon of the full-length human StARD5 gene was ligated
downstream of the SREP containing the SmaI site (Table 5.1). The expression
cassette was removed by digestion with NotI and SalI, and purified from agarose
gels. Pronuclear injection of the transgene cassette was carried out at The
Rockefeller University potential founders were screened by PCR using the gene
specific primers, and 2 founder mice were generated. These founders were mated
with C57Bl/6 animals to generate transgenic and wildtype littermates.
Creation of Knockout Mice
To generate the conditional knockout construct, the procedures from
Copeland

and

knockouts

were

adopted

(http://recombineering.ncifcrf.gov/default.asp). Only freshly prepared BAC DNA
(R24-252B21 was used for StARD5, RP- was used for StARD4, RP23-166M9 was
used for ADAM11) (BACPAC Resources, http://bacpac.chori.org) was used for
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experiments. After the design of StARD4cko, Joshua Riegelhaupt in our lab took
over the project. Primer sequences used for constructing the ADAM11, StARD5,
and StARD4 conditional knockout vectors are listed in Table 5.1. PCR amplification
was performed using the ROCHE Expand High-Fidelity Taq kit according to the
manufacturersʼinstructions. The PCR products were purified using a QIAGEN spin
column, digested with the appropriate restriction enzyme (NEB), and purified again
with QIAGEN spin columns. The retrieval vector was generated by mixing 3 µL of
PCR product 1 (A-B, NotI/HindIII), 3 µL of PCR product 2 (Y-Z, HindIII, BamHI), 2
µL of MC1TK (PL253, NotI/BamHI), 1 µL of 10x ligation buffer, and 1 µL of T4 DNA
ligase. The loxP-Neo-loxP targeting vector was generated by mixing 3 µL of PCR
product 1 (C-D, NotI/EcoRI), 3 µL of PCR product 2 (E-F, BamHI/SalI), 2 µL of
floxed Neo cassette (PL452, EcoRI/BamHI), 1 µL of pSK+ (NotI/SalI), 1.2 µL of 10x
ligation buffer, and 1 µL of T4 DNA ligase. The frt-Neo-frt-loxP targeting vector was
generated by mixing 3 µL of PCR product 1 (G-H, NotI/EcoRI), 3 µL of PCR product
2 (I-J, BamHI/SalI), 2 µL of floxed Neo cassette (PL451, EcoRI/BamHI), 1 µL of
pSK+ (NotI/SalI), 1.2 µL of 10x ligation buffer, and 1 µL of T4 DNA ligase. The
ligation mixtures were incubated at 16°C for 2 h, and 0.5 µL was transformed into
electro-competent DH10B cells (Invitrogen).

In brief summary of the

recombineering to generate the conditional knockouts, 1 µL of fresh BAC DNA (100
ng) was electroporated into EL350 cells and selected by chloramphenicol. These
cells were then targeted by electroporation with the modified retrieval vector PL253,
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which was digested with HindIII to linearize the plasmid, and were selected by
ampicillin. These cells were then targeted by electroporation with the modified
minitargeting vector (PL452), which was digested with NotI and SalI to excise the
targeting cassette, and were selected by ampicillin and kanamycin. Cre expression
in the EL350 strain was induced by arabinose-containing medium, leading to the
excision of the floxed Neo cassette, and cells were selected by ampicillin and the
loss of resistance to kanamycin. These cells were then targeted by electroporation
with the modified minitargeting vector (PL451), which was digested with NotI and
SalI to excise the targeting cassette, and were selected by ampicillin and
kanamycin. All cloning junctions and loxP and Frt site orientations were sequenceverified, using forward and reverse sequencing primers. For gene targeting, 20 µg
of NotI-linearized cko-targeting vector DNA was electroporated into ES cells by The
Rockefeller University Gene Targeting Facility. To screen for ES clones with
homologous recombination, southern probes upstream and downstream of the
targeting construct were designed. For ADAM11, three positive ES clones were
injected, one of which led to positive chimeras. For StARD5, five positive ES clones
were injected, one of which led to positive chimeras. For StARD4, one positive ES
clones was injected and has recently led to a putative positive chimera.
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Table 5.1. Primers for Recombineering
Primers for Creating StARD5cKO
Primer
ID Primer Description
A
B
C
D
E
F
G
H
I
J
Y
Z

NotI-AscI-StARD5 promoter for
HindIII-StARD5 promoter rev
NotI-StARD5 intron2-3 for
EcoRI-BsrGI-StARD5 intron2-3 rev
BamHI-StARD5 intron 2-3 for
SalI-StARD5 intron 2-3 rev
NotI-StARD5 intron3-4 for
EcoRI-EcoRV-StARD5 intron3-4 rev
BamHI-StARD5 intron 3-4 for
SalI-StARD5 intron 3-4 rev
HindIII-StARD5 intron 4-5 for
BamHI-SAlI StARD5 intron 4-5 rev

Sequence
ataagcggccgcaggcgcgccagggcagcagctggcaagc
aataag
gtcaagctttatgttttgatgctggaggcaggcc
ataagcggccgcgtgcgcacttttaacaaagtctgtc
gtcgaattctgtacaacacagcttgctagaaacga
ataggatccctgtgaggactttgtacctgtttg
gtcgtcgactggagaggaatttgatccaccgag
ataagcggccgcaggcaggatttctctgtatagcccag
gtcgaattcgatatcttccctagaacccacacacaagctg
ataggatccctaagttctgcttctcaccctggca
gtcgtcgacgtgtcagcctgtggatttcctagc
gtcaagcttagatcttcaaggaaagcttggtg
gtcggatccagtcgaccaggggcagatacagaggaatgac

To introduce ~8.5kb BAC into PL253/Retrieval Vector
AB
~530bp
YZ
~320bp
To introduce loxPNeoLoxP (PL452) into StARD5
CD
~250bp
EF
~180bp
To introduce FrtNeoFrtLoxP (PL451) into StARD5
GH
~250bp
IJ
~180bp
Primers for Creating StARD4cKO
Primer
Sequence
ID Primer Description
A
NotI-StARD4 promoter for
ataatgcggccgcttgatctgtacccgagaggt
B
HindIII-StARD4 promoter rev
gcagaagctttgtagtcaggaaaggccagt
C
NotI-StARD4 intron2-3 for
ataagcggccgcgtgtggaatggatgtacaat
D
EcoRI-StARD4 intron2-3 rev
gcgggaattccgtgtctgatatcagtgcaa
E
BamHI-StARD4 intron 2-3 for
ataaggatccagagcgtgtgagtggacagt
F
SalI-StARD4 intron 2-3 rev
gtcagtcgactttcagtagctcagagatcc
G
NotI-StARD4 intron3-4 for
ttatgcggccgccagagatgaatactcagcat
H
EcoRV-StARD4 intron3-4 rev
ccacgatatccaatcttcctgtccaggtca
I
BamHI-StARD4 intron 3-4 for
ttacggatccgtcagcagtctaggaatgag
J
SalI-StARD4 intron 3-4 rev
atctgtcgacaactaggccagagggcaaat
Y
HindIII-StARD4 intron 4-5 for
gcctaagcttcacacccacacatgagtgaa
Z
BamHI StARD4 intron 4-5 rev
acatggatccctcaacattcagaaggaggg
To inroduce ~8.5kb BAC into PL253/Retrieval Vector
AB
~280bp
YZ
~320bp
To introduce loxPNeoLoxP (PL452) into StARD5
CD
~180bp
EF
~360bp
To introduce FrtNeoFrtLoxP (PL451) into StARD5
GH
~380bp
IJ
~300bp
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Table 5.1. continued. Primers for Recombineering
Primers for Creating ADAM11cKO
Primer
Sequence
ID Primer Description
ataagcggccgcaggcgcgccagccagcagcccagtgctgg
A
NotI-AscI-Adam11 intron 2-3 for
gtcaagcttttctaagccccttcctttgatcc
B
HindIII-Adam11-intron2-3 rev
ataagcggccgcgtccccacactgtaccctgccag
C
NotI-Adam11 intron 11-12 for
D
EcoRI-DraI-Adam11 intron 11-12 rev gtcgaattctttaaaacattccctgcacagcccaaggt
ataggatccgctctttgcctttctctgcc
E
BamHI-Adam11 intron 11-12 for
gtcgtcgacgaagggagagagtggtcagg
F
SalI-Adam11 intron 11-12 rev
ataagcggccgccccttataagtttggcgctgaagag
G
NotI-Adam11 intron 18-19 for
H
EcoRI-EcoRV-Adam11 intron 18-19rev gtcgaattcgatatcagaatacactagacactgggcaggc
ataggatccgatctggtggatcgtaacatgggt
I
BamHI-Adam11 intron 18-19 for
gtcgtcgacgtagcccagagctgagctgaggtt
J
SalI-Adam11 intron 18-19 rev
gtcaagcttcaccctgaactcacacatcactc
Y
HindIII-Adam11 intron25-26 for
Z
BamHI-SalI-Adam11 intron 25-26rev gtcggatccagtcgaccctaactgcaacgttctggagttcctgg
To introduce ~8.5kb BAC into PL253/Retrieval Vector
AB
~420bp
YZ
~230bp
To introduce loxPNeoLoxP (PL452) into ADAM11
CD
~160bp
EF
~160bp
To introduce FrtNeoFrtLoxP (PL451) into ADAM11
GH
~200bp
IJ
~250bp

Primers for Creating Scavenger Receptor A Enhancer and Promoter -hStARD5
Primer
Sequence
ID Primer Description
attacccgggatggacccggcgctggcagcccagatga
A
SmaI-hStARD5 ATG
B
ClaI-hSTARD5 intron 1-2 rev
gatcatcgattccacgaagccgtctccgcgacccctt
Y
ClaI-hSTARD5 fownstream for
gatcatcgattgtgttccaaactccatctgcctg
gatcgtcgactccccagagttccccatgcagacatga
Z
SalI-hStARD5 downstream rev
To introduce ~11.5kb BAC into J900 (SR-A)
AB
~150bp
YZ
~500bp
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Genotyping Mice
Animal tail tips were digested with proteinase K, and the extracts were
ethanol-precipitated for DNA isolation. The primers and sequence for each PCR
are included in Table 5.2
Conditions for genotyping LDLR-/-: 5 min 940C; 10 cycles of 20 sec 950C,
30 sec 640C, 1 min 720C; 30 cycles of 20 sec 950C, 30 sec 580C, 1 min 720C; 5
min 720C
Conditions for genotyping Flp: 5 min 940C; 35 cycles of 30 sec 940C, 1 min
580C, 1 min 720C; 5 min 720C
Conditions for genotyping CMV-Cre: 3 min 940C; 12 cycles of 20 sec 940C,
30 sec 640C, 35 sec 720C; 25 cycles of 20 sec 940C, 30 sec 580C, 35 sec 720C;
5 min 720C
Conditions for genotyping Alb-Cre: 5min 940C; 35 cycles of 30 sec 940C, 1
min 510C, 1 min 720C; 5 min 720C
Conditions for genotyping LysM-Cre: 5min 940C; 35 cycles of 1 min 940C,
1 min 600C, 2 min 720C; 5 min 720C
Conditions for genotyping SR-hD5 transgenics: 5min 940C; 35 cycles of 30
sec 940C, 45 sec 600C, 1:15 min 720C; 5 min 720C
Conditions for genotyping ApoE-hD5 transgenics: 5min 940C; 35 cycles of
30 sec 940C, 1 min 600C, 1 min 720C; 5 min 720C
Conditions for genotyping ADAM11 KO (Sagane): 5min 940C; 35 cycles of
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30 sec 950C, 45 sec 610C, 1:30 min 720C; 5 min 720C
Conditions for genotyping ADAM11cko: 5min 940C; 35 cycles of 30 sec
940C, 30 sec 600C, 1:30 min 720C; 5 min 720C. For ADAM11cko southern
blotting, genomic DNA was digested with either BamHI (5ʼ probe) or EcoRV (3ʼ
probe) and probed with genomic DNA upstream or downstream of the targeted
genomic sequence.
Conditions for genotyping StARD5cko: 5min 940C; 35 cycles of 30 sec
940C, 45 sec 600C, 1:30 min 720C; 5 min 720C. For StARD5cko southern blotting,
genomic DNA was digested with either BsrGI (5ʼ probe) or BamHI (3ʼ probe) and
probed with genomic DNA upstream or downstream of the targeted genomic
sequence. All probes were labeled using the Decaprime II Kit (Ambion) and 32PdATP (GE Healthcare)
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Table 5.2. Sequences of Primers used for Genotyping
Primers for PCR Genotyping
Genotype
Name of Primer
LDLR
IMR59
IMR46
IMR14
ACTFLPe
oIMR0042
oIMR0043
oIMR1348
oIMR1349
LysM-Cre
Cre8
Mlys1
Mlys2
CMV-Cre
oIMR0042
oIMR0043
oIMR0567
oIMR0568
Alb-Cre
oIMR0042
oIMR0043
oIMR1084
oIMR1085
ApoEhD5
a
hApoEexon4 for
pLIV.7 down-rev
b
hApoE-F234for
hd5-176rev
c
hD5-Kpn for
hD5-Xho rev
SR-hD5
a
SREPfor
hD5int1-2rev
b
hD5ex2 for
hD5ex3rev
ADAM11 KO
Adam1227for
(Sagane)
AdamNeo-1952-for
Adam1772rev
ADAM11cKO deletion Adam11ex18for
Adam11ex19rev
Adam11ex11for
floxed
Adam11ex18for
Adam11-2ndloxprev
Neo
Adam11ex18for
Adam11neorev
StARD5cko deletion StARD5ex2for
StARD5ex3for
StARD5int3-4rev
floxed
StARD5ex3for
StARD5-2ndloxprev
Neo
StARD5ex3for
StARD5neorev

Sequence
cgcagtgctcctcatctgacttgt
accccaagacgtgctcccaggatga
aggtgagatgacaggagatc
ctaggccacagaattgaaagatct
gtaggtggaaattctagcatcatcc
cactgatattgtaagtagttt
ctagtgcgaagtagtgatcag
cccagaaatgccagattacg
ccttgggctgccagaatttctc
ttacagtcggccaggctgac
ctaggccacagaattgaaagatct
gtaggtggaaattctagcatcatcc
accagccagctatcaactcg
ttacattggtccagccacc
ctaggccacagaattgaaagatct
gtaggtggaaattctagcatcatcc
gcggtctggcagtaaaaactatc
gtgaaacagcattgctgtcactt
taggggtccaccccaggag
gcagatgcgtgaaacttggtgaatc
atggaattttctatggaggccg
gtcccacacctcctctagtgtcc
gtcgtggtaccatggacccggcgctggcagc
gtcgtctcgagttactcatggaattgcttcactgctttctg
gaagtggataaatcagtgctgc
acctccttagctgcgaccac
tagccctgggttgctcaaggaaac
accggtcacattctcatcccact
cgaaccgtgcctctctctac
tgaatgaactgcaggacgag
ctggctcctgcatccaaggggg
gcggtgaatgagtgtgacattg
accgtccagcttgtgaaggttag
ggttgccatggaaacgtgggca
gcggtgaatgagtgtgacattg
cgaagttatattatgtacctgactg
gcggtgaatgagtgtgacattg
accaaagaacggagccggttgg
ggaatcaagtcttgagatctcc
ctgggaatctgactctagca
ctggtaactgccttgaaagcactg
ctgggaatctgactctagca
cgaagttatattatgtacctgactg
ctgggaatctgactctagca
accaaagaacggagccggttgg
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Table 5.2. continued. Primers for Genotyping
Primers for Southern Blot
Genotype
Name of Primer
StARD5cko Upstream 5' Upstream For
5' Upstream Rev
Downstream3' Downstream For
3' Downstream Rev
ADAM11cko Upstream 5' Upstream For
5' Upstream Rev

Sequence
ggttctgcagtgcctggaatgtcc
ccaaatggctccatggaaacaaaatac
ggagcgcagtgtactgcctgag
gccttcccagagctgtttggagag
agtgttctgcctctgcccaga
gccacaggcccaatcttcttcca

Mouse Plasma, Liver, and Gallbladder Analysis
Plasma was immediately separated by centrifugation. Lipoproteins were
isolated by sequential ultracentrifugation from 60 µl of plasma at d <1.006 g/ml
[very low-density lipoprotein (VLDL)], 1.006 ≤d ≥1.063 g/ml (intermediate-density
lipoprotein and LDL), and d >1.063 g/ml (high-density lipoprotein). The cholesterol
in each of these fractions and in the total plasma was assayed enzymatically
(Roche/Hitachi) and free cholesterol was measured enzymatically (Wako). The level
of cholesterol ester was calculated by subtracting the free cholesterol content from
the total cholesterol content. The triglycerides in the total plasma were assayed
by enzymatic assay (Roche). For plasma plant sterol measurements, cholesterol,
campesterol, sitosterol, stigmasterol, and brassicasterol concentrations in plasma
and bile were determined by a recently described liquid chromatography tandem
mass spectrometry method in Leipzig, Germany. In this thesis, plasma plant sterol
“levels” are expressed as the ratio of absolute plasma plant sterol concentration
(in µg/dl) to absolute total plasma cholesterol concentration (in mg/dl). Gallbladder
bile was isolated and analyzed for cholesterol, phospholipids, and bile acids by
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enzymatic assay (Roche, Sigma). Total liver lipids were extracted according to a
modified method from Folch. Briefly, snap-frozen liver tissues (~100 mg) were
homogenized and extracted twice with chloroform/methanol (v/v = 2:1) solution.
The organic layer was dried under nitrogen gas and resolubilized in chloroform
containing 2% Triton X-100. This extract was dried again and resuspended and
then assayed for TG and TC concentration using commercial kits as described
above. 3HAO activity levels were measured as described by Muller (Muller et al.,
2007). Briefly, liver homogenate (3ml) containing 0.01M PBS pH7.4, 10uM 3-HA,
100 uM ferrous sulphate and 100uM ascorbic acid was incubated at 37C for 30min
in a shaking water bath. After incubate 2ml HCl (3M) was added to each test tube
to terminate the reaction. The resulting precipitate was then centrifuged at 4500xg
for 10min. An aliquot of the supernatant from each test tube was removed for
spectrophotometric analysis at 360nm. An extinction coefficient of 47500 M-1 cm1 was used to determine the concentration of 2-amino-3-carboxymuconic
semialdehyde.
Quantification of Atherosclerosis
To quantify cross-sectional lesion area in the aortic root, formalin-fixed hearts
were embedded in OCT. The heart was oriented so that the three valves of the
aortic root were in the same plane and 12mm sections were saved onto glass
slides. Sections were stained with oil red O. Lesion area was quantified in every
fourth section, and the average was reported for five measurements. To quantify
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cross-sectional lesion area in the brachiocephalic artery, the Y-shaped piece of
brachiocephalic artery was sectioned distally to proximally at 10mm thickness,
beginning from the branch point for the subclavian and carotid arteries.
Atherosclerotic lesions lumenal to the internal elastic lamina were quantified by oil
red O-stained sections at 200, 400, and 600 mm from the branching point of the
brachiocephalic into the carotid and subclavian arteries.
Intraperitoneal Glucose Tolerance Test
For the intraperitoneal glucose tolerance test (IPGTT), mice fasted for 6 h
following the dark (feeding) cycle. After intraperitoneal injection of of glucose (in
physiologic saline) (2g/kg of body weight), blood was drawn from the tail vein at 0,
15, 30, 60 and 120min Blood glucose levels were measured from tail blood using
a handheld blood glucometer (Bayer). IPGTT were performed on mice 3-4 days
prior to sacrifice. Area under curve (AUC) was calculated using the trapezoidal
method.
Culturing Mouse Bone Marrow Macrophages
Macrophages were obtained from mice. The macrophages were harvested
from bone marrow of the femur of mice. All macrophages were cultured in
Dulbeccoʼs modified Eagleʼs medium supplemented with 10% FBS and
recombinant GM-CSF for two weeks.
Cholesterol Efflux from Bone Marrow Macrophage
Bone marrow macrophages were incubated in 1-2 uCi/ml 3H cholesterol in
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minimal essential medium (MEM) containing 10% fetal bovine serum overnight in
12-well plates at 37°C and 5% CO2. The next day, cells were enriched with
cholesterol by incubation with acetylated LDL(BTI), 50 ug protein/ml, along with 12 uCi/ml 3H cholesterol (GE) in minimal essential medium (MEM) containing 10%
fetal bovine serum. The medium was removed and the cells were washed with
phosphate-buffered saline (PBS) and incubated with serum free MEM with either
no acceptor, lipid free ApoA-I (10ug/ml) (BTI), or HDL (50ug/ml) (BTI). Media with
these cholesterol acceptors were added for various lengths of time (4, 8, 24hours),
the media was removed, centrifuged, and 100ul aliquots were counted. The cells
were dissolved in 0.1M NaOH for several hours and 100ul aliquots were counted.
The percent efflux of lipid was calculated as cpm in medium divided by the sum of
the cpm in the media and in the cells. Cholesterol efflux experiments were
performed in triplicate, and the data (% efflux) are expressed as mean ± SEM for
3-4 animals per genotype.
Eliciting and Culturing Mouse Peritoneal Macrophages
Macrophages were obtained from mice. The macrophages were harvested
three to four days after intraperitoneal (i.p.) injection of concanavalin A by peritoneal
lavage. All macrophages were cultured in Dulbeccoʼs modified Eagleʼs medium
supplemented with 10% FBS, 1% glutamine, and 20% L-cell conditioned medium
for 48-72 h, at which point they were typically at ~90% confluency.
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Assay of Macrophage Apoptosis
Procedures were adapted from the Tabas laboratory (Columbia University,
New York, NY). Peritoneal macrophages were FC loaded by treating cells with 50
ug/ml ac-LDL and 10ug/ml ACAT inhibitor 58035 (Novartis; gift from Tabas lab) in
full media for 14-16 hours. Control cells were treated with either the ACAT inhibitor
or the ac-LDL. Midstage and late-stage apoptosis in peritoneal macrophages was
assayed by annexin V and propidium iodine staining, respectively, with the Vybrant
Apoptosis Assay Kit No. 2 (Molecular Probes, Carlsbad, Calif). At the end of
incubation, the macrophages were gently washed once with PBS and incubated
for 15 minutes at room temperature with 120 µL annexin-binding buffer (25 mmol/L
HEPES, 140 mmol/L NaCl, 1 mmol/L EDTA, pH 7.4, 0.1% BSA) containing 10 µL
Alexa Fluor 488–conjugated annexin V and 1 µL of 100-µg/mL propidium iodine.
The staining mixture was then removed and replaced with 120 µL annexin-binding
buffer. The cells were viewed immediately at room temperature with an inverted
fluorescent microscope equipped with filters appropriate for fluorescein and
rhodamine, and images were obtained with a camera equipped with imaging
software. Three fields of cells ({approx}650 cells per field) were photographed for
each condition, and the number of annexin V/propidium iodine–positive cells in
each field was counted and expressed as a percent of the total number of cells.
Sample Preparation for Gene Expression Analysis
Total RNA was isolated from cultured cells or tissue using TRIzol reagent
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(Invitrogen), followed by RNeasy cleanup (Qiagen), according to the manufacturerʼs
instructions. Total RNA was then subjected to RNeasy Cleanup (Qiagen) for
microarray and RT-PCR.
Quantitative RT-PCR
For RT-PCR analysis, RNA was treated with Dnase I (Ambion), and 1-5ug
was reverse transcribed using Superscript III (Invitrogen) with oligo-DT primers. A
7700 Sequence Detection System (Applied Biosystems) was used with the default
thermal cycling profile (95C for 10 min; 40 cycles of 95C 15sec, 60C 1 min; 4C
soak). The quencher dye (TAMRA) was the passive reference. The threshold was
set in the linear range of normalized fluorescence, and a threshold cycle (Ct) was
measured in each well. Each sample was amplified in duplicate for the genes of
interest and the housekeeping gene cyclophilin A. Each cDNA values for genes of
interest were normalized to the corresponding value for the housekeeping gene
cyclophilinA (Table 5.3) and expressed as a ratio, allowing for variability in the initial
quantities of mRNA.
Affymetrix Microarrays
Target Preparation and Hybridization—All protocols were conducted as
described in the Affymetrix GeneChip Expression Analysis technical manual with
the help of Wenxiang Zhang and Connie Zhoa at the Rockefeller Genomics Facility.
Briefly, 10ug of total RNA was converted to first strand cDNA using Superscript II
reverse transcriptase primed by a poly(T) oligomer that incorporated the T7

185

promoter. Second strand cDNA synthesis was followed by in vitro transcription for
linear amplification of each transcript and incorporation of biotinylated CTP and
UTP. The cRNA products were fragmented to 200 nucleotides or less, heated at
99 °C for 5 min, and hybridized for 16 h at 45 °C to mouse MOE 430A or MOE set
430A&B Affymetrix microarrays. The microarrays were then washed at low (6
SSPE) and high (100 mM MES, 0.1 M NaCl) stringency and stained with
streptavidin-phycoerythrin. Fluorescence was amplified by adding biotinylated antistreptavidin and an additional aliquot of streptavidin-phycoerythrin stain. A confocal
scanner was used to collect fluorescence signal at 3-m resolution after excitation
at 570 nm. The average signal from two sequential scans was calculated for each
microarray feature. Initial Data Analysis—Affymetrix Microarray Suite 5.0 was used
to quantitate expression levels for targeted genes; default values provided by
Affymetrix were applied to all analysis parameters. Border pixels were removed,
and the average intensity of pixels within the 75th percentile was computed for each
probe. The average of the lowest 2% of probe intensities occurring in each of 16
microarray sectors was set as background and subtracted from all features in that
sector. Probe pairs were scored positive or negative for detection of the targeted
sequence by comparing signals from the perfect match and mismatch probe
features. The number of probe pairs meeting the default discrimination threshold
(0.015) was used to assign a call of absent, present, or marginal for each assayed
gene, and a p value was calculated to reflect confidence in the detection call. A
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weighted mean of probe fluorescence (corrected for nonspecific signal by
subtracting the mismatch probe value) was calculated using the one-step Tukeyʼs
biweight estimate. This signal value, a relative measure of the expression level,
was computed for each assayed gene. Global scaling was applied to allow
comparison of gene signals across multiple microarrays; after exclusion of the
highest and lowest 2%, the average total chip signal was calculated and used to
determine what scaling factor was required to adjust the chip average to an arbitrary
target of 150. All signal values from one microarray were then multiplied by the
appropriate scaling factor (Genespring version 6.1 (Silicon Genetics Software)).
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Table 5.3. Primers for TaqMan quantitative RT-PCR
Gene
cyclophilin A

forward
reverse
probe

Sequence
GGCCGATGACGAGCCC
TGTCTTTGGAACTTTGTCTGCAA
6FAM-TGGGCCGCGTCTCCTTCGA

StARD5(1)

forward 1
reverse 1
probe 1

GACGCGTCGGGCTGG
AACTCCTCAGATGGCCTCCA
6FAM-TGTCGGGAAGGCAATGGAGTTTCAA

StARD5(2)

forward 1
reverse 1
probe 1

TGGCACCATCAGCTCCAAT
TCTCACAAAACCGGGCTTTG
6FAM-CCCATGTGGAACATCCATTGTGTCCC

hStARD5
human

forward 1
reverse 1
probe 1

TGTGACCGGTTTTGAAATTATCC
GCGGAGGGAGTGGAGGTT
6FAM-GCGGAGGGAGTGGAGGTT

StARD4 (1)

forward 1
reverse 1
probe 1

GAGAGATGGCTGACCCTGAGA
TCAGACAGTCCTTCCAGTTTGATC
6FAM-CCCGTGGTCACAGATTGGCAGGA

StARD4 (2)

forward 1
reverse 1
probe 1

TGCCGTGGTTTGCGG
AGGCAGGAACATGGCTTCTCTA
6FAM-CTCTGCTCCTACCCTGTCAGCTCCATGA

ADAM11 (1)

forward 1
reverse 1
probe 1

TGCCGGCCACGTCATC
CCCGGTCAACAGAATGCAA
6FAM-TCCCGCTGTCCTTGTCTCCATTTCATC

ADAM11 (2)

forward 1 TCAAGCCAGTGTCCCCCTAA
reverse 1 TACAGCGGCCTCCATAGCA
probe 1
6FAM-AAGCTGGACGGTTACTACTGTGATCATGAGCA
All primers and probes are to mouse genes unless indicated
All probes are labeled at the 5' end with 6'FAM and at the 3' end with TAMRA
Parenthesis indicates an alternative primer and probe for a given gene
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Western Blotting
Proteins were isolated from cells or mouse tissues by homogenization in
RIPA buffer (50 mM Tris, pH 7.4/150 mM NaCl/1 mM EDTA/0.1% SDS/1% Triton
X-100/1% deoxycholate) with complete mini protease inhibitor cocktail (Roche).
Crude extracts were centrifuged at 16,000 x g for 10 min to pellet cellular debris
and nuclei. Protein concentration was measured by the BCA assay (Pierce), and
5–50 µg of protein (depending on experiment) was electrophoresed for Western
blotting.

The following dilutions were used: anti-ADAM11a, 1:1,000(gift from

Sagane); anti-StARD5(PTG), 1:200; anti-GFP (Clontech), 1:2000, and anti--tubulin
(Sigma), 1:10,000; anti-beta actin (Sigma), 1:10,000. For the detection of antibody
protein complexes, the SuperSignal West Pico or Femto Kit (Pierce) was used
according to the manufacturerʼs instructions. Band intensities were measured by
using IMAGE Pro Plus.
Contextual Fear Conditioning
In collaboration with Erin Norris from the Strickland lab at Rockefeller
University, mice were not disturbed for 2 weeks before experimentation to ensure
that control animals were nonstressed. All experiments were conducted during the
light cycle. Each conditioning chamber was equipped with a speaker, house light,
and a video camera. The chamber floors consisted of rods that were connected to
a shock generator. Mice were habituated to the behavioral room for 2 hours on the
day of training. During habituation to the room, mice were placed individually into
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the conditioning chambers to expose them to a different territory. During the training
day, mice were placed individually into a conditioning chamber cleaned with an
ammonia-based solution for 2 minutes, during which time is considered the
“baseline period”. Mice were then exposed to three tone-footshock pairings (tone,
20 sec, 85 dB, 3.5 kHz; footshock, 1 sec, 0.6 mA) with an intertrial interval of 60
seconds. Upon completion of training, mice were returned to their home cages
and room to be tested 24 hrs later. The training sessions were video recorded in
order to analyze the animalsʼ baseline freezing behavior (every 5 seconds) during
training. During the testing day, mice were habituated to the behavioral room for 2
hours. Mice were then placed individually into the same chamber (same scent,
lighting, etc) as the previous day for a 2 minute period, during which time their
behavior was recorded. Freezing behavior, or the complete lack of movement in
response to the context, was scored every 5 seconds. After the contextual testing
is completed, the shape, floor, and walls of the chamber is altered significantly, and
the ammonia fragrance is replaced with an ethanol-based scent. The mice are
placed into this novel context for 2 minutes, during which time they will be exposed
to the tone (85 dB, 3.5 kHz) for 60 seconds. During this testing period, the mice
will be scored every 5 seconds for freezing behavior, first prior to the tone, which
ensures that the mice are not freezing to the new context, and during the tone.
Electroencephalographic (EEG) recordings
In collaboration with Dr. Noebels (Baylor, Texas, USA) adult ADAM11-/- and
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ADAM11+/+ littermate mice (aged 3-5 months) were implanted for EEG recordings
Yeast Two Hybrid
In collaboration with the Duke YMSG facility, the two cytoplasmic tails of
ADAM11 were cloned onto a Gal4 DNA binding domain (BD)(pGBT9).
The sequence that was used:
ADAM11a: GGCGGCACGGGCTGGGGATTTAAAAACATCCGTCGTGG
AAGGTACGACCCGACCCAGCAGGGGGCAGTGTGA
ADAM11b: GGCGGCACGGGCTGGGGATTTAAAAACATCCGTCGTGG
AAGGTCCGGAGGGGCCTAA
These vectors were transformed into yeast containing a library of mouse
liver proteins fused to the Gal4 activation domain (AD). Positive interactions were
detected by growth on plates with a selectable markers.
StARD5 Complementation Experiments
In collaboration with Steve Sturley (Columbia University, NY, NY), GFPtagged human StARD5 was cloned into pRS426 and transfected into yeast strains:
wildtype, upc2.1, and arv1. Yeast strains were grown in either YEPD (1% yeast
extract, 2% bacto-peptone, 2% glucose) or in synthetic minimal media containing
0.67% Yeast Nitrogen Base (Difco) supplemented with the appropriate amino acids
and adenine. Yeast transformations were performed using standard procedures.
For routine propagation of plasmids, Escherichia coli XL1Blue cells were used and
grown in Luria broth medium supplemented with ampicillin (200 µg/ml). Neutral lipid
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radiolabeling and TLC analysis was performed using standard conditions.
Data and Statistical Analysis
All data are expressed as mean ± SEM. Statistical analysis was performed
using SPSS. Because normality could not be assessed for our small sample sizes
and non-normal distributions have been reported in previous larger atherosclerosis
studies in mice, the non-parametric Mann-Whitney test was used to test
significance. Significance is indicated by an asterisk in the figures/tables.
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